16-Chloro-substituted prostaglandins and derivatives thereof

The present invention relates to compounds of the formula: ##STR1## wherein A represents a grouping of the formula: ##STR2## B represents a single bond or a straight- or branched-chain alkylene group containing from 1 to 9 carbon atoms, W represents ethylene or trans-vinylene, X represents ethylene or cis-vinylene, Y represents ethylene or trans-vinylene, R represents a hydroxymethyl group or a grouping of the formula --COOR.sup.4, in which R.sup.4 represents a hydrogen atom or a straight- or branched-chain alkyl group containing from 1 to 12 carbon atoms, R.sup.1 represents a hydrogen atom or a methyl or ethyl group, R.sup.2 represents a hydrogen atom or a methyl or ethyl group and R.sup.3 represents a hydrogen or chlorine atom or a hydroxy group and cyclodextrin clathrates of such alcohols, acids and esters and, when R.sup.4 in the formula --COOR.sup.4 represents a hydrogen atom, non-toxic salts thereof, and intermediates therefor. These compounds exhibit characteristic prostaglandin-like activity.

THIS INVENTION is concerned with new prostaglandin analogues. 
Prostaglandins are derivatives of prostanoic acid which has the following 
formula: 
##STR3## 
Various types of prostaglandins are known, the types depending inter alia 
on the structure and substituents on the alicyclic ring. For example, the 
alicyclic rings of prostaglandins F(PGF), E(PGE) and A(PGA) have the 
structures: 
##STR4## 
respectively. The dotted lines in the foregoing formulae and in other 
formulae throughout this specification denote, in accordacne with 
generally accepted rules of nomenclature, that the attached grouping lies 
behind the general plane of the ring system, i.e. that the grouping is in 
.alpha.-configuration, the thickened lines denote that the grouping lies 
in front of the general plane of the system, i.e. that the grouping is in 
.beta.-configuration, and the wavy line indicates the grouping is in 
.alpha.- or .beta.-configuration. 
Such compounds are sub-classified according to the position of double 
bond(s) in the side chain(s) attached to the 8- and 12- positions of the 
alicyclic ring. Thus PG.sub.1 compounds have a trans-double bond between 
C.sub.13 -C.sub.14 (trans-.DELTA..sup.13) and PG.sub.2 compounds have a 
cis-double bond between C.sub.5 -C.sub.6 and a trans-double bond between 
C.sub.13 -C.sub.14 (cis-.DELTA..sup.5, trans-.DELTA..sup.13). For example, 
prostaglandin F.sub.1.alpha. (PGF.sub.1.alpha. ) and prostaglandin E.sub.1 
(PGE.sub.1) are charcterized by the following structures V and VI. 
##STR5## 
respectively. The structure of PGF.sub.2.alpha. and PGE.sub.2, as members 
of the PG.sub.2 group, correspond to those of formulae V and VI 
respectively with a cis-double bond between the carbon atoms in positions 
5 and 6. Compounds in which the double bond between the carbon atoms in 
positions 13 and 14 of members of the PG.sub.1 group is replaced by 
ethylene are known as dihydroprostaglandins, e.g. 
dihydro-prostaglandin-F.sub.1.alpha. (dihydro-PGF.sub.1.alpha. ) and 
dihydro-prostaglandin-E.sub.1 (dihydro-PGE.sub.1). 
Moreover, when one or more methylene groups are added to, or eliminated 
from, the aliphatic group attached to the 12-position of the alicyclic 
ring of the prostaglandins the compounds are known, in accordance with the 
usual rules of organic nomenclature, a homoprostaglandins (methylene group 
added) or non-prostaglandins (methylene group eliminated), and, when more 
than one methylene group is added or eliminated, the number is indicated 
by di-, tri- etc. before the prefix "homo" or "nor." 
Prostaglandins are generally known to possess pharmacological properties, 
for example they stimulate smooth muscle, have hypotensive, diuretic, 
bronchodilating and antilipolytic activities, and als inhibit blood 
platelet aggregation and gastric acid secretion, and are, accordingly, 
useful in the treatment of hypertension, thrombosis, asthma and 
gastro-intestinal ulcers, in the induction of labour and abortion in 
pregnant female mammals, in the prevention of arteriosclerosis, and as 
diuretic agents. They are fat-soluble substances obtainable in very small 
quantities from various tissues of animals which secrete the 
prostaglandins in the living body. 
For example, PGEs and PGAs have an inhibiting effect on gastric acid 
secretion and may, accordingly, be used in the treatment of gastric 
ulcers. They also inhibit the release of free fatty acid induced by 
epinephrine and as a result they reduce the concentration of free fatty 
acid in blood, and are, accordingly, useful in the prevention of 
arteriosclerosis and hyperlipemia. PGE.sub.1 inhibits blood platelet 
aggregation and also removes the thrombus and prevents thrombosis. PGEs 
and PGFs have a stimulating effect on smooth muscle and increase the 
intestinal peristalsis; these actions indicate therapeutic utility on 
post-operative ileus and as purgatives. Furthermore, PGEs and PGEs may be 
used as oxytocics, as abortifacients in the first and second trimesters; 
in the post-labour abortion of the placenta, and as oral contraceptives 
because they regulate the sexual cycle of female mammals. PGEs and PGAs 
have vasodilator and diuretic activities. PGEs are useful for improvement 
in patients suffering from cerebral vascular disease because they increase 
the cerebral blood flow, and are also useful in the treatment of asthmatic 
conditions in patients because of their bronchodilating activity. 
During the past decade widespread investigations have been carried out in 
order to discover inter alia new products possessing the pharmacological 
properties of the `natural` prostaglandins or one or more of such 
proprties to an enhanced degree. It has now been found that by introducing 
a chlorine atom on the carbon atom in the 16-position of prostaglandins F, 
E and A and certain analogues thereof, new prostaglandin analogues are 
obtained which possess the pharmacological properties of the `natural` 
prostaglandins and are, in some aspects of their activities, an 
improvement, for example they possess an enhanced strength of activity 
and/or a prolonged duration of activity. 
The present invention accordingly provides the new prostaglandin analogues 
of the general formula: 
##STR6## 
(wherein A represents a grouping of formula IV as indicated hereinbefore 
or a grouping of the formula: 
##STR7## 
B represents a single bond or a straight- or branched- chain alkylene 
group containing from 1 to 9 (preferably 1 to 5) carbon atoms, W 
represents ethylene (i.e. --CH.sub.2 Ch.sub.2 --) or trans-vinylene (i.e. 
##STR8## 
X represents ethylene or cis-vinylene (i.e. 
##STR9## 
Y represents ethylene or trans-vinylene, R represents a hydroxymethyl 
group (i.e. --CH.sub.2 OH) or a grouping of the formula --COOR.sup.4, in 
which R.sup.4 represents a hydrogen atom or a straight- or branched-chain 
alkyl group containing from 1to 12 carbon atoms, R.sup.1 represents a 
hydrogen atom or a methyl or ethyl group, R.sup.2 represents a hydrogen 
atom or a methyl or ethyl group and R.sup.3 represents a hydrogen or 
chlorine atom or a hydroxy group) and cyclodextrin clathrates of such 
alcohols, acids and esters and, when R.sup.4 in the formula --COOR.sup.4 
represents a hydrogen atom, non-toxic (e.g. sodium) salts thereof. 
Preferably A represents a group of formula VIIIA or VIIIB, preferably B 
represents the n-propyl group, preferably W represents ethylene, 
preferably Y represents trans-vinylene, preferably R represents the 
carboxy or methoxycarbonyl group, preferably R.sup.1 represents a hydrogen 
atom or a methyl group, preferably R.sup.2 represents a hydrogen atom or a 
methyl group, preferably R.sup.3 represents a hydrogen atom, and 
preferably the hydroxy groups depicted in formulae VII, VIIIA and VIIIB in 
.alpha.- or .beta.-configuration are attached to the carbon atom in 
.alpha.-configuration. 
The present invention is concerned with all compounds of general formula 
VII in the `natural` form or its enantiomeric form, or mixtures thereof, 
more particularly the racemic form, consisting of equimolecular mixtures 
of natural and its enantiomeric form. 
As will be apparent to those skilled in the art, the compounds depicted in 
general formula VII have at least four centres of chirality, these four 
centres of chirality being at the alicyclic ring carbon atoms of group A 
identified as 8 and 12 and at the C.sub.15 and C.sub.16 carbon atoms which 
have attached to them a hydroxy group and a chlorine atom respectively. 
Still further centres of chirality occurs when the alicyclic group A 
carries a hydroxy group on the carbon atom in position 11 (i.e. when the 
ring is that of formula VIIIB) or hydroxy groups in positions 9 and 11 
(i.e. when the ring is that of formula VIIIA), and other centres of 
chirality may occur when B is a branched-chain alkylene group. The 
presence of chirality leads, as is well known, to the existence of 
isomerism. However, the compounds of general formula VII all have such a 
configuration that the side-chains attached to the ring carbon atoms in 
the positions identified as 8 and 12 are trans with respect to each other. 
Accordingly, all isomers of general formula VII, and mixtures thereof, 
which have those side-chains attached to the ring carbon atoms in 
positions 8 and 12 in the trans-configuration are to be considered within 
the scope of general formula VII. 
According to a feature of the present invention, the prostaglandin 
analogues of general formula VII, wherein A represents a grouping of 
formula VIIIA or VIIIB, R represents a grouping of the formula 
--COOR.sup.5 in which R.sup.5 represents a hydrogen atom or a straight- or 
branched-chain alkyl group containing from 1 to 4 carbon atoms, R.sup.3 
represents a hydrogen atom or a hydroxy group, and the other symbols are 
as hereinbefore defined, i.e. compounds of the general formula: 
##STR10## 
(wherein Z represents 
##STR11## 
represents a hydrogen atom or a straight- or branched-chain alkyl group 
containing from 1 to 4 carbon atoms, R.sup.6 represents a hydrogen atom or 
a hydroxy group, and the other symbols are as hereinbefore defined) are 
prepared by the process which comprises hydrolyzing to hydroxy groups the 
groups OR.sup.7, OR.sup.8 (when R.sup.8 is other than a hydrogen atom) and 
R.sup.9 (when R.sup.9 is other than a hydrogen atom) of a compound of the 
general formula: 
##STR12## 
wherein R.sup.7 represents a 2-tetrahydropyranyl group unsubstituted or 
substituted by at least one alkyl group, or a 2-tetrahydrofuranyl or 
1-ethoxyethyl group, R.sup.8 represents a hydrogen atom or a 
2-tetrahydropyranyl group unsubstituted or substituted by at least one 
alkyl group, or a 2-tetrahydrofuranyl or 1-ethoxyethyl group, R.sup.9 
represents a hydrogen atom or a grouping of the formula --OR.sup.7, in 
which R.sup.7 is as hereinbefore defined, and the other symbols are as 
hereinbefore defined. Preferably the symbols R.sup.7 represent the 
2-tetrahydropyranyl group, and preferably the symbol R.sup.8, when other 
than a hydrogen atom, also represents the 2-tetrahydropyranyl group. 
The groups OR.sup.7, OR.sup.8 (when R.sup.8 is other than a hydrogen atom) 
and R.sup.9 (when R.sup.9 is other than a hydrogen atom) of the compounds 
of general formula IX may be converted to hydroxy groups by mild 
hydrolysis with an aqueous solution of an organic acid, e.g. acetic acid, 
or with a dilute aqueous inorganic acid, e.g. hydrochloric acid, 
advantageously in the presence of a water-miscible organic solvent, e.g., 
tetrahydrofuran or an alkanol containing from 1 to 4 carbon atoms, e.g. 
methanol. The mild hydrolysis may be carried out at a temperature ranging 
from ambient to 70.degree.0 C (preferably at a temperature below 
45.degree. ) with an acid mixture, e.g. a mixture of hydrochloric acid 
with tetrahydrofuran or methanol, or a mixture of acetic acid, water and 
tetrahydrofuran. The products of formula VIIA may be purified by column 
chromatography on silica gel, which procedure may, when the starting 
material of formula IX is a mixture of compounds with the group OR.sup.8 
in the 15-position in .alpha.- and .beta.- configurations, lead to a 
separation of the resulting 15.alpha.-hydroxy and 15.beta.-hydroxy isomers 
of formula VIIA. 
If desired, acids of general formula VIIA, wherein R.sup.5 represents a 
hydrogen atom and the other symbols are as hereinbefore defined, may be 
prepared by treatment of corresponding esters of that formula, viz. 
compounds wherein R.sup.5 represents an alkyl group containing from 1 to 4 
carbon atoms, (1) when Z represents 
##STR13## 
with an aqueous solution of an alkali metal, e.g. sodium or potassium, 
hydroxide or carbonate in the presence of a wter-miscible organic solvent, 
e.g. tetrahydrofuran or an alkanol containing from 1 to 4 carbon atoms, 
e.g. methanol, or (2) when Z represents 
##STR14## 
with bakers's yeast [cf, C.J. Sih et al, J. Amer. Chem. Soc. 94, 3643-3644 
(1972)]. 
The PGE compounds of general formula VIIA wherein Z represents 
##STR15## 
may be converted to the corresponding PGA compounds of general formula 
VII, wherein A represents a grouping of formula IV, by subjecting the PGEs 
to dehydration using an aqueous solution of an organic or inorganic acid 
having a higher concentration than that employed for hydrolyzing the 
groups OR.sup.7 or compounds of general formula IX, e.g. 1N hydrochloric 
acid or acetic acid, and heating at a temprature of 30.degree. to 
60.degree. C. If desired, simultaneous hydrolysis and dehydration under 
acid conditions as hereinbefore described may be effected on compounds of 
general formula IX, wherein Z represents 
##STR16## 
and the other symbols are as hereinbefore defined, to produce directly PGA 
compounds of formula VII wherein A represents a grouping of formula IV. 
Compounds of general formula VIIA, wherein W, X and Y each represent an 
ethylene group and the other symbols are as hereinbefore defined, may be 
prepared from compounds of general formula VIIA, wherein W represents an 
ethylene or trans-vinylene group, X represents an ethylene or cis-vinylene 
group, Y represents a trans-vinylene group and the other symbols are as 
hereinbefore defined, by reduction. Suitably, the reduction may be 
effected by hydrogenation in the presence of a hydrogenation catalyst, 
e.g. palladium on charcoal, palladium black or platinum dioxide, in an 
inert organic solvent, for example a lower alkanol, e.g. methanol or 
ethanol, at laboratory temperature at normal or elevated pressure, for 
example at a hydrogen pressure from atmospheric to 15 kg./cm.sup.2. 
Compounds of general formula VII, wherein A represents a grouping of 
formula VIIIA or VIIIB, R represents a grouping of the formula 
--COOR.sup.5 in which R.sup.5 is as hereinbefore defined, R.sup.3 
represents a chlorine atom, and the other symbols are as hereinbefore 
defined, i.e. compounds of the general formula: 
##STR17## 
(wherein the various symbols are as hereinbefore defined), may be prepared 
from a compound of general formula: 
##STR18## 
(wherein Ts represents the tosyl group, and the other symbols are as 
hereinbefore defined) by chlorination. The chlorination may be suitably 
carried out by methods known per se, for example with lithium chloride in 
N,N-dimethylformamide at room temperature. By the term "methods known per 
se" as used in this specification is meant methods heretofore used or 
described in the chemical literature. 
Compounds of general formula X may be prepared from compounds of general 
formula VIIA, wherein R.sup.6 represents a hydroxy group and the other 
symbols are as hereinbefore defined, by tosylation with tosyl chloride in 
an inert organic solvent, e.g. methylene chloride, in the presence of a 
base, e.g. pyridine or triethylamine, at a temperature ranging from 
ambient to 0.degree. C. 
Compounds of general formula IX, wherein Z represents 
##STR19## 
R.sup.8 is other than a hydrogen atom and the other symbols are as 
hereinbefore defined, i.e. compounds of the general formula: 
##STR20## 
(wherein the various symbols are as hereinbefore defined) may be prepared 
from compounds of general formula IX, wherein Z represents 
##STR21## 
R.sup.8 is other than a hydrogen atom, and the other symbols are as 
hereinbefore defined), by methods known per se for the conversion of a 
hydroxy group in the 9-position of a prostaglandin compound to an oxo 
group, for example by means of a chromic acid solution (obtained from 
chromium trioxide, manganese sulphate and sulphuric acid in water), Jones' 
reagent or a dimethyl sulphide-N-chlorosuccinimide complex. 
Compounds of general formula IX, wherein Z represents 
##STR22## 
and the other symbols are as hereinbefore defined, i.e. compounds of the 
general formula: 
##STR23## 
(wherein the various symbols are as hereinbefore defined), may be prepared 
from a compound of the general formula: 
##STR24## 
(wherein R.sup.10 represents an alkylcarbonyl group containing from 2 to 5 
carbon atoms, and the other symbols are as hereinbefore defined) by 
hydrolysis under alkaline conditions. The hydrolysis under alkaline 
conditions may be effected (1) with an aqueous solution of an alkali 
metal, e.g. sodium or potassium, hydroxide or carbonate in the presence of 
a water-miscible solvent, e.g. tetrahydrofuran or an alkanol containing 
from 1 to 4 carbon atoms, to give a compound of general formula IXB 
wherein R.sup.5 represents a hydrogen atom, or (2) with anhydrous 
potassium carbonate in an anhydrous alkanol containing from 1 to 4 carbon 
atoms, preferably absolute methanol, to give a compound of general formula 
IXB wherein R.sup.5 represents an alkyl group containing from 1 to 4 
carbon atoms. 
Compounds of general formula IXB, wherein W and X each represent an 
ethylene group, Y represents a transvinylene group and the other symbols 
are as hereinbefore defined, may be prepared from compounds of general 
formula IXB, wherein W and/or X represent(s) a vinylene group, Y 
represents a trans-vinylene group and the other symbols are as 
hereinbefore defined, by reduction. Suitably, the reduction may be 
effected by hydrogenation in the presence of a hydrogenation catalyst, 
e.g. palladium on charcoal or palladium black, in an inert organic 
solvent, for example a lower alkanol, e.g. methanol or ethanol, at 
laboratory temperature at normal or elevated pressure, for example at a 
hydrogen pressure from atmospheric to 15 kg./cm.sup.2. 
Compounds of general formula XI, wherein R.sup.8 is other than a hydrogen 
atom and the other sumbols are as hereinbefore defined, i.e. compounds of 
the general formula: 
##STR25## 
(wherein the various symbols are as hereinbefore defined), may be prepared 
from compounds of general formula XI wherein R.sup.8 represents a hydrogen 
atom and the other symbols are as hereinbefore defined, i.e. compounds of 
the general formula: 
##STR26## 
(wherein the various symbols are as hereinbefore defined), by reaction 
with a dihydropyran, dihydrofuran or ethyl vinyl ether in an inert organic 
solvent, e.g. methylene chloride, in the presence of a condensing agent, 
e.g. p-toluenesulphonic acid. 
Compounds of general formula XIB, wherein Y represents a trans-vinylene 
group, R.sup.1 represents a hydrogen atom and the other symbols are as 
hereinbefore defined, i.e. compounds of the general formula 
##STR27## 
(wherein the various symbols are as hereinbefore defined), may be prepared 
from a compound of the general formula: 
##STR28## 
(wherein the various symbols are as hereinbefore defined) by reduction to 
convert the 15-oxo group to a hydroxy group. The reduction is suitably 
effected (1) with excess sodium borohydride in an alkanol containing from 
1 to 4 carbon atoms, e.g. methanol, at a low temperature, preferably at 
-30.degree. to -60.degree. C., or (2) with zinc borohydride in a suitable 
inert organic solvent, e.g. 1,2-dimethoxyethane, at -10.degree. to 
10.degree. C. The product thus obtained is a mixture of isomers in which 
the hydroxy group at position 15 is in .alpha.- or .beta.-configuration. 
If desired, the isomer having the hydroxy group in .alpha.-configuration 
may be separated from the isomer having the hydroxy group in 
.beta.-configuration by column chromatography of the mixture on silica 
gel. 
Compounds of general formula XIB, wherein Y represents a trans-vinylene 
group, R.sup.1 represents a methyl or ethyl group and the other symbols 
are as hereinbefore defined, i.e. compounds of the general formula: 
##STR29## 
(wherein R.sup.11 represents a methyl or ethyl group and the other symbols 
are as hereinbefore defined) may be prepared from compounds of general 
formula XII by treatment with an organometallic compound of the general 
formula: 
EQU R.sup.11 -Met XIII 
(wherein Met represents a lithium atom or a magnesium halide group and 
R.sup.11 is as hereinbefore defined) in an inert organic solvent, e.g. 
diethyl ether, tetrahydrofuran or n-hexane, at a low temperature, 
preferably below 0.degree. C., more particularly in the case of an 
organolithium compound below -20.degree. C., followed by hydrolysis of the 
resulting organometallic compound, for example by treatment with water or 
an aqueous solution of ammonium chloride or an acid, e.g. hydrochloric 
acid or oxalic acid, to give a mixture of the .alpha.- and .beta.-hydroxy 
isomers of compounds of general formula XID. 
Compounds of general formula XIB, wherein W, X and Y each represent an 
ethylene group and the other symbols are as hereinbefore defined, may be 
prepared from compounds of general formula XIC or XID by reduction. 
Suitably, the reduction may be effected by hydrogenation in the presence of 
a hydrogenation catalyst, e.g. palladium on charcoal, palladium black or 
platinum dioxide, in an inert organic solvent, for example a lower 
alkanol, e.g. methanol or ethanol, at laboratory temperature at normal or 
elevated pressure, for example at a hydrogen pressure from atmospheric to 
15 kg./cm.sup.2. 
Compounds of general formula IXB, wherein the various symbols are as 
hereinbefore defined, may be converted to compounds of the general 
formula: 
##STR30## 
(wherein the various symbols are as hereinbefore defined) by methods known 
per se for the conversion of an alkoxycarbonyl group to a hydroxymethyl 
group, for example by treatment with diisobutylaluminium hydride in an 
inert organic solvent, e.g. toluene or tetrahydrofuran, at a low 
temperature, e.g. at -78.degree. C. 
Compounds of general formula XIV may be converted to compounds of the 
general formula: 
##STR31## 
(wherein R.sup.12 represents the trimethylsilyl group or the trityl group 
and the other symbols are as hereinbefore defined) by reaction (1) with a 
suitable trimethylsilylating reagent, e.g. trimethylsilyl chloride, 
N-trimethylsilyldiethylamine or N,O-bis(trimethylsilyl)acetamide, in an 
inert organic solvent, e.g. methylene chloride or acetone, at a 
temperature ranging from ambient to 0.degree. C., or (2) with trityl 
chloride in pyridine or methylene chloride in the presence of a base, e.g. 
pyridine or a tertiary amine, at a temperature ranging from ambient to 
70.degree. C. 
Compounds of general formula XV may be converted to compounds of the 
general formula: 
##STR32## 
(wherein the various symbols are as hereinbefore defined) by oxidation 
with Collins' reagent or a dimethyl sulphide-N-chlorosuccinimide complex. 
Compounds of general formula XIV or XVI may be converted to compounds of 
general formula VII, wherein A represents a grouping of formula VIIIA or 
VIIB, R represents a hydroxymethyl group, R.sup.3 represents a hydrogen 
atom or a hydroxy group and the other symbols are as hereinbefore defined, 
i.e. compounds of the general formula: 
##STR33## 
(wherein the various symbols are as hereinbefore defined) by means 
heretofore mentioned for the conversion of compounds of general formula IX 
to those of general formula VIIA. 
The method hereinbefore described for the preparation of prostaglandin 
analogues of general formula VII may be represented by the series of 
reactions depicted schematically in Scheme A, wherein the various symbols 
are as hereinbefore defined. 
SCHEME A 
__________________________________________________________________________ 
##STR34## 
##STR35## 
##STR36## 
##STR37## 
##STR38## 
##STR39## 
##STR40## 
##STR41## 
XIC 
##STR42## 
##STR43## 
##STR44## 
##STR45## 
##STR46## 
XIA IXB 
##STR47## 
##STR48## 
##STR49## 
##STR50## 
IXA 
##STR51## 
VIIA 
##STR52## 
##STR53## 
##STR54## 
##STR55## 
VIIB 
##STR56## 
##STR57## 
##STR58## 
##STR59## 
##STR60## 
##STR61## 
##STR62## 
##STR63## 
VIIC XVI 
__________________________________________________________________________ 
Compounds of general formula XII, wherein R.sup.2 represents a hydrogen 
atom and the other symbols are as hereinbefore defined [hereinafter 
depicted in formula XIIA], may be prepared from a compound of the general 
formula: 
##STR64## 
(wherein TMS represents the trimethylsilyl group and the other symbols are 
as hereinbefore defined) by reaction with N-chlorosuccinimide in an inert 
organic solvent, e.g. tetrahydrofuran or carbon tetrachloride, at a low 
temperature, preferably at -20.degree. to -80.degree. C. 
Compounds of general formula XVII, wherein the various symbols are as 
hereinbefore defined, may be prepared from a compound of the general 
formula: 
##STR65## 
(wherein the various symbols are as hereinbefore defined) by reaction with 
a compound of the general formula: 
##STR66## 
(wherein R.sup.13 and R.sup.14 each represent an alkyl group containing 
from 1 to 6 carbon atoms or a cycloalkyl group containing from 3 to 6 
carbon atoms) in an inert organic solvent, e.g. tetrahydrofuran, diethyl 
ether or 1,2-dimethoxyethane, at a low temperature, preferably at 
0.degree. to -80.degree. C., and treatment of the resulting compound with 
a suitable trimethylsilylating reagent, e.g. 
trimethylchlorosilane-triethylamine complex, in an inert organic solvent, 
e.g. tetrahydrofuran or N,N-dimethylformamide, at a low temperature, 
preferably at 0.degree. to -80.degree. C. [Cf. H.O. House et al, J. Org. 
Chem., 34, 2324 (1969)]. 
Compounds of general formula XVIII, wherein the various symbols are as 
hereinbefore defined, may be prepared by the Wittig reaction of a compound 
of the general formula: 
##STR67## 
(wherein the various symbols are as hereinbefore defined) with the sodium 
derivative of a diakyl phosphonate of the general formula: 
##STR68## 
wherein R.sup.15 represents an alkyl group containing from 1 to 4 carbon 
atoms and the other symbols are as hereinbefore defined. The reaction is 
preferably effected by suspending sodium hydride in an inert organic 
solvent, e.g. tetrahydrofuran or 1,2-dimethoxyethane, and adding the 
dialkyl phosphonate of formula XXI. The resulting sodium derivative of the 
dialkyl phosphonate may be reacted with compounds of general formula XX at 
20.degree. to 45.degree. C. to form the trans-enone compound of general 
formula XVIII stereoselectively. 
The method hereinbefore described for the preparation of compounds of 
general formula XIIA may be represented by the series of reactions 
depicted schematically in Scheme B, wherein the various symbols are as 
hereinbefore defined. 
##STR69## 
Compounds of general formula XX, used as a starting material in the 
hereinbefore described procedure, may themselves be prepared by methods 
known per se from compounds of general formula XXII depicted hereafter by 
the series of reactions depicted schematically in Scheme C, wherein Q 
represents the group --SeC.sub.6 H.sub.5 or --SR.sup.16, wherein R.sup.16 
represents an alkyl group containing from 1to 4 carbon atoms or a phenyl 
group, and the other symbols are as hereinbefore defined. 
##STR70## 
Compounds of general formula XXII may be converted to compounds of the 
general formula: 
##STR71## 
(wherein the various symbols are as hereinbefore defined) by reaction with 
compounds of general formula XIX, (1) when R.sup.5 represents an alkyl 
group, in tetrahydrofuran at a low temperature, e.g. at -78.degree. C., or 
(2) when R.sup.5 represents a hydrogen atom, in tetrahydrofuran in the 
presence of hexamethylphosphotriamide at 0.degree. C. 
Compounds of general formula XXIII may be prepared from compounds of 
general formula XXVIII by reaction with benzeneselenenyl bromide (i.e. 
C.sub.6 H.sub.5 SeBr) or diphenyldiselenide (i.e. C.sub.6 H.sub.5 
SeSeC.sub.6 H.sub.5) or a dialkyldisulphide or a diphenyldisulphide of the 
formula R.sup.16 SSR.sup.16, wherein R.sup.16 is as hereinbefore defined, 
in an inert organic solvent, e.g. tetrahydrofuran, 
hexamethylphosphotriamide, diethyl ether, n-hexane or n-pentane or a 
mixture of two or more of them, at a low temperature, when R.sup.5 is an 
alkyl group, e.g. at -78.degree. C., or, when R.sup.5 is a hydrogen atom, 
at 0.degree. C., followed by hydrolysis of the resulting organolithium 
compound, for example by treatment with an aqueous solution of ammonium 
chloride to give compounds of general formula XXIII. 
Compounds of general formula XXIII, wherein Q represents the group 
--SeC.sub.6 H.sub.5, may be converted to compounds of general formula XXIV 
by reaction (1) with hydrogen peroxide in a mixture of ethyl acetate and 
tetrahydrofuran or methanol, preferably in the presence of sodium 
bicarbonate at a temperatur below 30.degree. C., or (2) with sodium 
periodate in a mixture of water and a lower alkanol, e.g. methanol or 
ethanol, preferably in the presence of sodium bicarbonate at a temperature 
below 30.degree. C. 
Compounds of general formula XXIII, wherein Q represents the group 
--SR.sup.16 (R.sup.16 being as hereinbefore defined), may be converted to 
compounds of the general formula: 
##STR72## 
(wherein the various symbols are as hereinbefore defined) by means 
heretofore mentioned for the conversion of compounds of general formula 
XXIII, wherein Q represents the group --SeC.sub.6 H.sub.5, to those of 
general formula XXIV. 
Compounds of general formula XXIX may be converted to compounds of general 
formula XXIV by treatment (1) when R.sup.16 represents an alkyl group, in 
toluene, preferably in the presence of a small amount of calcium 
carbonate, at a temperature of 100.degree. to 120.degree. C., or (2) when 
R.sup.16 represents a phenyl group, in carbon tetrachloride, preferably in 
the presence of small amount of calcium carbonate, at a temperature of 
about 50.degree. C. 
Compounds of general formula XXII or XXIV may be converted to compounds of 
general formula XXV by reaction with trimethylchlorosilane in an inert 
organic solvent, e.g. methylene chloride, in the presence of a base, e.g. 
pyridine or a tertiary amine, at a low temperature, e.g. at -30.degree. to 
0.degree. C. 
Compounds of general formula XXV may be converted to compounds of general 
formula XXVI by reaction with an acyl chloride or an acid anhydride in an 
inert organic solvent, e.g. methylene chloride, in the presence of a base, 
e.g. pyridine or a tertiary amine, at a low temperature, e.g. at 0.degree. 
to 30.degree. C. 
Compounds of general formula XXVI may be converted to compounds of general 
formula XXVII by methods known per se for the removal of the 
trimethylsilyl group, for example by treatment with an acid; it is 
preferable not to use a strong acid in order to avoid the risk of the 
removal of the group R.sup.7. 
Compounds of general formula XXVII may be converted to compounds of general 
formula XX under mild and neutral conditions, for example with chromium 
trioxide-pyridine complex of Jones' reagent in an inert organic solvent, 
e.g. methylene chloride, at a moderately low temperature, preferably at 
0.degree. C. 
Compounds of general formula XXII may be prepared by the method described 
in Japanese Pat. Publication Nos. 49-102646 and 49-134656 from compounds 
of formula XXX depicted hereafter, which may be represented by the series 
of reactions depicted schematically below in Scheme D, wherein Ac 
represents the acetyl group (i.e. --COCH.sub.3), R.sup.5' represents a 
straight- or branched-chain alkyl group containing 1 to 4 carbon atoms and 
the other symbols are as hereinbefore defined. 
##STR73## 
Compounds of formula XXI may be prepared by hydrolysis under alkaline 
conditions of compounds of formula XXX. Compounds of formula XXXII may be 
obtained by the acetylation of compounds of formula XXXI under mild 
conditions and may be converted to compounds of general formula XXXIII by 
reaction with a dihydropyran, dihydrofuran or ethyl vinyl ether in an 
inert organic solvent, e.g. methylene chloride, in the presence of a 
condensing agent, e.g. p-toluenesulphonic acid. Compounds of general 
formula XXXIV may be prepared by reducing compounds of general formula 
XXXIII with diisobutylaluminium hydride in an inert organic solvent, e.g. 
toluene, n-hexane or n-pentane, at -60.degree. C. 
Compounds of general formula XXIIA may be prepared from compounds of 
general formula XXXIV by reaction with 
(4-carboxybutylidene)triphenylphosphorane of the formula (C.sub.6 
H.sub.5).sub.3 P.dbd.CH(CH.sub.2).sub.3 COOH. The reaction between the 
compounds of general formula XXXIV with 
(4-carboxybutylidene)triphenylphosphorane [obtained by the reaction of 
sodium methylsulphinylmethylide with (4-carboxybutyl)triphenylphosphonium 
bromide] is carried out under the normal conditions utilized for the 
Wittig reacton, for example in an inert organic solvent, at ambient 
temperature. The reaction is preferably carried out in dimethyl sulphoxide 
because the phosphorane compound is practically insoluble in other 
solvents, e.g. tetrahydrofuran, and because a cis-double bond must be 
formed stereospecifically in the Wittig reaction. The reaction is 
generally effected at a temperature of 10.degree. to 40.degree. C., 
preferably at 20.degree. to 30.degree. C. The acid product of general 
formula XXIIA may be extracted from the reaction mixture by conventional 
procedures and further purified by column chromatography on silica gel. 
Compounds of general formula XXIIA may, if desired, be reacted with a 
diazoalkane containing from 1 to 4 carbon atoms, e.g. diazomethane, in an 
inert organic solvent, e.g. diethyl ether, to give compounds of general 
formula XXIIB. 
Compounds of general formulae XXIIA and XXIIB may, if desired, be reduced 
to give compounds of general formula XXIIC. Suitably, the reduction may be 
effected by hyrogenation in the presence of a hydrogenation catalyst, e.g. 
palladium on charcoal, palladium black or platinum dioxide, in the 
presence of an inert organic solvent, for example a lower alkanol, e.g. 
methanol or ethanol, at laboratory temperature at normal or elevated 
pressure, e.g. at a hydrogen pressure from atmospheric to 15 kg./cm.sup.2. 
The starting compounds of formula XXX wherein the group OAc is in 
.alpha.-configuration, i.e. the compound of the formula: 
##STR74## 
wherein Ac is as hereinbefore defined, may be prepared as described in J. 
Amer. Chem. Soc., 91. 5675, (1969) and ibid, 92, 397 (1970) by E. J. Corey 
et al. 
A method for the preparation of the starting materials of formula XXX, 
wherein the group OAc is in .beta.-configuration, hereinafter depicted in 
formula XXXB, utilizing known procedures may be represented by the series 
of reactions depicted schematically below in Scheme E [cf. E. J. Corey and 
Shiro Terashima, Tetrahedron Letters No. 2,111-113 (1972)], wherein Ts 
represents the tosyl group and Ac is as hereinbefore defined. 
##STR75## 
The various reactions depicted above in Scheme E may be effected by methods 
known per se. Compounds of formula XXXVII may be prepared by reacting 
compounds of formula XXXVI with tetraethylammonium acetate. 
A method for the preparation of the compounds of general formula XXXIII, 
wherein the group OR.sup.7 is in .beta.-configuration [hereafter depicted 
in formula XXXIIIA], may be represented by the series of reactions 
depicted schematically below in Scheme F, wherein Mes represents the 
methylsulphonyl group (i.e. --SO.sub.2 CH.sub.3) and the other symbols are 
as hereinbefore defined. 
##STR76## 
Compounds of general formula XXXVIII may be prepared from compounds of 
formula XXXIIA by reaction with methanesulphonyl chloride in an inert 
organic solvent, e.g. methylene chloride, in the presence of triethylamine 
at a temperature below -20.degree. C. 
Compounds of formula XXXIX may be prepared from compounds of formula 
XXXVIII by reaction with sodium benzoate in N,N-dimethylformamide or 
dimethyl sulphoxide or a mixture thereof at a temperature ranging from 
ambient to 90.degree. C. 
Compounds of formula XXXIA may be prepared from compounds of formula XXXIX 
by hydrolysis under alkaline conditions, for example with potassium 
carbonate in methanol at a temperature below 60.degree. C. 
The conversion of compounds of formula XXXIA to those of general formula 
XXXIIIA may be carried out by means heretofore mentioned for the 
conversion of compounds of formula XXXI to those of general formula 
XXXIII. 
Compounds of general formula XII may also be prepared from compounds of 
general formula XX by reaction with the sodium derivative of a compound of 
the general formula: 
##STR77## 
wherein the various symbols are as hereinbefore defined. The reaction may 
be carried out by means heretofore mentioned for the conversion of 
compounds of general formula XX to those of general formula XVIII. 
The dialkyl phosphonates of general formula XXI may be prepared by reacting 
a solution of n-butyllithium in an inert organic solvent, e.g. diethyl 
ether, n-hexane or n-pentane, with a solution of dialkyl methylphosphonate 
of the general formula: 
##STR78## 
(wherein R.sup.15 is as hereinbefore defined), e.g. dimethyl 
methylphosphonate or diethyl methylphosphonate, at a temperature below 
-50.degree. C. and then adding dropwise to the reaction mixture a solution 
of a compound of the general formula: 
EQU R.sup.17 OOCCH.sub.2 --B--CH.sub.2 R.sup.9 XLII 
(wherein R.sup.17 represents an alkyl group containing from 1 to 4 carbon 
atoms and the other symbols are as hereinbefore defined) in 
tetrahydrofuran at a temperature below -50.degree. C., and then stirring 
at a moderately low temperature, e.g. at 0.degree. C., to give the desired 
dialkyl phosphonate of general formula XXI. 
The dialkyl phosphonates of general formula XL may be prepared by reacting 
a solution of a compound of general formula: 
##STR79## 
(wherein the various symbols are as hereinbefore defined) in 
tetrahydrofuran with a suspension of sodium hydride in tetrahydrofuran at 
room temperature, and adding to the reaction mixture a solution of 
n-butyllithium in an inert organic solvent, e.g. n-hexane, at a 
temperature below 0.degree. C., and adding to the resulting reaction 
mixture a solution of benzenesulphonyl chloride in tetrahydrofuran at 
-78.degree. C., then stirring at a temperature ranging from ambient to 
0.degree. C. to give the desired dialkyl phosphonate of general formula 
XL. 
Compounds of general formula XLIII may be prepared from a compound of the 
general formula: 
##STR80## 
(wherein the various symbols are as hereinbefore defined) by means 
heretofore mentioned for the conversion of compounds of general formula 
XLII to those of general formula XXI. 
Compounds of general formula XLII or XLIV may be prepared by methods known 
per se 
According to another feature of the present invention, the prostaglandin 
analogues of general formula VII, wherein A represents a grouping of 
formula VIIIB and the other symbols are as hereinbefore defined 
[hereinafter depicted in formula VIID], are prepared by the process which 
comprises hydrolyzing the trimethylsilyloxy groups of a compound of the 
general formula: 
##STR81## 
(wherein R' represents the group --COOR.sup.4, in which R.sup.4 is as 
hereinbefore defined, or a trimethylsilyloxymethyl group (i.e. --CH.sub.2 
OTMS), R.sup.3' represents a hydrogen or chlorine atom or a 
trimethylsilyloxy group and the other symbols are as hereinbefore defined) 
to hydroxy groups under extremely mild acidic conditions, for example by 
treatment of a solution of such a compound in an inert organic solvent, 
e.g. ethyl acetate or diethyl ether, with an aqueous solution of oxalic 
acid, preferably at room temperature. 
Compounds of general formula XLV may be prepared by oxidation of a compound 
of the general formula: 
##STR82## 
(wherein the various symbols are as hereinbefore defined) with Collins' 
reagent in the presence of an inert organic solvent, e.g. methylene 
chloride, preferably at a temperature of about 10.degree. C., or with 
dimethyl sulphide-N-chlorosuccinimide complex at 0.degree. to -30.degree. 
C. [cf. E. J. Corey and C. U. Kim, J. Amer. Chem. Soc., 94, 7586 (1972)]. 
Compounds of general formula XLVI may be prepared from a compound of the 
general formula: 
##STR83## 
(wherein the various symbols are as hereinbefore defined) by reaction with 
a suitable trimethylsilylating reagent, e.g. N-trimethylsilyldiethylamine 
or N,O-bis(trimethylsilyl)acetamide, in an inert organic solvent, e.g. 
acetone or methylene chloride, preferably at room temperature. 
The hereinbefore described sequence of reactions is illustrated 
schematically in following Scheme G, wherein the various symbols are as 
hereinbefore defined. 
##STR84## 
According to still another feature of the present invention, the 
prostaglandin analogues of general formula VIIA, wherein Z represents 
##STR85## 
Y represents a transvinylene group, R.sup.2 represents a hydrogen atom and 
the other symbols are as hereinbefore defined, i.e. compounds of the 
general formula: 
##STR86## 
(wherein the various symbols are as hereinbefore defined), are prepared by 
the process which comprises hydrolyzing to hydroxy groups, the groups 
OR.sup.7 of a compound of the general formula: 
##STR87## 
(wherein the various symbols are as hereinbefore defined) by means 
heretofore mentioned for the conversion of compounds of general formula IX 
to those of general formula VIIA. 
Compounds of general formula XLVII, wherein the various symbols are as 
hereinbefore defined, may be prepared from a compound of the general 
formula: 
##STR88## 
(wherein the various symbols are as hereinbefore defined) by means 
heretofore mentioned for the conversion of compounds of general formula 
XII to those of general formula XI. The product thus obtained is a mixture 
of isomers in which the hydroxy group at position 15 is in .alpha.- or 
.beta.-configuration respectively. If desired, the isomer having the 
hydroxy group in .alpha.-configuration may be separated from the isomer 
having the hydroxy group in .beta.-configuration by column chromatography 
of the mixture on silica gel. 
Compounds of general formula XLVIII, wherein the various symbols are as 
hereinbefore defined, may be prepared from a compound of the general 
formula: 
##STR89## 
(wherein the various symbols are as hereinbefore defined) by means 
heretofore mentioned for the conversion of compounds of general formula 
XVII to those of general formula XIIA. 
Compounds of general formula XLIX, wherein the various symbols are as 
hereinbefore defined, may be prepared from a compound of the general 
formula: 
##STR90## 
(wherein the various symbols are as hereinbefore defined) by means 
heretofore mentioned for the conversion of compounds of general formula 
XVIII to those of general formula XVII. 
Compounds of general formula L, wherein the various symbols are as 
hereinbefore defined, may be prepared from a compound of the general 
formula: 
##STR91## 
(wherein the various symbols are as hereinbefore defined) by reaction with 
a dihydropyran, dihydrofuran or ethyl vinyl ether in an inert organic 
solvent, e.g. methylene chloride, in the presence of a condensing agent, 
e.g. p-toluenesulphonic acid. 
Compounds of general formula LI, wherein the various symbols are as 
hereinbefore defined, may be prepared from a compound of the general 
formula: 
##STR92## 
(wherein the various symbols are as hereinbefore defined) by means 
heretofore mentioned for the conversion of compounds of general formula XX 
to those of general formula XVIII. 
Compounds of general formula LII, wherein the various symbols are as 
hereinbefore defined, may be prepared from compounds of general formula 
XXII or XXIV by reaction with a chromium trioxide-pyridine complex in an 
inert organic solvent, e.g. methylene chloride, at a low temperature, 
preferably at 0.degree. C. 
If desired, compounds of general formula L, wherein the grouping 
--B--CH.sub.2 --R.sup.9 represents the n-butyl group and the other symbols 
are as hereinbefore defined, may be prepared from a compound of the 
general formula: 
##STR93## 
(wherein the various symbols are as hereinbefore defined) by means 
heretofore mentioned for the conversion of compounds of general formula LI 
to those of general formula L. 
Compounds of general formula LIII wherein the various symbols are as 
hereinbefore defined, may be prepared from a compound of the general 
formula: 
##STR94## 
(wherein the various symbols are as hereinbefore defined) by oxidation 
with active manganese dioxide in an inert organic solvent, e.g. methylene 
chloride, preferably at room temperature. 
Compounds of general formula LIV, wherein W represents a trans-vinylene 
group and the other symbols are as hereinbefore defined, are described in 
Belgium Pat. No. 823778. 
The method hereinbefore described for the preparation of compounds of 
general formula VIIF may be represented by the series of reactions 
depicted schematically below in Scheme H, wherein the various symbols are 
as hereinbefore defined. 
##STR95## 
According to a still further feature of the present invention, the 
compounds of general formula VII, wherein A, B, W, X, Y, R.sup.1, R.sup.2 
and R.sup.3 are as hereinbefore defined and R represents a grouping 
--COOR.sup.4' in which R.sup.4' represents a straight- or branched-chain 
alkyl group containing from 1 to 12 carbon atoms, are prepared by 
esterification of the corresponding acids of formula VII wherein R 
represents a carboxy group (i.e. --COOH) by methods known per se, for 
example by reaction with (i) the appropriate diazoalkane in an inert 
organic solvent, e.g. diethyl ether, at a temperature of from -10.degree. 
C. to 25.degree. C. and preferably 0.degree. C., (ii) the appropriate 
alcohol in the presence of dicyclohexylcarbodiimide as condensing agent, 
or (iii) the appropriate alcohol following formation of a mixed anhydride 
by adding a tertiary amine and pivaloyl halide or an alkylsulphonyl or 
arylsulphonyl halide (cf. our British Pat. Nos. 1362956 and 1364125). 
Compounds of general formula VII wherein R represents a carboxy group may, 
if desired, be converted by methods known per se into non-toxic salts. 
By the term "non-toxic salts," as used in this specification, is meant 
salts the cations of which are relatively innocuous to the animal organism 
when used in therapeutic doses so that the beneficial pharmacological 
properties of the acids within general formula VII are not vitiated by 
side-effects ascribable to those cations. Preferably the salts are 
water-soluble. Suitable salts include the alkali metal, e.g. sodium and 
potassium, and ammonium salts and pharmaceutically-acceptable (i.e. 
non-toxic) amine salts. Amines suitable for forming such salts with 
carboxylic acids are well known and include, for example, amines derived 
in theory by the replacement of one or more of the hydrogen atoms of 
ammonia by groups, which may be the same or different when more than one 
hydrogen atom is replaced, selected from, for example, alkyl groups 
containing from 1 to 6 carbon atoms and hydroxyalkyl groups containing 
from 1 to 3 carbon atoms. 
The non-toxic salts may be prepared from acids of general formula VII 
wherein R represents a carboxy group by, for example, reaction of 
stoichiometric quantities of an acid of general formula VII and the 
appropriate base, e.g. an alkali metal hydroxide or carbonate, ammonium 
hydroxide, ammonia or an amine, in a suitable solvent. The salts may be 
isolated by lyophilisation of the solution, or, if sufficiently insoluble 
in the reaction medium, by filtration, if necessary after removal of part 
of the solvent. 
Cyclodextrin clathrates of the prostaglandin analogues of general formula 
VII may be prepared by dissolving the cyclodextrin in water or an organic 
solvent which is miscible with water and adding to the solution the 
prostaglandin analogue in a water-miscible organic solvent. The mixture is 
then heated and the desired cyclodextrin clathrate product isolated by 
concentrating the mixture under reduced pressure or by cooling and 
separating the product by filtration or decantation. The ratio of organic 
solvent to water may be varied according to the solubilities of the 
starting materials and products. Preferably the temperature is not allowed 
to exceed 70.degree. C. during the preparation of the cyclodextrin 
clathrates. .alpha.-, .beta.- or .gamma.-Cyclodextrins or mixtures thereof 
may be used in the preparation of the cyclodextrin clathrates. Conversion 
into their cyclodextrin clathrates serves to increase the stability of the 
prostaglandin analogues. 
The present invention also includes, as further features, the hitherto 
unknown compounds of general formulae IX, X, XIV, XV, XVI, XVII, XLV and 
XLVII, and the methods heretofore described for their preparation. 
The prostaglandin analogues of general formula VII and their cyclodextrin 
clathrates and, when R represents a carboxy group, non-toxic salts possess 
the valuable pharmacological properties typical of the prostaglandins in a 
selective fashion, in particular hypotensive activity, inhibitory activity 
on blood platelet aggregation, inhibitory activity on gastric acid 
secretion and gastric ulceration, stimulatory activity on uterine 
contraction and abortifacient, luteolytic and antinidatory activity, and 
are useful in the treatment of hypertension, in the treatment of disorders 
of the peripheral circulation, in the prevention and treatment of cerebral 
thrombosis and myocardial infarction, in the treatment of gastric 
ulceration, in the termination of pregnancy and induction of labour in 
pregnant female mammals and in the treatment of impaired fertility, in the 
control of oestrus, contraception and menstrual regulation in female 
mammals. For example, in standard laboratory tests (i) by intravenous 
administration to the allobarbital-anaesthetized dog, 
16.xi.-chloro-PGE.sub.2 methyl ester products falls in blood pressure of 
20 mm.Hg and 30 mm.Hg lasting 8 and 16 minutes at the doses of 0.2 and 0.5 
.mu.g./kg. animal body weight, respectively, 16.xi.-chloro-PGE.sub.1 
methyl ester produces falls in blood pressure of 20 mm.Hg and 36 mm.Hg 
lasting 28 and 59 minutes at the doses of 0.2 and 0.5 .mu.g./kg. animal 
body weight, respectively, 16.xi.-chloro-13,14-dihydro-PGE.sub.1 methyl 
ester produces falls in blood pressure of 26 mm.Hg, 30 mm.Hg and 44 mm.Hg 
lasting 20, 22 and 23 minutes at the doses of 0.2, 0.5 and 1.0 .mu.g./kg. 
animal body weight, respectively, 16.xi.-chloro-15-epi-PGE.sub.2 methyl 
ester produces falls in blood pressure of 24 mm.Hg and 60 mm.Hg lasting 14 
and 44 minutes at the doses of 5 and 10 .mu.g./kg. animal body weight, 
respectively, 16.xi.-chloro-11-epi-PGE.sub.1 methyl ester produces falls 
in blood pressure of 24 mm.Hg and 50 mm.Hg lasting 16 and 30 minutes at 
the doses of 10 and 20 .mu.g./kg. animal body weight, respectively, 
16.xi.-chloro-PGE.sub.2 alcohol produces falls in blood pressure of 20 
mm.Hg and 26 mm.Hg lasting 50 and 52 minutes at the doses of 2 and 5 
.mu.g./kg. animal body weight, respectively, 
15.xi.-methyl-16.xi.-chloro-PGE.sub.1 methyl ester produces falls in 
blood pressure of 12 mm.Hg, 26 mm.Hg and 38 mm.Hg lasting 16, 34 and 37 
minutes at the doses of 2, 5 and 10 .mu.g./kg. animal body weight, 
respectively, 16.xi.-chloro-16-methyl-PGE.sub.1 methyl ester produces 
falls in blood pressure of 16 mm.Hg and 24 mm.Hg lasting 24 and 43 minutes 
at the doses of 1 and 2 .mu.g./kg. animal body weight, respectively, and 
16.xi.-chloro-trans-.DELTA..sup.2 -PGE.sub.1 methyl ester produces falls 
in blood pressure of 18 mm.Hg and 38 mm.Hg lasting 16 and 26 minutes at 
the doses of 0.2 and 0.5 .mu.g./kg. animal body weight, respectively; (ii) 
by oral administration to the conscious spontaneously hypertensive rat, 
16.xi.-chloro-PGE.sub.2 methyl ester produces falls in blood pressure of 
54 mm.Hg, 37 mm.Hg and 29 mm.Hg at 0.5, 1.0 and 3.0 hours after 
administration, respectively, at the dose of 0.1 mg./kg. animal body 
weight, 16.xi.-chloro-PGE.sub.1 methyl ester produces falls in blood 
pressure of 38 mm.Hg, 16 mm.Hg and 12 mm.Hg at 0.5, 1.0 and 3.0 hours 
after administration, respectively, at the dose of 0.1 mg./kg. animal body 
weight, 16.xi.-chloro-13,14-dihydro-PGE.sub.1 methyl ester produces falls 
in blood pressure of 39 mm.Hg, 32 mm.Hg and 26 mm.Hg at 0.5, 1.0 and 3.0 
hours after administration, respectively, at the dose of 1.0 mg./kg. 
animal body weight, 16.xi.-chloro-16-methyl-PGE.sub.1 methyl ester 
produces falls in blood pressure of 33 mm.Hg, 20 mm.Hg and 28 mm.Hg at 
0.5, 1.0 and 3.0 hours after administration, respectively, at the dose of 
0.1 mg./kg. animal body weight and 16.xi.-chloro-trans-.DELTA..sup.2 
-PGE.sub.1 methyl ester produces falls in blood pressure of 37 mm.Hg, 27 
mm.Hg and 18 mm.Hg at 0.5, 1.0 and 3.0 hours after administration, 
respectively, at the dose of 0.1 mg./kg. animal body weight; (iii) 
16.xi.-chloro-PGE.sub.1 methyl ester produces a 50% inhibition of 
adenosine diphosphate-induced blood platelet aggregation in platelet-rich 
plasma of rats at the concentration of 5.6 .times. 10.sup.-2 .mu.g./ml. in 
comparison with controls, 16.xi.-chloro-13,14-dihydro-PGE.sub.1 methyl 
ester produces a 50% inhibition of adenosine diphosphate-induced blood 
platelet aggregation in platelet-rich plasma of rats at the concentration 
of 7.4 .times. 10.sup.-2 .mu.g./ml. in comparison with controls and 
16.xi.-chloro-trans-.DELTA..sup.2 -PGE.sub.1 methyl ester produces a 50% 
inhibition of adenosine diphosphate-induced blood platelet aggregation in 
platelet-rich plasma of rats at the concentration of 2.2 .times. 10.sup.-2 
.mu.g./ml. in comparison with controls; (iv) in stress ulceration of rats 
[produced according to the method of Takagi and Okabe - Jap. J. Pharmac., 
18, 9-18 (1968) by soaking rats in a water bath at 19.degree. C. for 6 
hours], 16.xi.-chloro-PGE.sub.2 methyl ester produces 64.8% and 80.7% 
inhibitions of stress ulceration of oral administration at the doses of 10 
and 20 .mu.g./kg. animal body weight, respectively, 
16.xi.-chloro-PGE.sub.1 methyl ester produces 84.9% inhibition of stress 
ulceration by oral administration at the dose of 50 .mu.g./kg. animal body 
weight, 16.xi.-chloro-13,14-dihydro-PGE.sub.1 methyl ester produces 36.9% 
inhibition of stress ulceration by oral administration at the dose of 100 
.mu.g./kg. animal body weight, 16.xi.-chloro-PGE.sub.2 alcohol produces 
70.1% inhibition of stress ulceration by oral administration at the dose 
of 50 .mu.g./kg. animal body weight, 15.xi.-methyl-16.xi.-chloro-PGE.sub.1 
methyl ester produces 44.0% and 62.1% inhibitions of stress ulceration by 
oral administration at the doses of 100 and 200 .mu.g./kg. animal body 
weight, respectively, 16.xi.-chloro-16-methyl-PGE.sub.1 methyl ester 
produces 81.3% inhibition of stress ulceration by oral administration at 
the dose of 200 .mu.g./kg. animal body weight, 
16.xi.-chlorotrans-.DELTA..sup.2 -PGE.sub.1 methyl ester produces 62.3% 
inhibition of stress ulceration of oral administration at the dose of 200 
.mu.g./kg. animal body weight, 16.xi. -chloro-20-hydroxy-PGE.sub.1 methyl 
ester produces 52.5% and 53.3% inhibitions of stress ulceration by oral 
administration at the doses of 100 and 200 .mu.g./kg. animal body weight, 
respectively, and 16.xi.,20-dichloro-PGE.sub.1 methyl ester produces 55.4% 
and 87.9% inhibitions of stress ulceration by oral administration at the 
doses of 100 and 200 .mu.g./kg. animal body weight, respectively; (v) 
16.xi.-chloro-PGE.sub.2 methyl ester, 
15.xi.-methyl-16.xi.-chloro-PGE.sub.1 methyl ester and 
16.xi.-chloro-16-methyl-PGE.sub.1 methyl ester produce an increase in 
gastric acid pH from 2.0-2.5 to at least 4.0 in 50% of 
pentagastrin-treated rats when perfused into the stomach at the rates of 
0.11, .gtoreq.1 and &lt;1 .mu.g./animal/minute, respectively; (vi) 
16.xi.-chloro-PGF.sub.2.alpha. methyl ester, 16.xi.-chloro-PGE.sub.2 
methyl ester, 16.xi.-chloro-PGE.sub.1 methyl ester, 
16.xi.-chloro-13,14-dihydro-PGE.sub.1 methyl ester, 
16.xi.-chloro-15-epi-PGE.sub.2 methyl ester, 
16.xi.-chloro-11-epi-PGE.sub.1 methyl ester, 16.xi.-chloro-PGE.sub.2 
alcohol, 15.xi.-methyl-16.xi.-chloro-PGE.sub.1 methyl ester, 
16.xi.-chloro-16-methyl-PGE.sub.1 methyl ester, 
16.xi.-chlorotrans-.DELTA..sup.2 -PGE.sub.1 methyl ester, 
16.xi.-chloro-20-hydroxy-PGE.sub.1 methyl ester and 
16.xi.,20-dichloro-PGE.sub.1 methyl ester stimulate uterine contraction in 
the pregnant female rat when administered intravenously on the 20th day of 
gestation at the doses of 5-10, 2, 1, 5-10, 10-20, 10-20, 1-2, 1, 0.2- 
0.5, 5, 1-2 and 1-2.mu.g./kg. animal body weight, respectively, and (vii) 
16.xi.-chloro-PGF.sub.2.alpha. methyl ester inhibits implantation in 
pregnant female rats when administered subcutaneously on the 3rd, 4th and 
5th days of pregnancy at the daily dose of 0.20 mg./kg. animal body 
weight. 
The prostaglandin analogues of the present invention, their cyclodextrin 
clathrates and non-toxic salts can cause diarrhoea, the doses by oral 
administration of 16.xi.-chloro-PGF.sub.2.alpha. methyl ester, 
16.xi.-chloro-PGE.sub.2 methyl ester, 16.xi.-chloro-PGE.sub.1 methyl 
ester, 16.xi.-chloro-13,14-dihydro-PGE.sub.1 methyl ester, 
16.xi.-chloro-15-epi-PGE.sub.2 methyl ester, 
16.xi.-chloro-11-epi-PGE.sub.1 methyl ester, 16.xi.-chloro-PGE.sub.2 
alcohol, 15.xi.-methyl-16.xi.-chloro-PGE.sub.1 methyl ester, 
16.xi.-chloro-16-methyl-PGE.sub.1 methyl ester, 
16.xi.-chloro-trans-.DELTA..sup.2 -PGE.sub.1 methyl ester, 
16.xi.-chloro-20-hydroxy-PGE.sub.1 methyl ester and 
16.xi.,20-dichloro-PGE.sub.1 methyl ester required to produce diarrhoea in 
50% of mice so treated are &lt;0.5, 0.09, 0.20, 0.9, 7.2, 5-10, 0.046, 
0.2-0.4, 0.22, 0.09, 2.0 and 0.65 mg./kg. animal body weight, 
respectively. 
The following Reference Examples and Examples illustrate the preparation of 
new prostaglandin analogues of the present invention. In them `IR`, `NMR` 
and `TLC` represent respectively `Infrared absorption spectrum` `Nuclear 
magnetic resonance spectrum` and `Thin layer chromatography`. Where 
solvent ratios are specified in chromatographic separations and otherwise 
the ratios are by volume. 
REFERENCE EXAMPLE 1 
15-Oxo-PGE.sub.2.alpha. methyl ester 
100 g. of active manganese dioxide were added to a solution of 15.47 g. of 
PGF.sub.2.alpha. methyl ester in 700 ml. of methylene chloride, and the 
mixture was stirred at room temperature for 2 hours and then filtered. The 
precipitate was washed thoroughly with ethyl acetate, and the filtrate and 
washing were combined and concentrated under reduced pressure. The residue 
was purified by column chromatography on silica gel using a mixture of 
benzene and ethyl acetate (2:1) as eluent to give 8.8 g. of the title 
compound having the following physical characteristics:- 
Tlc (developing solvent, benzene-ethyl acetate = 1:2): 
Rf = 0.44; 
Ir (liquid film):.nu.; 1740, 1695, 1670, 1624, 1436, 1240, 980 cm.sup.-1 ; 
Nmr (cdcl.sub.3 solution): .delta.; 6.89-6.53 (1H, d--d), 6.34-6.08 (1H, 
d), 5.53-5.32 (2H, m), 4.36-3.93 (2H, m), 3.66 (3H, s). 
REFERENCED EXAMPLE 2 
Methyl 
9.alpha.,11.alpha.-bis(2-tetrahydropyranoyloxy)-15-oxoprosta-cis-5,trans-1 
3-dienoate 
A catalytic amount of p-toluenesulphonic acid and 10 ml. of 
2,3-dihydropyran were added to a solution of 2.527 g. of 
15-oxo-PGF.sub.2.alpha. methyl ester (prepared as described in Reference 
Example 1) in 50 ml. of methylene chloride and the reaction mixture was 
stirred at room temperature for 15 minutes and then diluted with 100 ml. 
of ethyl acetate. The mixture was washed with an aqueous sodium 
bicarbonate solution and an aqueous sodium chloride solution, dried over 
sodium sulphate and concentrated under reduced pressure. The residue was 
purified by column chromatography on silica gel using a mixture of benzene 
and ethyl acetate (10:1) as eluent to give 3.136 g. of the title compound 
having the following physical characteristics:- 
Tlc (developing solvent, benzene-ethyl acetate = 1:1): 
Rf = 0.61; 
Ir (liquid film):.nu.; 1740, 1695, 1670, 1624, 1436, 1350, 1138, 1080, 
1030, 990, 873 cm.sup.-1 ; 
Nmr (cdcl.sub.3 solution): .delta.; 6.9-6.48 (1H, m), 6.18 (1H, d--d), 
5.58-5.25 (2H, m), 4.78-4.45 (2H, m), 4.29-3.3 (6H, m), 3.66 (3H, s), 2.54 
(2H, t), 2.31 (2H, t). 
REFERENCE EXAMPLE 3 
Methyl 
9.alpha.,11.alpha.-bis(2-tetrahydropyranyloxy)-15-trimethylsilyloxyprosta- 
cis-5,trans-13,cis(or trans)-15-trienoate 
70 ml. of 0.15M lithium diisopropylamide solution in a mixture of 
tetrahydrofuran and diethyl ether (4:3) were added dropwise over a period 
of 3 hours to a solution of 4.272 g. of methyl 
9.alpha.,11.alpha.-bis(2-tetrahydropyranyloxy)-15-oxoprosta-cis-5,trans-13 
-dienoate (prepared as described in Reference Example 2) in 17 ml. of dry 
tetrahydrofuran at -78.degree. C. under an atmosphere of nitrogen, and the 
reaction mixture was stirred at the same temperature for 30 minutes. To 
the reaction mixture thus obtained, there was added dropwise over a period 
of 15 minutes of 8.16 g. of trimethylchlorosilane and 2.02 g. of 
triethylamine in 30 ml. of dry diethyl ether with stirring and the 
reaction mixture was stirred at room temperature for 20 minutes, and then 
concentrated under reduced pressure. The residue was purified by column 
chromatography on silica gel using a mixture of cyclohexane and ethyl 
acetate (10:1) as eluent to give 1.227 g. of the title compound having the 
following physical characteristics:- 
Tlc (developing solvent, benzene-ethyl acetate = 5:1): 
Rf = 0.47; 
Ir (liquid film):.nu.; 1741, 1660-1610, 1255, 1140, 1025, 845 cm.sup.-1 ; 
Nmr (cdcl.sub.3 solution): .delta.; 5.78-5.13 (4H, m), 4.9-4.35 (3H, m), 
4.35-3.26 (6H, m), 3.65 (3H, s), 2.3 (3H, t), 0.21-0.05 (9H, m). 
REFERENCE EXAMPLE 4 
Methyl 
9.alpha.,11.alpha.-bis(2-tetrahydropyranyloxy)-15-oxo-16.xi.-chloroprosta- 
cis-5,trans-13-dienoate 
63 mg. of N-chlorosuccinimide were added portionwise to a solution of 248 
mg. of methyl 
9.alpha.,11.alpha.-bis(2-tetrahydropyranyloxy)-15-trimethylsilyloxyprostac 
is-5,trans-13-cis(or trans)-15-trienoate (prepared as described in 
Reference Example 3) in 3 ml of tetrahydrofuran at -78.degree. C., and the 
mixture was stirred at the same temperatue for 30 minutes. The reaction 
mixture was then diluted with 50 ml. of ethyl acetate, washed with 1N 
hydrochloric acid, an aqueous sodium bicarbonate solution and an aqueous 
sodium chloride solution, dried over sodium sulphate and concentrated 
under reduced pressure. The residue was purified by column chromatography 
on silica gel using a mixture of benzene and ethyl acetate (15:1) as 
eluent to give 128 mg. of the title compound having the following physical 
characteristics: 
Tlc (developing solvent, benzene-ethyl acetate = 5:1):- 
Rf = 0.41; 
Ir (liquid film):.nu.; 1740, 1695, 1680, 1622, 1438, 1356, 1140, 1085, 
1038, 995, 880 cm.sup.-1 ; 
Nmr (cdcl.sub.3 solution): .delta.; 7.3-6.7 (1H, m), 6.5 (1H, d--d), 
5.55-5.15 (2H, m), 4.8-4.9 (2H, m), 4.4-3.2 (7H, m), 3.62 (3H, s), 2.3 
(2H, t).

EXAMPLE 1 
Methyl 
9.alpha.,11.alpha.-bis(2-tetrahydropyranyloxy)-15.xi.-hydroxy-16.xi.-chlor 
oprosta-cis-5,trans-13-dienoate 
54.7 mg. of sodium borohydride were added to a solution of 546 mg. of 
methyl 9.alpha.,11.alpha.-bis(2-tetrahydropyranyloxy)-15-oxo-16.xi.-chloro 
prosta-cis-5,trans-13-dienoate (prepared as described in Reference Example 
4) in 15 ml. of methanol at -30.degree. C., and the mixture was stirred at 
the same temperature for 1 hour. The reaction mixture was then diluted 
with 50 ml. of ethyl acetate, washed with a dilute aqueous hydrochloric 
acid solution, an aqueous sodium bicarbonate solution and an aqueous 
sodium chloride solution, dried over sodium sulphate and concentrated 
under reduced pressure to give 604 mg. of the title compound having the 
following physical characteristic:- 
Tcl (developing solvent, benzene-ethyl acetate = 2:1): 
Rf = 0.53 and Rf = 0.61. 
EXAMPLE 2 
Methyl 
9.alpha.,11.alpha.,15.alpha.-trihydroxy-16.xi.-chloroprosta-cis-5,trans-13 
-dienoate [or 16.xi.-chloro-PGF.sub.2.alpha. methyl ester] 
604 mg. of methyl 
9.alpha.,11.alpha.-bis(2-tetrahydropyranyloxy)-15.xi.-hydroxy-16.xi.-chlor 
oprosta-cis-5,trans-13-dienoate (prepared as described in Example 1) were 
dissolved in a mixture of 1.26 ml. of tetrahydrofuran and 12.6 ml. of a 
65% acetic acid aqueous solution and the reaction mixture was stirred at 
60.degree. C. for 30 minutes and then concentrated under reduced pressure. 
The residue was purified by column chromatography on silica gel using a 
mixture of cyclohexane and ethyl acetate (1:1) as eluent to give 226 mg. 
of the title compound and 102 mg. of its 15.beta.-hydroxy isomer having 
the following physical characteristics:- 
Tlc (developing solvent, ethyl acetate): Rf = 0.3; 
(15.beta.-hydroxy isomer, Rf = 0.4); 
Ir (liquid film): .nu.; 3360, 1740, 1435, 1375, 1247, 1055, 980 cm.sup.-1 ; 
Nmr (cdcl.sub.3 solution): .delta.; 5.75-5.52 (2H, m), 5.52-5.2 (2H, m), 
4.3-4.04 (1H, m), 4.04-3.5 (3H, m), 3.67 (3H, s), 2.33 (2H, t). 
REFERENCE EXAMPLE 5 
Methyl 
9.alpha.-hydroxy-11.alpha.,15.alpha.-bis(trimethylsilyloxy)-16.xi.-chlorop 
rosta-cis-5,trans-13-dienoate 
1.24 ml. of trimethylsilyldiethylamine were added to a solution of 260 mg. 
of 16.xi.-chloro-PGF.sub.2.alpha. methyl ester (prepared as described in 
Example 2) in 3.3 ml. of dry acetone at 0.degree. C. and the reaction 
mixture was stirred at the same temperature for 1.5 hours, and then 
concentrated under reduced pressure to give 350 mg. of the title compound 
having the following physical characteristics: 
TLC (developing solvent, cyclohexane-ethyl acetate = 3:1): Rf =0.4. 
EXAMPLE 3 
Methyl 
9-oxo-11.alpha.,15.alpha.-bis(trimethylsilyloxy)-16.xi.-chloroprosta-cis-5 
,trans-13-dienoate 
Under an atmosphere of nitrogeh, 0.26 ml. of dimethyl sulphide were added 
to a solution of 393 mg. of N-chlorosuccinimide in 10 ml. of dry toluene 
and the reaction mixture was cooled to -26.degree. C. There was then added 
a solution of 350 mg. of methyl 
9.alpha.-hydroxy-11.alpha.,15.alpha.-bis(trimethylsilyloxy)-16.xi.-chlorop 
rosta-cis-5,trans-13-dienoate (prepared as described in Reference Example 
5) in 2 ml. of dry toluene. After stirring at the same temperature for 2 
hours, a solution of 0.83 ml. of triethylamine in 1 ml. of dry pentane was 
added and the mixture stirred at -15.degree. C., for 15 minutes, and then 
at room temperature for 15 minutes. The reaction mixture was extracted 
with diethyl ether. The organic solution was washed with a dilute aqueous 
hydrochloric acid solution, an aqueous sodium bicarbonate solution and an 
aqueous sodium chloride solution, dried over sodium sulphate and 
concentrated under reduced pressure to give 327 mg. of the title compound 
having the following physical characteristic: 
TLC (developing solvent, cyclohexane-ethyl acetate = 3:1): Rf = 0.46. 
EXAMPLE 4 
Methyl 
9-oxo-11.alpha.,15.alpha.-dihydroxy-16.xi.-chloroprosta-cis-5,trans-13-die 
noate [or 16.xi.-chloro-PGE.sub.2 methyl ester] 
2 ml. of a saturated aqueous oxalic acid solution were added to a solution 
of 327 mg. of methyl 
9-oxo-11.alpha.,15.alpha.-bis(trimethylsilyloxy)-16.xi.-chloroprosta-cis-5 
,trans-13-dienoate (prepared as described in Example 3) in 10 ml. of ethyl 
acetate. After stirring for 2 hours at room temperature, the reaction 
mixture was diluted with 50 ml. of ethyl acetate, washed with an aqueous 
sodium bicarbonate solution, water and an aqueous sodium chloride 
solution, dried over sodium sulphate and concentrated under reduced 
pressure. The residue was purified by column chromatography on silica gel 
using a mixture of cyclohexane and ethyl acetate (7:5) as eluent to give 
83 mg. of the title compound having the following physical 
characteristics: 
TLC (developing solvent, ethyl acetate): Rf = 0.41; 
IR (liquid film): .nu.; 3360, 1740, 1720, 1420, 1240, 1180, 1095, 980 
cm.sup.-1 ; 
NMR (CDC.sub.3 solution): .delta.; 5.72-5.61 (2H, m), 5.40-5.20 (2H, m), 
4.45-3.75 (3H, m), 3.66 (3H, s), 2.76 (2H,d--d). 
REFERENCE EXAMPLE 6 
Methyl 
9.alpha.-acetoxy-11.alpha.-(2-tetrahydropyranyloxy)-15-oxo-prosta-cis-5,tr 
ans-13-dienoate 
457 mg. of sodium hydride (63% content) were suspended in 150 ml. of 
anhydrous tetrahydrofuran. With stirring under an atmosphere of nitrogen, 
2.89 g. of dimethyl 2-oxo-heptylphosphonate in 7 ml. of anhydrous 
tetrahydrofuran were added dropwise to the suspension and the mixture was 
stirred at room temperature for 30 minutes until the solution became 
clear. 3.96 g. of 
1.alpha.-acetoxy-2.alpha.-(6-methoxycarbonylhex-cis-2-enyl)-3.beta.-formyl 
-4.alpha.-(2-tetrahydropyranyloxy)-cyclopentane (prepared as described 
hereafter) in 30 ml. of anhydrous tetrahydrofuran were added and the 
reaction mixture was stirred at room temperature for 2 hours. The reaction 
mixture was then neutralized with acetic acid. The mixture was filtered 
through a pad of silica gel, and the filtrate was concentrated under 
reduced pressure. The residue was purified by column chromatography on 
silica gel using a mixture of benzene and ethyl acetate (20:1) as eluent 
to give 4.15 g. of the title compound having the following physical 
characteristics: 
TLC (developing solvent, benzene-ethyl acetate = 2:1): 
Rf = 0.48; 
IR (liquid film):.nu.; 1740, 1695, 1670, 1625 cm.sup.-1 ; 
NMR (CDCl.sub.3 solution): .delta.; 6.70 and 6.44 (1H, d--d), 5.99 (1H, d), 
5.50-5.05 (2H, m), 5.05-4.70 (1H, m), 4.60-4.20 (1H, m), 3.53 (3H, s), 
2.00 (3H, s). 
1.alpha.-Acetoxy-2.alpha.-(6-methoxycarbonylhex-cis-2-enyl)-3.beta.-formyl- 
4.alpha.-(2-tetrahydropyranyloxy)cyclopentane, used as a starting material 
in the above procedure, was prepared from 
2-oxa-3-oxo-6-syn-hydroxymethyl-7-anti-acetoxy-cis-bicyclo[3,3,0]octane 
[prepared as described by E. J. Corey et al., J. Amer. Chem. Soc., 92, 397 
(1970)] as follows: 
190 g. of 
2-oxa-3-oxo-6-syn-hydroxymethyl-7-anti-acetoxy-cis-bicyclo[3,3,0]octane in 
1.5 liters of absolute methanol and 130 g. of potassium hydroxide were 
stirred at room temperature for one hour, and then successively cooled in 
an ice-bath, and neutralized with hydrochloric acid. The precipitate was 
filtered off and the filtrate was concentrated under reduced pressure. The 
residue was washed with ethanol, and then with ethyl acetate, and dried to 
give 124 g. of 
2-oxa-3-oxo-6-syn-hydroxymethyl-7-anti-hydroxy-cis-bicyclo[3,3,0]octane as 
white crystallites having the following physical characteristics: 
m.p. 119.degree. C.; 
IR (KBr tablet): .nu.; 3350, 2970-2880, 1740, 1480, 1440, 1410, 1380, 1335, 
1305, 1270, 1205, 1100, 1080, 1060, 1040, 1020, 1000 and 975 cm.sup.-1 ; 
NMR (in CDCl.sub.3 + deutero dimethyl sulphoxide solution): .delta.; 
5.10-4.60 (1H, m), 4.29 (2H, s), 4.13-3.77 (1H, m), and 3.38 (2H, d); 
TLC (developing solvent, methylene chloride - methanol = 20:1): Rf = 0.27. 
124 g. of 
2-oxa-3-oxo-6-syn-hydroxymethyl-7-anti-hydroxy-cis-bicyclo[3,3,0]octane 
obtained above were dissolved in absolute pyridine (1.4 liters) and cooled 
to -40.degree. C. 74 g. of acetic anhydride were added dropwise and the 
mixture stirred for 5 hours at -40.degree. to -20.degree. C. and then for 
16 hours at 0.degree. C. The pyridine was evaporated off under reduced 
pressure and the residue was dissolved in 1 liter of ethyl acetate. 200 g. 
of sodium bisulphate were added, stirred vigorously and filtered. The 
filtrate was concentrated under reduced pressure and the residue was 
purified by column chromatography on silica gel using a benzene-ethyl 
acetate mixture (1:3) as eluent to give 112 g. of 
2-oxa-3-oxo-6-syn-acetoxymethyl-7-anti-hydroxy-cis-bicyclo[3,3,0]octane as 
colourless needles having the following physical characteristics: 
m.p. 36.degree. to 37.degree. C.; 
IR (KBr tablet): .nu.; 3450, 2960, 2850, 1775, 1740, 1420, 1370, 1250, 
1190, 1120, 1090, 1040 and 980 cm.sup.-1 ; 
NMR (in CDCl.sub.3 solution): .delta.; 5.15-4.60 (1H, m), 4.3-3.75 (3H, m), 
3.50 (1H, s) and 2.02 (3H, s); 
TLC (developing solvent, methylene chloride - methanol = 20:1): Rf = 0.50. 
43 g. of 
2-oxa-3-oxo-6-syn-acetoxymethyl-7-anti-hydroxy-cis-bicyclo[3,3,0]octane, 
obtained as described above, were dissolved in 520 ml. of methylene 
chloride, 25 g. of 2,3-dihydropyran and 0.52 g. of p-toluenesulphonic acid 
were added and the mixture was stirred for 20 minutes at room temperature. 
The reaction mixture was then neutralized with an aqueous solution of 
sodium bicarbonate, diluted with ethyl acetate, washed with water, dried 
and concentrated under reduced pressure to give 56 g. of 
2-oxa-3-oxo-6-syn-acetoxymethyl-7-anti-(2-tetrahydropyranyloxy)-cis-bicycl 
o[3,3,0]octane as a colourless oil having the following physical 
characteristics: 
IR (liquid film): .nu.; 2950-2840, 1775, 1740, 1465, 1440, 1390-1340, 1240, 
1180, 1140-1120, 1080, 1040 and 980 cm.sup.-1 ; 
NMR (in CDCl.sub.3 solution): .delta.; 5.2-4.72 (1H, m), 4.72-4.30 (1H, m), 
4.2-3.2 (5H, m) and 2.01 (3H, s); 
TLC (developing solvent, methylene chloride - methanol = 20:1): Rf = 0.74. 
56 g. of the acetyl ether, prepared as described above, were dissolved in 
900 ml. of toluene and cooled to -60.degree. C. 456 ml. of a 25(w/v)% 
toluene solution of diisobutylaluminium hydride were added and the mixture 
stirred for 20 minutes at the same temperature; aqueous methanol was added 
in order to decompose the excess of diisobutylaluminium hydride. The 
resulting precipitate was filtered off and the filtrate was dried and 
concentrated under reduced pressure to give 35.2 g. of 
2-oxa-3-hydroxy-6-syn-hydroxymethyl-7-anti-(2-tetrahydropyranyloxy)-cis-bi 
cyclo[3,3,0]octane as a colourless oil having the following physical 
characteristics: 
IR (liquid film): .nu.; 3400, 2940-2860, 1465-1440, 1380, 1355, 1325, 1260, 
1200, 1140, 1120, 1075 and 1020 cm.sup.-1 ; 
TLC (developing solvent, ethyl acetate): Rf = 0.25. 
37.6 g. of sodium hydride (content 63.5%) were suspended in 400 ml. of 
dimethyl sulphoxide and stirred at 70.degree. C. for 1.5 hours to obtain 
sodium methylsulphinylmethylide. The reaction mixture was allowed to cool 
to room temperature and then added dropwise to a solution of 226 g. of 
(4-carboxybutyl)triphenylphosphonium bromide in 460 ml. of dimethyl 
sulphoxide, the reaction temperature being kept within the range of 
20.degree. to 25.degree. C. 
A solution of 35.2 g. of 
2-oxa-3-hydroxy-6-syn-hydroxymethyl-7-anti-(2-tetrahydropyranyloxy)-cis-bi 
cyclo-[3,3,0]octane, prepared as described above, in 90 ml. of dimethyl 
sulphoxide was added to the above reaction mixture and stirred at 
35.degree. to 40.degree. C. for 1.5 hours. The reaction mixture was poured 
into 6 liters of ice-water and the neutral substances were removed by 
extraction with an ethyl acetate-diethyl ether mixture (1:1). The aqueous 
layer was acidified to pH 2 with saturated aqueous oxalic acid solution 
and extracted with a diethyl ether-n-pentane mixture (1:1). The organic 
layer was washed with water, dried over sodium sulphate and concentrated 
under reduced pressure. The residue was subjected to column chromatography 
on silica gel using a benzene-methanol mixture (10:1) as eluent to give 35 
g. of 
2.alpha.-(6-carboxyhex-cis-2-enyl)-3.beta.-hydroxymethyl-4.alpha.-(2-tetra 
hydropyranyloxy)cyclopentan-1.alpha.-ol as a colourless oil having the 
following physical characteristics: 
IR (liquid film): .nu.; 3400, 2940-2860, 2300, 1710, 1450, 1435, 1400, 
1355, 1245, 1200, 1140, 1120, 1075 and 1025 cm.sup.-1 ; 
NMR (in CDCl.sub.3 solution): .delta.; 6.20 (3H, s), 5.50-5.10 (2H, m), 
4.75-4.36 (1H, m), 4.24-3.85 (2H, m) and 3.85-3.0 (4H, m); 
TLC (developing solvent, chloroform - tetrahydrofuran - acetic acid = 
10:2:1): Rf = 0.53. 
To a solution of 18.8 g. of 
2.alpha.-(6-carboxyhex-cis-2-enyl)-3.beta.-hydroxymethyl-4.alpha.-(2-tetra 
hydropyranyloxy)-cyclopentan-1.alpha.-ol, obtained as described above, in 
130 ml. of diethyl ether, a freshly prepared ethereal solution of 
diazomethane was added with cooling in an ice-bath until the reaction 
mixture showed a pale yellow colour. The reaction mixture was concentrated 
in vacuo, and the residue was subjected to column chromatography on silica 
gel using a cyclohexan-ethyl acetate mixture (2:1) as eluent to give 15.4 
g. of 
2.alpha.-(6-methoxycarbonylhex-cis-2-enyl)-3.beta.-hydroxymethyl-4.alpha.- 
(2-tetrahydropyranyloxy)cyclopentan- 1.alpha.-ol as a colourless oil having 
the following physical characteristics: 
IR (liquid film): .nu.; 3450, 2950, 2870, 1740, 1440, 1360, 1325, 1250, 
1200, 1140, 1120, 1080 and 1025 cm.sup.- 1 ; 
NMR (in CDCl.sub.3 solution): .delta.; 5.55-5.00 (2H, m), 4.78-4.30 (1H, 
m), 4.20-3.06 (6H, m), 3.55 (3H, s) and 2.97 (2H, s); 
TLC (developing solvent, methylene chloride - methanol = 19:1): Rf = 0.43. 
13.1 g. of 
2.alpha.-(6-methoxycarbonylhex-cis-2-enyl)-3.beta.-hydroxymethyl-4.alpha.- 
(2-tetrahydropyranyloxy)cyclopentan-1.alpha.-ol, obtained as described 
above, were dissolved in 250 ml. of absolute methylene chloride, and 25 
ml. of pyridine were added. The air in the apparatus was replaced with 
nitrogen and the contents cooled to -20.degree. C. To the reaction mixture 
was added dropwise a solution of 5.1 ml. of trimethylchlorosilane in 30 
ml. of methylene chloride with stirring and the mixture was stirred at the 
same temperature for 30 minutes. A sample of the product thus obtained had 
the following physical characteristic: 
TLC (developing solvent, benzene - ethyl acetate = 2:1): Rf = 0.61. 
A solution of 2.9 ml. of acetyl chloride in 20 ml. of methylene chloride 
was added dropwise to the above reaction mixture and stirred at room 
temperature for 30 minutes. Then 2 ml. of ethanol were added to decompose 
the excess of acetyl chloride. Pyridine in the reaction mixture was 
neutralized by the addition of 50 g. of sodium bisulphate, and the 
resulting precipitate was filtered off. The filtrate was concentrated 
under reduced pressure to give a residue having the following physical 
characteristic: 
TLC (developing solvent, benzene - ethyl acetate = 2:1): Rf = 0.82. 
The residue was dissolved in 300 ml. of ethyl acetate, 100 ml. of aqueous 
oxalic acid solution were added and the mixture was stirred vigorously at 
room temperature. The organic layer was separated, washed successively 
with water, aqueous sodium bisulphate solution, water and an aqueous 
sodium chloride solution, dried over sodium sulphate and concentrated 
under reduced pressure to give 13.7 g. of crude product. The crude product 
was subjected to column chromatography on silica gel using a benzene-ethyl 
acetate mixture (3:1) as eluent to give 7.45 g. of 
1.alpha.-acetoxy-2.alpha.-(6-methoxycarbonylhex-cis-2-enyl)-3.beta.-hydrox 
ymethyl-4.alpha.-(2-tetrahydropyranyloxy)-cyclopentane, 2.40 g. of 
1.alpha.-hydroxy-2.alpha.-(6-methoxycarbonylhex-cis-2-enyl)-3.beta.-hydrox 
ymethyl-4.alpha.-(2-tetrahydropyranyloxy)-cyclopentane, 720 mg. of 
1.alpha.-acetoxy-2.alpha.-(6-methoxycarbonylhex-cis-2-enyl)-3.beta.-acetox 
ymethyl-4.alpha.-(2-tetrahydropyranyloxy)cyclopentane, and 1.45 g. of 
1.alpha.-acetoxy-2.alpha.-(6-methoxycarbonylhex-cis-2-enyl)-3.beta.-acetox 
ymethyl-4.alpha.-(2-tetrahydropyranyloxy)cyclopentane. 
1.alpha.-Acetoxy-2.alpha.-(6-methoxycarbonylhex-cis-2-enyl)-3.beta.-hydroxy 
methyl-4.alpha.-(2-tetrahydropyranyloxy)cyclopentane had the following 
physical characteristic: 
IR (liquid film): .nu.; 3450, 3000, 2950, 2870, 1740, 1440, 1380, 1330, 
1250, 1200, 1160, 1140, 1080, 1030, 980, 920, 875 and 815 cm.sup.-1 ; 
NMR (in CDCl.sub.3 solution): .delta.; 5.45-5.27 (2H, m), 5.16-4.92 (1H, 
m), 4.76-4.46 (1H, m), 4.27-3.96 (1H, m), 3.67 (3H, s), 2.98-2.64 (1H, m) 
and 2.05 (3H, s); 
TLC (developing solvent, benzene-ethyl acetate = 2:1): Rf = 0.27. 
Under an atmosphere of nitrogen, 4.4 ml. of pyridine were dissolved in 80 
ml. of methylene chloride, 2.88 g. of chromium trioxide were added with 
stirring and the mixture was then stirred for 15 minutes. 12 g. of 
infusorial earth were added to the reaction mixture, and then there was 
added a solution of 956 mg. of 
1.alpha.-acetoxy-2.alpha.-(6-methoxycarbonylhex-cis-2enyl)-2.beta.-hydroxy 
methyl-4.alpha.-(2-tetrahydropyranyloxy)cyclopentane (prepared as described 
above) in 20 ml. of methylene chloride. After stirring for 10 minutes, 20 
g. of sodium bisulphate were added to the reaction mixture and stirring 
was continued for a further 10 minutes. The resulting precipitate was 
filtered off and the filtrate was concentrated under reduced pressure. The 
residue was subjected to silica gel column chromatography using a 
benzene-ethyl acetate mixture (5:1) as eluent to give 768 mg. of 
1.alpha.-acetoxy-2.alpha.-(6-methoxycarbonylhex-cis-2-enyl)-3.beta.-formyl 
-4.alpha.-(2-tetrahydropyranyloxy)cyclopentane as a colourless oil having 
the following physical characteristics: 
Ir (liquid film) .nu.; 3000, 2950, 2860, 2725, 2740, 1440, 1380, 1325, 
1255, 1200, 1165, 1140, 1085, 1030, 980, 920, 880 and 820 cm.sup.-1 ; 
Nmr (in CDCl.sub.3 solution): .delta.; 9.85-9.68 (1H, m), 5.45-4.96 (1H, 
m), 4.68-4.48 (1H, m), 4.48-4.25 (1H, m), 3.67 (3H, s), and 2.08 (3H, s); 
Tlc (developing solvent, benzene-ethyl acetate = 2:1): 
Rf = 0.66. 
REFERENCE EXAMPLE 7 
Methyl 9.alpha.-acetoxy-11.alpha.-(2-tetrahydropyranyloxy)- 
15-trimethylsilyloxyprosta-cis-5,trans-13,cis(or trans)-15-trienoate 
130 ml. of 0.29M lithium diisopropylamide solution in a mixture of 
tetrahydrofuran and diethyl ether (10:3) were added dropwise over a period 
of 3 hours to a solution of 4.15 g. of methyl 
9.alpha.-acetoxy-11.alpha.-(2-tetrahydropyranyloxy)-15-oxoprosta-cis-5, 
trans-13-dienoate (prepared as described in Reference Example 6) in 20 ml. 
of tetrahydrofuran under an atmosphere of nitrogen at -78.degree. C. The 
reaction mixture was stirred at the same temperature for 30 minutes. To 
the reaction mixture thus obtained, there was added dropwise over a period 
of 15 minutes a solution of 9.15 g. of trimethylchlorosilane and 2.13 g. 
of triethylamine in 30 ml. of diethyl ether and the reaction mixture was 
stirred at -78.degree. C. for 15 minutes, and allowed to warm to room 
temperature and then stirred for 30 minutes at room temperature. The 
reaction mixture was then concentrated under reduced pressure. The residue 
was purified by column chromatography on silica gel using a mixture of 
cyclohexane and ethyl acetate (10:1) as eluent to give 1.19 g. of the 
title compound having the following physical characteristics: 
Tlc (developing solvent, benzene-ethyl acetate =5:1): 
Rf = 0.6; 
Ir (liquid film): .nu.; 1740, 1660-1610, 1250, 1140, 1080, 1030, 845 
cm.sup.-1. 
REFERENCE EXAMPLE 8 
Methyl 9.alpha.-acetoxy-11.alpha.-(tetrahydropyranyloxy)-15-oxo 
16.xi.-chloroprosta-cis-5,trans-13-dienoate 
To a solution of 1.872 g. of methyl 
9.alpha.-acetoxy-11.alpha.-(2-tetrahydropyranyloxy)-15-trimethylsilyloxypr 
ostacis-5,trans-13,cis(or trans)-15-trienoate (prepared as described in 
Reference Example 7) in 30 ml. of tetrahydrofuran, there was added 
dropwise a solution of 2.02 g. of N-chlorosuccinimide in 20 ml. of 
tetrahydrofuran at -30.degree. C. and the mixture was stirred at the same 
temperature for hour. The reaction mixture was then quenched with a dilute 
hydrochloric acid solution and extracted with diethyl ether. The extract 
was washed with an aqueous sodium bicarbonate solution and an aqueous 
sodium chloride solution, dried over sodium sulphate, and concentrated 
under reduced pressure. The residue was purified by column chromatography 
on silica gel using a mixture f cyclohexane and ethyl acetate (10:1) as 
eluent to give 186 mg. of the title compound having the following physical 
characteristics: 
Tlc (developing solvent, benzene-ethyl acetate = 5:1): 
Rf = 0.5; 
Ir (liquid film): .nu.; 1740, 1695, 1680, 1625, 1440, 1355, 1140, 1085, 
1030, 990, 880 cm.sup.=1 ; 
REFERENCE EXAMPLE 9 
Methyl 
9.alpha.-acetoxy-11.alpha.-(2-tetrahydropyranyloxy)-15.xi.-hydroxy-16.xi.- 
chloroprosta-cis-5,trans-13-dienoate 
20 mg. of sodium borohydride were added to a solution of 186 mg. of methyl 
9.alpha.-acetoxy-11.alpha.-(2-tetrahydropyranyloxy)-5-oxo-16.xi.-chloropro 
sta-cis-5,trans-13-dienoate (prepared as described in Reference Example 8) 
in 7 ml. of absolute methanol at -26.degree. C. and the mixture was 
stirred at the same temperature for 2 hours. The reaction mixture was 
diluted with 50 ml. of ethyl acetate, washed with a dilute aqueous 
hydrochloric acid solution, an aqueous sodium bicarbonate solution and an 
aqueous sodium chloride solution, dried over sodium sulphate and 
concentrated under reduced pressure. The residue was purified by column 
chromatography ion silica gel using a mixture of benzene and ethyl acetate 
(9:1) as eluent to give 84 mg. of the title compound having the following 
physical characteristics: 
Tlc (developing solvent, benzene - ethyl acetate = 5:1): 
Rf = 0.2; 
Ir (liquid film): .nu.; 3360, 1740, 1440, 1360, 1140, 1080, 1030, 980 
cm.sup.-1. 
REFERENCE EXAMPLE 10 
Methyl 
9.alpha.-acetoxy-11.alpha.,15.xi.-bis(2-tetrahydropranyloxy)-16.xi.-chlorr 
oprosta-cis-5,trans-13-dienoate 
A catalytic amount of p-toluenesulphonic acid and 0.1 ml. of 
2,3-dihydropyran were added to a solution of 84 mg. of methyl 
9.alpha.-acetoxy-11.alpha.-(2-tetrahydropyranyloxy)-15.xi.-hydroxy-16.xi.- 
chloroprosta-cis-5,trans-13-dienoate (prepared as described in Reference 
Example 9) in 5 ml. of methylene chloride, and the reaction mixture was 
stirred at room temperature for 15 minutes and then diluted with 20 ml. of 
ethyl acetate. The mixture was washed with an aqueous sodium bicarbonate 
solution and an aqueous sodium chloride solution, dried over sodium 
sulphate and concentrated under reduced pressure to give 98 mg. of the 
title compound having the following physical characteristics: 
Tlc (developing solvent, benzene-ethyl acetate = 5:1): 
Rf = 0.38; 
Ir (liquid film): .nu.; 1740, 1440, 1365, 1140, 1080, 1030, 975 cm.sup.-1. 
REFERENCE EXAMPLE 11 
Methyl 
9.alpha.-hydroxy-11.alpha.,15.xi.-bis(2-tetrahydropyranyloxy)-16.xi.-chlor 
oprosta-cis-5,trans-13-dienoate 
24 mg. of potassium carbonate were added to a solution of 98 mg. of methyl 
9.alpha.-acetoxy-11.alpha.,15.xi.-bis(2-tetrahydropyranyloxy-16.xi.-chloro 
prosta-cis-5,trans-13-dienoate (prepared as described in Reference Example 
10) in 1 ml. of methanol and the mixture was stirred at 40.degree. C. for 
1 hour. After cooling to room temperature, the reaction mixture was 
diluted with 20 ml. of ethyl acetate, washed with a dilute aqueous 
hydrochloric acid solution, an aqueous sodium bicarbonate solution and an 
aqueous sodium chloride solution, dried over sodium sulphate and 
concentrated under reduced pressure to give 99 mg. of the title compound 
having the following physical characteristics: 
Tlc (developing solvent, benzene-ethyl acetate = 5:1): 
Rf = 0.14; 
Ir (liquid film): .nu.; 3370, 1740, 1440, 1360, 1140, 1085, 1025, 980 
cm.sup.-1. 
EXAMPLE 5 
Methyl 
9-oxo-11.alpha.,15.xi.-bis(2-tetrahydropyranyloxy)-16.xi.-chloroprosta-cis 
-5,trans-13-dienoate 
Under an atmosphere of nitrogen, 0.07 ml. of dimethyl sulphide were added 
to a solution of 98 mg. of N-chlorosuccinimide in 2 ml. of dry toluene and 
the mixture was cooled to -26.degree. C. There was then added a solution 
of 99 mg. of methyl 
9.alpha.-hydroxy-11.alpha.,15.xi.-bis(2-tetrahydropyranyloxy)-16.xi.-chlor 
oprosta-cis-5,trans-13-dienoate (prepared as described in Reference Example 
11) in 2 ml. of dry toluene. After stirring at the same temperature for 2 
hours, a solution of 0.2 ml. of triethylamine in 0.3 ml. of dry pentane 
was added and the reaction mixture was stirred at -26.degree. C. for 15 
minutes and then stirred at room temperature for 15 minutes. The reaction 
mixture was diluted with 220 ml. of diethyl ether, washed with a dilute 
aqueous hydrochloric acid solution, an aqueous sodium bicarbonate solution 
and an aqueous sodium chloride solution, dried over sodium sulphate and 
concentrated under reduced pressure. The residue was purified by column 
chromatography on silica gel using a mixture of cyclohexane and ethyl 
acetate (10:1) as eluent to give 70 mg. of the title compound having the 
following physical characteristics: 
Tlc (developing solvent, benzene-ethyl acetate = 5:1): 
Rf = 0:25; 
Ir (liquid film): .nu.; 1740, 1720, 1430, 1120, 1090, 1030, 980 cm.sup.-1. 
EXAMPLE 6 
Methyl 
9-oxo-11.alpha.,15.alpha.-dihydroxy-16.xi.-chloroprosta-cis-5,trans-13-die 
noate [or 16.xi.-chloro-PGE.sub.2 methyl ester] 
70 mg. of methyl 
9-oxo-11.alpha.,15.xi.-bis(2-tetrahydropyranyloxy)-15.xi.-chloroprosta-cis 
-5,trans-13-dienoate (prepared as described in Example 5) were dissolved in 
a mixture of 0.1 ml. of tetrahydrofuran and 1 ml. of 65% aqueous acetic 
acid and the reaction mixture was stirred at 60.degree. C. for 20 minutes 
and then concentrated under reduced pressure. The resulting oil was 
dissolved in 20 ml. of ethyl acetate, and washed with an aqueous sodium 
bicarbonate solution and an aqueous sodium chloride solution, dried over 
sodium sulphate and concentrated under reduced pressure. The residue was 
purified by column chromatography on silica gel using a mixture of benzene 
and ethyl acetate (5:1) as eluent to give 28 mg. of the title compound and 
14 mg. of its 15.beta.-hydroxy isomer having the following physical 
characteristics: 
Tlc (developing solvent, ethyl acetate): Rf = 0.41; 
(15.beta.-hydroxy isomer, Rf = 0.51); 
Ir (liquid film): .nu.; 3360, 1740, 1720, 1420, 1240, 1180, 1095, 980 
cm.sup.-1 ; 
Nmr (cdcl.sub.3 solution): .delta.; 5.72-5.61 (2H, m), 5.40-5.20 (2H, m), 
4.45-3.75 (3H, m), 3.66 (3H, s), 2.76 (2H, d--d). 
REFERENCE EXAMPLE 12 
Methyl 
9.alpha.-acetoxy-11.alpha.-(2-tetrahydropyranyloxy)-15-oxo-16.xi.-chloropr 
osta-cis-5,trans-13-dienoate 
By proceeding as described in Reference Example 6 but replacing the 
dimethyl 2-oxo-heptylphosphonate by 2.822 g. of dimethyl 
2-oxo-3-chloroheptylphosphonate (prepared as described hereafter) 
dissolved in 5 ml. of tetrahydrofuran and utilizing a suspension of 240 
mg. of sodium hydride in 50 ml. of tetrahydrofuran and a solution of 3.96 
g. of 
1.alpha.-acetoxy-2.alpha.-(6-methoxycarbonylhex-cis-2-enyl)-3.beta.-formyl 
-4.alpha.-(2-tetrahydropyranyloxy)-cylopentane (prepared as described in 
Reference Example 6) in 10 ml. of tetrahydrofuran, there were obtained 
4.162 g. of the title compound having the following physical 
characteristics: 
Tlc (developing solvent, benzene-ethyl acetate = 5:1): 
Rf = 0.45; 
Ir (liquid film): .nu.; 1740, 1695, 1622, 1245, 1030 cm.sup.-1 ; 
Nmr (cdcl.sub.3 solution): .delta.; 7.04 (1H, dd), 6.6 (1H, d), 5.55-5.22 
(2H, m), 5.22-4.95 (1H, m), 4.72-4.49 (1H, m), 4.36 (1H, t), 4.4-3.2 (3H, 
m), 3.67 (3H, s), 2.07 (3H, s). 
Dimethyl 2-oxo-3-chloroheptylphosphonate, used as a starting material in 
the above procedure, was prepared as follows: 
Under an atmosphere of nitrogen, a solution of 6.66 g. of dimethyl 
2-oxo-heptylphosphonate in 20 ml. of tetrahydrofuran was added to a 
suspension of 720 mg. of sodium hydride in 100 ml. of tetrahydrofuran at 
room temperature and the mixture was stirred at the same temperature for 
20 minutes. After cooling to 0.degree. C., there were added to the 
solution 24 ml. of a 1.38M solution of n-butyllithium in n-hexane at that 
temperature and the mixture was stirred for 30 minutes. After cooling to 
-78.degree. C., there was added to the solution thus obtained dropwise a 
solution of 5.82 g. of benzenesulphonyl chloride in 20 ml. of 
tetrahydrofuran and the mixture was stirred at -78.degree. C. for 30 
minutes and then at room temperature for one hour. The reaction mixture 
was acidified with acetic acid, diluted with 200 ml. of ethyl acetate, 
washed with an aqueous solution of sodium chloride, dried over sodium 
sulphate and concentrated under reduced pressure. The residue was purified 
by column chromatography on silica gel using a mixture of benzene and 
ethyl acetate (1:3) as eluent to give 4.56 g. of dimethyl 
2-oxo-3-chloroheptylphosphonate having the following physical 
characteristics: 
Tlc (developing solvent, ethyl acetate): Rf = 0.41; 
Ir (liquid film): .nu.; 1725, 1260, 1190, 1100-1000, 900-780 cm.sup.-1 ; 
Nmr(cdcl.sub.3 solution): .delta.; 4.44 (1H, dd), 3.80 (6H, d), 3.71-3.02 
(2H, m). 
REFERENCE EXAMPLE 13 
Methyl 
9.alpha.-acetoxy-11.alpha.-(2-tetrahydropyranyloxy)-15.alpha.-hydroxy-16.x 
i.-chloroprosta-cis-5,trans-13-dienoate 
By proceeding as described in Example 1 but replacing the methyl 
9.alpha.,11.alpha.-bis(2-tetrahydropyranyloxy)-15-oxo-16.xi.-chloroprosta- 
cis-5,trans-13-dienoate by 4.169 g. of methyl 
9.alpha.-acetoxy-11.alpha.-(2-tetrahydropyranyloxy)-15-oxo-16.xi.-chloropr 
osta-cis-5,trans-13-dienoate (prepared as described in Reference Example 
12) dissolved in 80 ml. of methanol and utilizing 361 mg. of sodium 
borohydride, there were obtained 2.98 g. of the title compound and 1.06 g. 
of its 15.beta.-hydroxy isomer. The title compound showed the following 
physical characteristics: 
Tlc (developing solvent, benzene-ethyl acetate = 2:1): 
Rf = 0.36, (15.beta.-hydroxy isomer, Rf = 0.43); 
Ir (liquid film): .nu.; 3600-3100, 1740, 1245, 1100-1000 cm.sup.-1 ; 
Nmr(cdcl.sub.3 solution): .delta.; 5.87-5.60 (2H, m), 5.60-5.27 (2H, m), 
5.27-4.95 (1H, m), 4.72-4.55 (1H, m), 3.70 (3H, s), 2.07 (3H, s). 
REFERENCE EXAMPLE 14 
Methyl 
9.alpha.-acetoxy-11.alpha.,15.alpha.-bis(2-tetrahydropyranyloxy)-16.xi.-ch 
loroprosta-cis-5,trans-13-dienoate 
By proceeding as described in Reference Example 2 but replacing the 
15-oxo-PGF.sub.2.alpha. methyl ester by 2.98 g. of methyl 
9.alpha.-acetoxy-11.alpha.-(2-tetrahydropyranyloxy)-15.alpha.-hydroxy-16.x 
i.-chloroprosta-cis-5,trans-13-dienoate (prepared as described in Reference 
Example 13) dissolved in 30 ml. of methylene chloride and utilizing 15 mg. 
of p-toluenesulphonic acid and 952 mg. of 2,3-dihydropyran, there were 
obtained 3.7 g. of the title compound having the following physical 
characteristics: 
Tlc (developing solvent, benzene-ethyl acetate = 2:1): 
Rf = 0.50; 
Ir (liquid film): .nu.; 1740, 1465-1405, 1390-1130, 1240, 1110, 1070, 
1050-1000, 990 cm.sup.-1 ; 
Nmr (cdcl.sub.3 solution): .delta.; 5.65-5.50 (2H, m), 5.50-5.20 (2H, m), 
5.20-4.95 (1H, m), 4.90-4.50 (2H, m), 3.68 (3H, s), 2.05 (3H, s). 
EXAMPLE 7 
Methyl 
9.alpha.-hydroxy-11.alpha.,15.alpha.-bis(2-tetrahydropyranyloxy)-16.xi.-ch 
loroprosta-cis-5,trans-13-dienoate 
By proceeding as described in Reference Example 11 but replacing the methyl 
9.alpha.-acetoxy-11.alpha.,15.xi.-bis(2-tetrahydropyranyloxy)-16.xi.-chlor 
oprosta-cis-5,trans-13-dienoate by 3.7 g. of methyl 
9.alpha.-acetoxy-11.alpha.,15.alpha.-bis(2-tetrahydropyranyloxy)-16.xi.-ch 
loroprosta-cis-5,trans-13-dienoate (prepared as described in Reference 
Example 14) dissolved in 40 ml. of methanol and utilizing 616 mg. of 
potassium carbonate, there were obtained 2.961 g. of the title compound 
having the following physical characteristics:- 
Tlc (developing solvent, benzene-ethyl acetate = 2:1): 
Rf = 0.42; 
Ir (liquid film): .nu.; 3600-3100, 1740, 1460-1420, 1200, 1120-1100, 1075, 
1010, 970 cm.sup.-1 ; 
Nmr (cdcl.sub.3 solution: .delta.; 5.72-5.20 (4H, m), 4.95-4.59 (2H, m), 
4.42-3.20 (8H, m), 3.68 (3H, s). 
EXAMPLE 8 
Methyl 
9-oxo-11.alpha.,15.alpha.-bis(2-tetrahydropyranyloxy)-16.xi.-chloroprosta- 
cis-5,trans-13-dienoate 
By proceeding as described in Example 3 but replacing the methyl 
9.alpha.-hydroxy-11.alpha.,15.alpha.-bis(trimethylsilyloxy)-16.xi.-chlorop 
rosta-cis-5,trans-13-dienoate by 570 mg. of methyl 
9.alpha.-hydroxy-11.alpha.,15.alpha.-bis(2-tetrahydropyranyloxy)-16.xi.-ch 
loroprosta-cis-5,trans-13-dienoate (prepared as described in Example 7) 
dissolved in 10 ml. of toluene and utilizing a suspension of 862 mg. of 
N-chlorosuccinimide in 10 ml. of toluene, 0.1 ml. of dimethyl sulphide and 
1 ml. of triethylamine, there were botained 544 mg. of the title compound 
having the following physical characteristics:- 
Tlc (developing solvent, benzene-ethyl acetate = 2:1): 
Rf = 0.50; 
Ir (liquid film): .nu.; 1740, 1710, 1435, 1390-1310, 1240, 1160, 1130, 
1080, 1030-1010, 975 cm.sup.-1 ; 
Nmr (cdcl.sub.3 solution): .delta.; 5.85-5.51 (2H, m), 5.51-5.20 (2H, m), 
4.85-4.50 (2H, m), 4.50-3.20 (7H, m), 3.67 (3H, s). 
EXAMPLE 9 
Methyl 
9-oxo-11.alpha.,15.alpha.-dihydroxy-16.xi.-chloroprosta-cis-5,trans-13-die 
noate [or 16.xi.-chloro-PGE.sub.2 methyl ester ] 
By proceeding as described in Example 2 but replacing the methyl 
9.alpha.,11.alpha.-bis(2-tetrahydropyranyloxy)-15.xi.-hydroxy-16.xi.-chlor 
oprosta-cis-5,trans-13-dienoate by 520 mg. of methyl 
9-oxo-11.alpha.,15.alpha.-bis(2-tetrahydropyranyloxy)-16.xi.-chloroprosta- 
cis-5,trans-13-dienoate (prepared as described in Example 8) dissolved in a 
mixture of 1 ml. of tetrahydrofuran and 10 ml. of 65% aqueous acetic acid, 
there were obtained 247 mg. of the title compound having the same physical 
characteristics as those of the product of Example 6. 
EXAMPLE 10 
Methyl 
9.alpha.-hydroxy-11.alpha.,15.alpha.-bis(2-tetrahydropyranyloxy)-16.xi.-ch 
loroprost-trans-13-enoate 
1.0 g. of methyl 
9.alpha.-hydroxy-11.alpha.,15.alpha.-bis(2-tetrahydropyranyloxy)-16.xi.-ch 
loroprosta-cis-5,trans-13-dienoate (prepared as described in Example 7) was 
hydrogenated at a pressure of one atmosphere in 30 ml. of methanol 
containing 330 mg. of 5% palladium on charcoal. The reduction was stopped 
after the absorption of one equivalent of hydrogen gas. The catalyst was 
filtered off and the filtrate was concentrated under reduced pressure to 
give 982 mg. of the crude title compound having the following physical 
characteristics: 
Tlc (developing solvent, benzene-ethyl acetate = 2:1): 
Rf = 0.33; 
Ir (liquid film): .nu.; 3600-3200, 1740, 1715, 1622, 1445-1420, 1390-1330, 
1240, 1200, 1140-1100, 1075, 1025-1010, 975 cm.sup.-1 ; 
Nmr (cdcl.sub.3 solution): .delta.; 5.73-5.30 (2H, m), 4.88-4.45 (2H, m), 
4.35-3.25 (8H, m), 3.62 (3H, s). 
EXAMPLE 11 
Methyl 
9-oxo-11.alpha.,15.alpha.-bis(2-tetrahydropyranyloxy)-16.xi.-chloroprost-t 
rans-13-enoate 
By proceeding as described in Example 3 but replacing the methyl 
9.alpha.-hydroxy-11.alpha.,15.alpha.-bis(trimethylsilyloxy)-16.xi.-chlorop 
rosta-cis-5,trans-13-dienoate by 982 mg. of methyl 
9.alpha.-hydroxy-11.alpha.,15.alpha.-bis(2-tetrahydropyranyloxy)-16.xi.-ch 
loroprost-trans-13-enoate (prepared as described in Example 10) dissolved 
in 18 ml. of toluene and utilizing a suspension of 1.38 g. of 
N-chlorosuccinimide in 18 ml. of toluene, 0.18 ml. of dimethyl sulphide 
and 1.8 ml. of triethylamine, there were obtained 769 mg. of the title 
compound having the following physical characteristics: 
Tlc (developing solvent, benzene-ethyl acetate = 2:1): 
Rf = 0.58; 
Ir (liquid film): .nu.; 1740, 1470-1420, 1390-1335, 1262, 1242, 1200, 
1142-1100, 1080, 1060-1010, 978 cm.sup.-1 ; 
Nmr (cdcl.sub.3 solution): .delta.; 5.9-5.5 (2H, m), 4.92-4.5 (2H, m), 
4.5-3.2 (7H, m), 3.67 (3H, s). 
EXAMPLE 12 
Methyl 
9-oxo-11.alpha.,15.alpha.-dihydroxy-16.xi.-chloroprost-trans-13-enoate [or 
16.xi.-chloro-PGE.sub.1 methyl ester ] 
By proceeding as described in Example 2 but replacing the methyl 
9.alpha.,11.alpha.-bis(2-tetrahydropyranyloxy)-15.xi.-hydroxy-16.xi.-chlor 
oprosta-cis-5,trans-13-dienoate by 769 mg. of methyl 
9-oxo-11.alpha.,15.alpha.-bis(2-tetrahydropyranyloxy)-16.xi.-chloroprost-t 
rans-13-enoate (prepared as described in Example 11) dissolved in a mixture 
of 1.5 ml. of tetrahydrofuran and 13 ml. of 65% aqueous acetic acid, there 
were obtained 254 mg. of the title compound having the following physical 
characteristics: 
Tlc (developing solvent, ethyl acetate): Rf = 0.48; 
Ir (liquid film): .nu.; 3600-3100, 1740, 1715, 1460, 1433, 1245, 1200, 
1180, 1075, 970 cm.sup.-1 ; 
Nmr (cdcl.sub.3 solution): .delta.; 5.82-5.60 (2H, m), 4.35-3.10 (3H, m), 
3.66 (3H, s), 2.74 (1H, dd). 
REFERENCE EXAMPLE 15 
Methyl 
9.alpha.-acetoxy-11.beta.-(2-tetrahydropyranyloxy)-15-oxo-16.xi.-chloropro 
st-trans-13-enoate 
By proceeding as described in Reference Example 12 but replacing the 
1.alpha.-acetoxy-2.alpha.-(6-methoxycarbonylhex-cis-2-enyl)-3.beta.-formyl 
-4.alpha.-(2-tetrahydropyranyloxy)-cyclopentane by 796 mg. of 
1.alpha.-acetoxy-2.alpha.-(6-methoxycarbonylhexyl)-3.beta.-formyl-4.beta.- 
(2-tetrahydropyranyloxy)-cyclopentane (prepared as described hereafter) 
dissolved in 2 ml. of tetrahydrofuran and utilizing a suspension of 62.5 
mg. of sodium hydride in a mixture of 10 ml. of tetrahydrofuran and 0.5 
ml. of hexamethylphosphotriamide and 769 mg. of dimethyl 
2-oxo-3-chloroheptylphosphonate (prepared as described in Reference 
Example 12), there were obtained 628 mg. of the title compound and 245 mg. 
of the starting material. The title compound showed the following physical 
characteristics: 
Tlc (developing solvent, benzene-ethyl acetate = 4:1): 
Rf = 0.45; 
Ir (liquid film): .nu.; 1740, 1695, 1680, 1625, 1440, 1435, 1370, 1240, 
1200, 1170, 1113, 1075, 1020, 980 cm.sup.-1 ; 
Nmr (cdcl.sub.3 solution): .delta.; 7.32-6.30 (1H, m), 6.42 (1H, d), 
5.45-5.15 (1H, m), 4.74-4.18 (3H, m), 4.10-3.30 (2H, m), 3.66 (3H, s), 
2.04 (3H, s). 
1.alpha.-Acetoxy-2.alpha.-(6-methoxycarbonylhexyl)-3.beta.-formyl-4.beta.-( 
2-tetrahydropyranyloxy)cyclopentane, used as a starting material in the 
above procedure, was prepared from 
2-oxa-3-oxo-6-syn-acetoxymethyl-7-anti-hydroxy-cis-bicyclo[3,3,0]octane 
(prepared as described in Reference Example 6) as follows: 
1. 
2-Oxa-3-oxo-6-syn-acetoxymethyl-7-anti-methylsulphonyloxy-cis-bicyclo[3,3, 
0]octane 
Under an atmosphere of nitrogen, 6.87 g. of methanesulphonyl chloride were 
added portionwise to a solution of 10.7 g. of 
2-oxa-3-oxo-6-syn-acetoxymethyl-7-anti-hydroxy-cis-bicyclo[3,3,0]octane 
and 6.06 g. of triethylamine in 150 ml. of methylene chloride at 
-20.degree. C. and the mixture was stirred at the same temperature for one 
hour. The reaction mixture was quenched with dilute hydrochloric acid and 
extracted with ethyl acetate. The extract was washed with water and an 
aqueous solution of sodium chloride, dried over sodium sulphate and 
concentrated under reduced pressure to give 16 g. of the crude title 
compound having the following physical characteristic: 
Tlc (developing solvent, ethyl acetate): Rf = 0.39. 
2. 
2-Oxa-3-oxo-6-syn-acetoxymethyl-7-syn-benzoyloxy-cis-bicyclo[3,3,0]octane 
To a solution of 16 g. of 
2-oxa-3-oxo-6-syn-acetoxymethyl-7-anti-methylsulphonyloxy-cis-bicyclo[3,3, 
0]octane (prepared as described above) in 100 ml. of N,N-dimethylformamide 
were added 9.7 g. of sodium benzoate at room temperature and the mixture 
was heated to 90.degree. C. and then stirred at that temperature for one 
hour. To the solution were added 30 ml. of dimethyl sulphoxide and the 
mixture stirred at 90.degree. C. for 4.5 hours. After cooling to room 
temperature, the reaction mixture was diluted with 180 ml. of water and 
extracted with ethyl acetate. The extract was washed with water and an 
aqueous solution of sodium chloride, dried over sodium sulphate and 
concentrated under reduced pressure. The residue was purified by column 
chromatography on silica gel using a mixture of benzene and ethyl acetate 
(3:1) as eluent to give 12.592 g. of the title compound having the 
following physical characteristics: 
Tlc (developing solvent, benzene-ethyl acetate = 1:1): 
Rf = 0.45; 
Nmr (cdcl.sub.3 solution): .delta.; 8.25-7.8 (2H, m), 7.65-7.23 (3H, m), 
5.80-5.45 (1H, m), 5.45-4.90 (1H, m), 4.40-4.15 (2H, m), 2.05 (3H, s). 
3. 2-Oxa-3-oxo-6-syn-hydroxymethyl-7-syn-hydroxy-cis-bicyclo[3,3,0]octane 
To a solution of 12.6 g. of 
2-oxa-3-oxo-6-syn-acetoxymethyl-7-syn-benzyloxy-cis-bicyclo[3,3,0]octane 
(prepared as described above) in 60 ml. of methanol were added 6.9 g. of 
potassium carbonate and the mixture stirred at 50.degree. C. for 2.5 
hours. The reaction mixture was acidified to pH 1 with conc. hydrochloric 
acid, stirred at room temperature for 30 minutes and filtered. The 
filtrate was concentrated under reduced pressure to give 8.4 g. of the 
crude title compound having the following physical characteristic: 
Tlc (developing solvent, ethyl acetate-methanol = 95:1): 
Rf = 0.22. 
4. 2-Oxa-3-oxo-6-syn-acetoxymethyl-7-syn-hydroxy-cis-bicyclo[3,3,0]octane 
Under an atmosphere of nitrogen, a solution of 3.56 ml. of acetyl chloride 
in 60 ml. of methylene chloride was added dropwise to a solution of 8.4 g. 
of 2-oxa-3-oxo-6-syn-hydroxymethyl-7-syn-hydroxy-cis-bicyclo[3,3,0]octane 
(prepared as described above) in a mixture of 25 ml. of pyridine and 40 
ml. of methylene chloride at -20.degree. C. and the mixture was stirred at 
the same temperature for 3 hours. The reaction was then acidified to pH 1 
with conc. hydrochloric acid, poured into 150 ml. of a saturated aqueous 
solution of ammonium sulphate and extracted with ethyl acetate. The 
extract was dried over sodium sulphate and concentrated under reduced 
pressure to give 4.01 g. of the crude title compound as white powder 
having the following physical characteristics: 
Tlc (developing solvent, ethyl acetate): Rf = 0.36; 
Nmr 
##STR96## 
.delta.; 5.17-4.87 (1H, m), 4.38-4.02 (3H, m), 2.02 (3H, s). 
5. 
2-Oxa-3-oxo-6-syn-acetoxymethyl-7-syn-(2-tetrahydropyranyloxy)-cis-bicyclo 
[3,3,0]octane 
To a solution of 4 g. of 
2-oxa-3-oxo-6-syn-acetoxymethyl-7-syn-hydroxy-cis-bicyclo[3,3,0]octane 
(prepared as described above) in 70 ml. of methylene chloride were added 
50 mg. of p-toluenesulphonic acid and 2.52 g. of 2,3-dihydropyran and the 
mixture was stirred at room temperature for 30 minutes. The reaction 
mixture was diluted with ethyl acetate, washed with an aqueous solution of 
sodium bicarbonate and an aqueous solution of sodium chloride, dried over 
sodium sulphate and concentrated under reduced pressure to give 6.3 g. of 
the crude title compound having the following physical characteristic: 
Tlc (developing solvent, ethyl acetate): Rf = 0.54. 
6. 
2-Oxa-3-hydroxy-6-syn-hydroxymethyl-7-syn-(2-tetrahydropyranyloxy)-cis-bic 
yclo[3,3,0]octane 
Under an atmosphere of nitrogen, 26.5 ml. of a 25(w/v)% solution of 
diisobutylaluminium hydride in toluene were added portionwise to a 
solution of 6.3 g. of 
2-oxa-3-oxo-6-syn-acetoxymethyl-7-syn-(2-tetrahydropyranyloxy)-cis-bicyclo 
[3,3,0]octane (prepared as described above) in 70 ml. of toluene at 
-78.degree. C. and the mixture was stirred at the same temperature for 40 
minutes. Aqueous methanol was added in order to decompose the excess of 
diisobutylaluminium hydride and the resulting precipitate was filtered 
off. The filtrate was concentrated under reduced pressure and the residue 
was purified by column chromatography on silica gel using a mixture of 
benzene and ethyl acetate (2:5) as eluent to give 3.627 g. of the title 
compound having the following physical characteristics: 
Tlc (developing solvent, ethyl acetate): Rf = 0.15; 
Nmr (cdcl.sub.3 solution): .delta.; 5.70-5.45 (1H, m), 5.15-4.27 (3H, m), 
4.15-3.30 (4H, m). 
7. 
2.alpha.-(6-Carboxyhex-cis-2-enyl)-3.beta.-hydroxymethyl-4.beta.-(2-tetrah 
ydropyranyloxy)-cyclopentan-1.alpha.-ol 
A suspension of 4.27 g. of sodium hydride (63% content) in 90 ml. of 
dimethyl sulphoxide was stirred at 70.degree. C. for one hour to obtain 
sodium methylsulphinylmethylide. The reaction mixture was allowed to cool 
to room temperature and then added dropwise to a solution of 24.8 g. of 
(4-carboxybutylidene)-triphenylphosphonium bromide in 50 ml. of dimethyl 
sulphoxide, the reaction temperature being kept within the range of 
20.degree. to 25.degree. C. 
To the solution thus obtained was added a solution of 3.6 g. of 
2-oxa-3-hydroxy-6-syn-hydroxymethyl-7-syn-(2-tetrahydropyranyloxy)-cis-bic 
yclo[3,3,0]octane (prepared as described above) in 10 ml. of dimethyl 
sulphoxide at room temperature and the mixture stirred at room temperature 
for 2 hours. The reaction mixture was poured into 500 ml. of ice-water and 
the neutral substance was removed by extraction with a mixture of ethyl 
acetate and diethyl ether (1:1). The aqueous layer was acidified to pH 2 
with a saturated aqueous solution of oxalic acid and extracted with a 
mixture of diethyl ether and n-pentane (1:1). The extract was washed with 
water, dried over sodium sulphate and concentrated under reduced pressure 
to give 4.7 g. of the crude title compound having the following physical 
characteristic: 
Tlc (developing solvent, ethyl acetate-methanol = 95:5): 
Rf = 0.39. 
8. 
2.alpha.-(6-Methoxycarbonylhex-cis-2-enyl)-3.beta.-hydroxymethyl-4.beta.-( 
2-tetrahydropyranyloxy)cyclopentan-1.alpha.-ol 
To a solution of 4.7 g. of 
2.alpha.-(6-carboxyhex-cis-2-enyl)-3.beta.-hydroxymethyl-4.beta.-(2-tetrah 
ydropyranyloxy)-cyclopentan-1.alpha.-ol (prepared as described above) in 50 
ml. of diethyl ether, a freshly prepared solution of diazomethane in 
diethyl ether was added with cooling in an ice-bath until the reaction 
mixture showed a pale yellow colour. The reaction mixture was concentrated 
under reduced pressure and the residue was purified by column 
chromatography on silica gel using a mixture of ethyl acetate and benzene 
(2:1) as eluent to give 3.98 g. of the title compound having the following 
physical characteristics: 
Tlc (developing solvent, ethyl acetate): Rf = 0.43; 
Ir (liquid film): .nu.; 3400, 1738, 1432, 1200, 1158, 1120, 1070, 1023, 993 
cm.sup.-1 ; 
Nmr (cdcl.sub.3 solution): .delta.; 5.65-5.23 (2H, m), 4.85-4.14 (3H, m), 
4.14-3.25 (4H, m), 3.65 (3H, s). 
9. 
1.alpha.-Acetoxy-2.alpha.-(6-methoxycarbonylhex-cis-2-enyl)-3.beta.-hydrox 
ymethyl-4.beta.-(2-tetrahydropyranyloxy)cyclopentane 
Under an atmosphere of nitrogen, 1.79 g. of trimethylsilyldiethylamine were 
added dropwise to a solution of 3.98 g. of 
2.alpha.-(6-methoxycarbonylhex-cis-2-enyl)-3.beta.-hydroxymethyl-4.beta.-( 
2-tetrahydropyranyloxy)-cyclopentan-1.alpha.-ol (prepared as described 
above) in 50 ml. of acetone at -20.degree. C. and the mixture was stirred 
at the same temperature for one hour and then at room temperature for 1.5 
hours. The reaction mixture was concentrated under reduced pressure. The 
residue showed the following physical characteristic: 
Tlc (developing solvent, benzene-ethyl acetate = 1.1): 
Rf = 0.47. 
The crude product thus obtained was dissolved in a mixture of 30 ml. of 
methylene chloride and 1.97 g. of pyridine and to the solution were added 
dropwise 1.57 g. of acetyl chloride at room temperature. After one hour of 
stirring at room temperature, the reaction mixture was diluted with ethyl 
acetate, washed with 0.5N hydrochloric acid, an aqueous solution of sodium 
bicarbonate and an aqueous solution of sodium chloride, dried over sodium 
sulphate and concentrated under reduced pressure to give a residue having 
the following physical characteristic: 
Tlc (developing solvent, benzene-ethyl acetate = 2:1): 
Rf = 0.58. 
To a solution of the crude product in 50 ml. of ethyl acetate were added 10 
ml. of a saturated aqueous solution of oxalic acid and the mixture was 
stirred vigorously at room temperature for one hour. The reaction mixture 
was extracted with ethyl acetate and the extract was washed with an 
aqueous solution of sodium bicarbonate and an aqueous solution of sodium 
chloride, dried over sodium sulphate and concentrated under reduced 
pressure. The residue was purified by column chromatography on silica gel 
using a mixture of benzene and ethyl acetate (4:1) as eluent to give 2.472 
g. of the title compound and 661 mg. of 
1.alpha.-acetoxy-2.alpha.-(6-methoxycarbonylhex-cis-2-enyl)-3.beta.-acetox 
ymethyl-4.beta.-(2-tetrahydropyranyloxy)cyclopentane. The title compound 
showed the following physical characteristics: 
Tlc (developing solvent, benzene-ethyl acetate = 1:1): 
Rf = 0.38, (the diacetate, Rf = 0.54); 
Ir (liquid film): .nu.; 3450, 1738, 1433, 1375, 1241, 1155, 1130, 1075, 
1030, 995 cm.sup.-1 ; 
Nmr (cdcl.sub.3 solution): .delta.; 5.60-5.10 (3H, m) 4.90-4.25 (2H, m), 
4.25-3.35 (4H, m), (3H, s), 2.03 (3H, s). 
10. 
1.alpha.-Acetoxy-2.alpha.-(6-methoxycarbonylhexyl)-3.beta.-hydroxymethyl-4 
.beta.-(2-tetrahydropyranyloxy)cyclopentane 
2.45 g. of 
1.alpha.-acetoxy-2.alpha.-(6-methoxycarbonylhex-cis-2-enyl)-3.beta.-hydrox 
ymethyl-4.beta.-(2-tetrahydropyranyloxy)-cyclopentane (prepared as 
described above) were hydrogenated at a pressure of one atmosphere in 25 
ml. of methanol containing 1.0 g. of 5% palladium on charcoal. The 
reduction was stopped after the absorption of one equivalent of hydrogen 
gas. The catalyst was filtered off and the filtrate was concentrated under 
reduced pressure. The residue was purified by column chromatography on 
silica gel using a mixture of benzene and ethyl acetate (5:1) as eluent to 
give 1.987 g. of the title compound having the following physical 
characteristics: 
Tlc (developing solvent, benzene-ethyl acetate = 1.1): 
Rf = 0.42 and 0.38; 
Ir (liquid film): .nu.; 3460, 1739, 1438, 1375, 1250, 1135, 1077, 1030 
cm.sup.-1 ; 
Nmr (cdcl.sub.3 solution): .delta.; 5.55-5.15 (1H, m), 4.82-4.25 (2H, m), 
4.25-3.35 (4H, m), 3.65 (3H, s), 2.03 (3H, s). 
11. 
1.alpha.-Acetoxy-2.alpha.-(6-methoxycarbonylhexyl)-3.beta.-formyl-4.beta.- 
(2-tetrahydropyranyloxy)cyclopentane 
By proceeding as described in Reference Example 6 but replacing the 
1.alpha.-acetoxy-2.alpha.-(6-methoxycarbonylhex-cis-2-enyl)-3.beta.-hydrox 
ymethyl-4.alpha.-(2-tetrahydropyranyloxy)-cyclopentane by 1.07 g. of 
1.alpha.-acetoxy-2.alpha.-(6-methoxycarbonylhexyl)-3.beta.-hydroxymethyl-4 
.beta.-(2-tetrahydropyranyloxy)-cyclopentane (prepared as described above) 
dissolved in 25 ml. of methylene chloride and utilizing a solution of 2.69 
g. of chromium trioxide and 4.27 ml. of pyridine in 75 ml. of methylene 
chloride, 14.5 g. of infusorial earth and 14.5 g. of sodium bisulphate, 
there were obtained 801 mg. of the title compound having the following 
physical characteristics: 
Tlc (developing solvent, benzene-ethyl acetate = 1:1): 
Rf = 0.59; 
Ir (liquid film): .nu.; 1740, 1435, 1372, 1240, 1120, 1075, 1030, 1020 
cm.sup.-1 ; 
Nmr (cdcl.sub.3 solution): .delta.; 9.90-9.60 (1H, m), 5.55-5.20 (1H, m), 
4.90-4.43 (2H, m), 4.00-3.30 (2H, m), 3.65 (3H, s), 2.03 (3H, s). 
REFERENCE EXAMPLE 16 
Methyl 
9.alpha.-acetoxy-11.beta.-(2-tetrahydropyranyloxy)-15.alpha.-hydroxy-16.xi 
.-chloroprost-trans-13 -enoate 
By proceeding as described in Example 1 but replacing the methyl 
9.alpha.,11.alpha.-bis(2-tetrahydropyranyloxy)-15-oxo-16.xi.-chloroprosta- 
cis-5,trans-13-dienoate by 628 mg. of methyl 
9.alpha.-acetoxy-11.beta.-(2-tetrahydropyranyloxy)-15-oxo-16.xi.-chloropro 
st-trans-13-enoate (prepared as described in Reference Example 15) 
dissolved in 10 ml. of methanol and utilizing 54.3 mg. of sodium 
borohydride, there were obtained 385 mg. of the title compound and 198 mg. 
of its 15.beta.-hydroxy isomer. The title compound showed the following 
physical characteristics: 
Tlc (developing solvent, benzene-ethyl acetate = 4:1): 
Rf = 0.33, (15.beta.-hydroxy isomer, Rf = 0.21); 
Ir (liquid film): .nu.; 3450, 1740, 1435, 1375, 1246, 1200, 1130, 1113, 
1020, 982 cm.sup.-1 ; 
Nmr (cdcl.sub.3 solution): .delta.; 6.10-5.43 (2H, m), 5.43-5.15 (1H, m), 
4.68-4.46 (1H, m), 4.40-3.25 (5H, m), 3.65 (3H, s), 2.02 (3H, s). 
REFERENCE EXAMPLE 17 
Methyl 
9.alpha.-acetoxy-11.beta.,15.alpha.-bis(2-tetrahydropyranyloxy)-16.xi.-chl 
oroprost-trans-13-enoate 
By proceeding as described in Reference Example 2 but replacing the 
15-oxo-PGF.sub.2.alpha. methyl ester by 385 mg. of methyl 
9.alpha.-acetoxy-11.beta.-(2-tetrahydropyranyloxy)-15.alpha.-hydroxy-16.xi 
.-chloroprost-trans-13-enoate (prepared as described in Reference Example 
16) dissolved in 5 ml. of methylene chloride and utilizing 3 mg. of 
p-toluenesulphonic acid and 0.1 ml. of 2,3-dihydropyran, there were 
obtained 463 mg. of the crude title compound having the following physical 
characteristic: 
Tlc (developing solvent, benzene-ethyl acetate = 4:1): 
Rf = 0.39. 
EXAMPLE 13 
Methyl 
9.alpha.-hydroxy-11.beta.,15.alpha.-bis(2-tetrahydropyranyloxy)-16.xi.-chl 
oroprost-trans-13-enoate 
By proceeding as described in Reference Example 11 but replacing the methyl 
9.alpha.-acetoxy-11.alpha.,15.xi.-bis(2-tetrahydropyranyloxy)-16.xi.-chlor 
oprosta-cis-5,trans-13-dienoate by 463 mg. of methyl 
9.alpha.-acetoxy-11.beta.,15.alpha.-bis(2-tetrahydropyranyloxy)-16.xi.-chl 
oroprost-trans-13-enoate (prepared as described in Reference Example 17) 
dissolved in 4 ml. of methanol and utilizing 70 mg. of potassium 
carbonate, there were obtained 362 mg. of the title compound having the 
following physical characteristics: 
Tlc (developing solvent, benzene-ethyl acetate = 4:1): 
Rf = 0.19; 
Ir (liquid film): .nu.; 3460, 1740, 1465, 1450, 1438, 1380, 1375, 1322, 
1262, 1243, 1200, 1180, 1130, 1118, 1078, 1033, 1020, 982 cm.sup.-1 ; 
Nmr (cdcl.sub.3 solution): .delta.; 6.20-5.20 (2H, m), 4.85-4.45 (3H, m), 
4.45-3.30 (7H, m), 3.65 (3H, s). 
EXAMPLE 14 
Methyl 
9-oxo-11.beta.,15.alpha.-bis(2-tetrahydropyranyloxy)-16.xi.-chloroprost-tr 
ans-13-enoate 
By proceeding as described in Example 3 but replacing the methyl 
9.alpha.-hydroxy-11.alpha.,15.alpha.-bis(trimethylsilyloxy)-16.xi.-chlorop 
rosta-cis-5,trans-13-dienoate by 362 mg. of methyl 
9.alpha.-hydroxy-11.beta.,15.alpha.-bis(2-tetrahydropyranyloxy)-16.xi.-chl 
oroprost-trans-13-enoate (prepared as described in Example 13) dissolved in 
6 ml. of toluene and utilizing a suspension of 505 mg. of 
N-chlorosuccinimide in 6 ml. of toluene, 0.06 ml. of dimethyl sulphide and 
0.6 ml. of triethylamine, there were obtained 360 mg. of the crude title 
compound having the following physical characteristic: 
Tlc (developing solvent, benzene-ethyl acetate = 2:1): 
Rf = 0.53. 
EXAMPLE 15 
Methyl 
9-oxo-11.beta.,15.alpha.-dihydroxy-16.xi.-chloroprost-trans-13-enoate [or 
16.xi.-chloro-11-epi-PGE.sub.1 methyl ester] 
By proceeding as described in Example 2 but replacing the methyl 
9.alpha.,11.alpha.-bis(2-tetrahydropyranyloxy)-15.xi.-hydroxy-16.xi.-chlor 
oprosta-cis-5,trans-13-dienoate by 360 mg. of methyl 
9-oxo-11.beta.,15.alpha.-bis(2-tetrahydropyranyloxy)-16.xi.-chloroprost-tr 
ans-13-enoate (prepared as described in Example 14) dissolved in a mixture 
of 0.6 ml. of tetrahydrofuran and 6 ml. of 65% aqueous acetic acid, there 
were obtained 160 mg. of the title compound having the following physical 
characteristics: 
Tlc (developing solvent, ethyl acetate): Rf = 0.48; 
Ir (liquid film): .nu., 3445, 1740, 1460, 1435, 1375, 1245, 1167, 1047, 980 
cm.sup.-1 ; 
Nmr (cdcl.sub.3 solution): .delta.; 6.13-5.53 (2H, m), 4.32-4.10 (1H, m), 
4.53-4.32 (1H, m), 4.10-3.76 (1H, m), 3.65 (3H, s). 
EXAMPLE 16 
11.alpha.,15.alpha.-Bis(2-tetrahydropyranyloxy)-16.xi.-chloroprosta-cis-5,t 
rans-13-dien-1,9.alpha.-diol 
Under an atmosphere of nitrogen, 1.84 ml. of a 25(w/v)% solution of 
diisobutylaluminium hydride in toluene were added dropwise to a solution 
of 559 mg. of methyl 
9.alpha.-hydroxy-11.alpha.,15.alpha.-bis(2-tetrahydropyranyloxy)-16.xi.-ch 
loroprosta-cis-5,trans-13-dienoate (prepared as described in Example 7) in 
5 ml. of toluene at -78.degree. C. and the mixture was stirred at the same 
temperature for 30 minutes and then at -10.degree. C. for 1.5 hours. The 
reaction mixture was quenched with methanol, diluted with 20 ml. of ethyl 
acetate, washed with 1N hydrochloric acid, an aqueous solution of sodium 
bicarbonate and an aqueous solution of sodium chloride, dried over sodium 
sulphate and concentrated under reduced pressure to give 575 mg. of the 
crude title compound having the following physical characteristics: 
Tlc (developing solvent, benzene-ethyl acetate = 1:1): 
Rf = 0.26; 
Ir (liquid film): .nu.; 3420, 1462, 1448, 1437, 1376, 1353, 1260, 1240, 
1200, 1130, 1110, 1073, 1032, 1020, 972 cm.sup.-1. 
EXAMPLE 17 
1-Trimethylsilyloxy-11.alpha.,15.alpha.-bis(2-tetrahydropyranyloxy)-16.xi.- 
chloroprosta-cis-5,trans-13-dien-9.alpha.-ol 
By proceeding as described in Reference Example 5 but replacing the 
16.xi.-chloro-PGF.sub.2.alpha. methyl ester by 575 mg. of 
11.alpha.,15.alpha.-bis(2-tetrahydropyranyloxy)-16.xi.-chloroprosta-cis-5, 
trans-13-dien-1,9.alpha.-diol (prepared as described in Example 16) 
dissolved in 5 ml. of methylene chloride and utilizing 0.21 ml. of 
N-trimethylsilyldiethylamine, there were obtained 607 mg. of the crude 
title compound having the following physical characteristic: 
Tlc (developing solvent, benzene-ethyl acetate = 2:1): 
Rf = 0.50. 
EXAMPLE 18 
1-Trimethylsilyloxy-11.alpha.,15.alpha.-bis(2-tetrahydropyranyloxy)-16.xi.- 
chloroprosta-cis-5,trans-13-dien-9-one 
By proceeding as described in Example 3 but replacing the methyl 
9.alpha.-hydroxy-11.alpha.,15.alpha.-bis(trimethylsilyloxy)-16.xi.-chlorop 
rosta-cis-5,trans-13-dienoate by 607 mg. of 
1-trimethylsilyloxy-11.alpha.,15.alpha.-bis(2-tetrahydropyranyloxy)-16.xi. 
-chloroprosta-cis-5,trans-13-dien-9.alpha.-ol (prepared as described in 
Example 17) dissolved in 10 ml. of toluene and utilizing a suspension of 
667.5 mg. of N-chlorosuccinimide in 10 ml. of toluene, 0.1 ml. of dimethyl 
sulphide and 1 ml. of triethylamine, there were obtained 595 mg. of the 
crude title compound having the following physical characteristic: 
Tlc (developing solvent, benzene-ethyl acetate = 2:1): 
Rf = 0.49. 
EXAMPLE 19 
1,11.alpha.,15.alpha.-Trihydroxy-16.xi.-chloroprosta-cis-5,trans-13-dien-9- 
one [or 16.xi.-chloro-PGE.sub.2 alcohol] 
By proceeding as described in Example 2 but replacing the methyl 
9.alpha.,11.alpha.-bis(2-tetrahydropyranyloxy)-15.xi.-hydroxy-16.xi.-chlor 
oprosta-cis-5,trans-13-dienoate by 595 mg. of 
1-trimethylsilyloxy-11.alpha.,15.alpha.-bis(2-tetrahydropyranyloxy)-16.xi. 
-chloroprosta-cis-5,trans-13-dien-9-one (prepared as described in Example 
18) dissolved in a mixture of 1 ml. of tetrahydrofuran and 9 ml. of 65% 
aqueous acetic acid, there were obtained 57 mg. of the title compound 
having the following physical characteristics: 
Tlc (developing solvent, ethyl acetate): Rf = 0.25; 
Ir (liquid film): .nu.; 3400, 1730, 1420, 1370, 1240, 1155, 1070, 1040, 968 
cm.sup.-1 ; 
Nmr (cdcl.sub.3 solution): .delta.; 5.83-5.55 (2H, m), 5.55-5.10 (2H, m), 
4.40-3.74 (3H, m), 3.74-3.36 (2H, m), 2.75 (1H,dd). 
REFERENCE EXAMPLE 18 
Methyl 
9.alpha.-acetoxy-11.alpha.-(2-tetrahydropyranyloxy)-15-oxo-16.xi.-chloropr 
ost-trans-13-enoate 
By proceeding as described in Reference Example 12 but replacing the 
1.alpha.-acetoxy-2.alpha.-(6-methoxycarbonylhex-cis-2-enyl)-3.beta.-formyl 
-4.alpha.-(2-tetrahydropyranyloxy)-cyclopentane by 720 mg. of 
1.alpha.-acetoxy-2.alpha.-(6-methoxycarbonylhexyl)-3.beta.-formyl-4.alpha. 
-(2-tetrahydropyranyloxy)-cyclopentane (prepared as described hereafter) 
dissolved in 4 ml. of tetrahydrofuran and utilizing a suspension of 89.5 
mg. of sodium hydride (63% content) in 3 ml. of tetrahydrofuran and a 
solution of 695 mg. of dimethyl 2-oxo-3-chloroheptylphosphonate (prepared 
as described in Reference Example 12) in 3 ml. of tetrahydrofuran, there 
were obtained 783 mg. of the title compound having the following physical 
characteristics: 
Tlc (developing solvent, benzene-ethyl acetate = 2:1): 
Rf = 0.58; 
Ir (liquid film): .nu.; 1740, 1696, 1680, 1627, 1437, 1375, 1223, 1200, 
1130, 1078, 1032, 1020, 970 cm.sup.-1 ; 
Nmr (cdcl.sub.3 solution): .delta.; 7.14-6.70 (1H, m), 6.68-6.36 (1H, m), 
5.26-5.00 (1H, m), 4.66-4.43 (1H, m), 4.43-4.22 (1H, m), 4.22-3.24 (3H, 
m), 3.66 (3H, s), 2.29 (2H, t), 2.06 (3H, s). 
1.alpha.-Acetoxy-2.alpha.-(6-methoxycarbonylhexyl)-3.beta. 
-formyl-4.alpha.-(2-tetrahydropyranyloxy)-cyclopentane, used as a starting 
material in the above procedure, was prepared from 
1.alpha.-acetoxy-2.alpha.-(6-methoxycarbonylhex-cis-2-enyl)-3.beta.-formyl 
-4.alpha.-(2-tetrahydropyranyloxy)cyclopentane (prepared as described in 
Reference Example 6 ) as follows: 
1.15 g. of 
1.alpha.-acetoxy-2.alpha.-(6-methoxycarbonylhex-cis-2-enyl)-3.beta.-formyl 
-4.alpha.-(2-tetrahydropyranyloxy)cyclopentane were hydrogenated at a 
pressure of one atmosphere in 30 ml. of methanol containing 290 mg. of 5% 
palladium on charcoal. The reduction was stopped after the absorption of 
one equivalent of hydrogen gas. The catalyst was filtered off and the 
filtrate was concentrated under reduced pressure to give 1.12 g. of 
1.alpha.-acetoxy-2.alpha.-(6-methoxycarbonylhexyl)-3.beta.-formyl-4.alpha. 
-(2-tetrahydropyranyloxy)-cyclopentane having the following physical 
characteristics: 
Tlc (developing solvent, benzene-ethyl acetate = 2:1): 
Rf = 0.49; 
Ir (liquid film): .nu.; 2970, 2880, 2730, 1740, 1430, 1370, 1240, 1125, 
1015, 960 cm.sup.-1 ; 
Nmr (cdcl.sub.3 solution): .delta.; 9.75 (1H, t), 5.3-4.9 (1H, m), 4.8-4.1 
(1H, m), 3.65 (3H, s), 2.06 (3H, s). 
REFERENCE EXAMPLE 19 
Methyl 
9.alpha.-acetoxy-11.alpha.-(2-tetrahydropyranyloxy-15.xi.-hydroxy-15-methy 
l-16.xi.-chloroprost-trans-13-enoate. 
Under an atmosphere of nitrogen, 2.5 ml. of a 0.9M solution of metyllithium 
in diethyl ether were added dropwise to a solution of 768 mg. of methyl 
9.alpha.-acetoxy-11.alpha.-(2-tetrahydropyranyloxy)-15-oxo-16.xi.-chloropr 
ost-trans-13-enoate (prepared as described in Reference Examples 18) in 10 
ml. of tetrahydrofuran at -78.degree. C. and the mixture was stirred at 
the same temperature or 1 hour. The reaction mixture was quenched with 
acetic acid and poured into 20 ml. of water. The solution was extracted 
with ethyl acetate and the extract was washed with a saturated aqueous 
solution of sodium bicarbonate and an aqueous solution of sodium chloride, 
dried over sodium sulphate and concentrated under reduced pressure. The 
residue was purified by column chromatography on silica gel using a 
mixture of benzene and ethyl acetate (9:1) as eluent to give 296 mg. of 
the title compound having the following physical characteristics:- 
Tlc (developing solvent, benzene-ethyl acetate = 2:1): 
Rf = 0.39; 
Ir (liquid film): .nu.; 3460, 1740, 1438, 1377, 1249, 1200, 1133, 1079, 
1030, 1021, 975 cm.sup.-1 ; 
Nmr (cdcl.sub.3 solution): .delta.; 5.78-5.56 (2H, m), 5.22-5.00 (1H, m), 
4.71-4.52 (1H, m), 4.30-3.20 (4H, m), 3.66 (3H, s), 2.29 (2H, m), 2.05 
(3H, s), 1.42-1.24 (3H, m). 
REFERENCE EXAMPLE 20 
Methyl 9.alpha.-acetoxy-11.alpha., 
15.xi.-bis(2-tetrahydropyranyloxy)-15-methyl-16.xi.-chloroprost-trans-13-e 
noate 
By proceeding as described in Reference Examples 2 but replacing the 
15-oxo-PGF.sub.2.alpha. methyl ester by 283 mg. of methyl 
9.alpha.-acetoxy-11.alpha.-(2-tetrahydropyranyloxy)-15.xi.-hydroxy-15-meth 
yl-16.xi.-chloroprost-trans-13-enoate (prepared as described in Reference 
Example 19) dissolved in 5 ml. of methylene chloride and utilized a 
catalytic amount of p-toluenesulphonic acid and 0.2 ml. of 
2,3-dihydropyran, there were obtained 296 mg. of the title compound having 
the following physical characteristics:- TLC (developing solvent, 
benzene-ethyl acetate = 2:1): 
Rf = 0.55; 
Ir (liquid film): .nu.; 1740, 1436, 1373, 1242, 1200, 1120, 1033, 1020, 979 
cm.sup.-1. 
EXAMPLE 20 
Methyl 9.alpha.-hydroxy-11.alpha.,15.xi.-bis(2-tetrahydropyranyloxy)- 
15-methyl-16.xi.-chloroprost-trans-13-enoate 
By proceeding as described in Reference Example 11 but replacing the methyl 
9.alpha.-acetoxy-11.alpha., 
15.xi.-bis(2-tetrahydropyranyloxy)-16.xi.-chloroprosta-cis-5,trans-13-dien 
oate by 296 mg. of methyl 9.alpha.-acetoxy-11.alpha., 
15.xi.-bis(2-tetrahydropyranyloxy)-15-methyl-16.xi.-chloroprost-trans-13-e 
noate (prepared as described in Reference Example 20) dissolved in 5 ml. of 
methanol and utilizing 120 mg. of potassium carbonate, there were obtained 
204 mg. of the title compound having the following physical 
characteristics:- 
Tlc (developing solvent, benzene-ethyl acetate = 2:1): 
Rf = 0.35; 
Ir (liquid film): .nu.; 3460, 1740, 1439, 1380, 1260, 1242, 1200, 1120, 
1075, 1031, 1021, 980 cm.sup.-1 ; 
Nmr (cdcl.sub.3 solution): .delta.; 5.78-5.42 (2H, m), 4.90-4.55 (2H, m), 
4.35-3.20 (7H, m), 3.66 (3H, s), 1.52-1.33 (3H, m). 
EXAMPLE 21 
Methyl 9-oxo-11.alpha., 
15.xi.-bis(2-tetrahydropyranyloxy)-15-methyl-16.xi.-chloroprost-trans-13-e 
noate 
By proceeding as described in Example 3 but replacing the methyl 
9.alpha.-hydroxy-11.alpha., 
15.alpha.-bis-(trimethylsilyloxy)-16.xi.-chloroprosta-cis-5,trans-13-dieno 
ate by 204 mg. of methyl 9.alpha.-hydroxy-11.alpha. 
,15.xi.-bis(2-tetrahydropyranyloxy)-15-metyl-16.xi.-chloroprost-trans-13-e 
noate (prepared as described in Example 20) dissolved in 4 ml. of toluene 
and utilizing a suspension of 280 mg. of N-chlorosuccinimide in 4 ml. of 
toluene, 0.04 ml. of dimethyl sulphide and 0.4 ml. of triethylamine, there 
were obtained 230 mg. of the crude title compound having the following 
physical characteristic:- 
Tlc (developing solvent, benzene-ethyl acetate = 2:1): 
Rf = 0.55. 
EXAMPLE 22 
Methyl 9-oxo-11.alpha. 
,15.xi.-dihydroxy-15-methyl-16.xi.-chloroprost-trans-13-enoate [or 
15.xi.-methyl-16.xi.-chloro-PGE.sub.1 methyl ester] 
By proceeding as described in Example 2 but replacing the methyl 9.alpha. 
,11.alpha.-bis(2-tetrahydropyranyloxy)-15.xi.-hydroxy-16.xi.-chloroprosta- 
cis-5,trans-13-dienoate by 230 mg. of methyl 9-oxo-11.alpha. 
,15.xi.-bis(2-tetrahydropyranyloxy)-15-methyl-16.xi.-chloroprost-trans-13- 
enoate (prepared as described in Example 21) dissolved in a mixture of 0.5 
ml. of tetrahydrofuran and 4 ml. of 65% aqueous acetic acid, there were 
obtained 100 mg. of the title compound having the following physical 
characteristics:- 
Tlc (developing solvent, ethyl acetate): Rf = 0.48; 
Ir (liquid film): .nu.; 3420, 1740, 1435, 1372, 1243, 1163, 1073, 975 
cm.sup.-1 ; 
Nmr (cdcl.sub.3 solution): .delta.; 5.85-5.64 (2H, m), 4.25-3.70 (2H, m), 
3.65 (3H, s), 2.75 (1H, dd), 1.39 (3H, s). 
REFERENCE EXAMPLE 21 
Methyl 9.alpha.-acetoxy-11.alpha. 
-(2-tetrahydropyranyloxy)-15-oxo-16.xi.-chloro-16-methylprost-trans-13-eno 
ate 
By proceeding as described in Reference Example 18 but replacing the 
dimethyl 2-oxo-3-chloroheptylphosphonate by 376 mg. of dimethyl 
2-oxo-3-chloro-3-methylheptylphosphonate (prepared as described hereafter) 
dissolved in 2 ml. of tetrahydrofuran and utilizing a suspension of 45.7 
mg. of sodium hydride (63% content) in 3 ml. of tetrahydrofuran and a 
solution of 394 mg. of 
1.alpha.-acetoxy-2.alpha.-(6-methoxycarbonylhexyl)-3.beta.-formyl-4.alpha. 
-(2-tetrahydropyranyloxy)cyclopentane (prepared as described in Reference 
Example 18) in 5 ml. of tetrahydrofuran, there were obtained 431 mg. of 
the title compound having the following physical characteristics:- 
Tlc (developing solvent, benzene-ethyl acetate = 2:1): 
Rf = 0.59; 
Ir (liquid film): .nu.; 1739, 1696, 1624, 1437, 1376, 1222, 1200, 1130, 
1074, 1031, 1020, 970 cm.sup.-1 ; 
Nmr (cdcl.sub.3 solution): .delta.; 7.2-6.72 (2H, m), 5.26-5.00 (1H, m), 
4.68-4.42 (1H, m), 4.30-3.26 (3H, m), 3.66 (3H, s), 2.06 (3H, s), 1.66 
(3H, s). 
Dimethyl 2-oxo-3-chloro-3-methylheptylphosphonate, used as a starting 
material, was prepared from dimethyl 2-oxo-3-methylheptylphosphonate 
(described in British Pat. Specification No. 1398291) as follows: 
Under an atmosphere of nitrogen, a solution of 9.44 g. of dimethyl 
2-oxo-3-methylheptylphosphonate in 20 ml. of tetrahydrofuran was added 
dropwise to a suspension of 1.68 g. of sodium hydride (63% content) in 80 
ml. of tetrahydrofuran at room temperature and the mixture stirred at room 
temperature for 30 minutes. After cooling the solution to 0.degree. C., 
there was added dropwise 36 ml. of a 1.4M solution of n-butyllithium in 
n-hexane and the mixture was stirred at that temperature for 45 minutes. 
After cooling the resulting solution to -78.degree. C., there was added 
dropwise a solution of 8.83 g. of benzenesulphonyl chloride in 20 ml. of 
tetrahydrofuran and the mixture was stirred at -78.degree. C. for 30 
minutes, then at 0.degree. C. for 30 minutes and at room temperature for 
30 minutes. The reaction mixture was then acidified to pH 3 with acetic 
acid, diluted with 50 ml. of chloroform, washed with water and an aqueous 
solution of sodium chloride, dried over sodium sulphate an concentrated 
under reduced pressure. The residue was purified by column chromatography 
on silica gel using a mixture of benzene and ethyl acetate (1:2) as eluent 
to give 3.18 g. of dimethyl 2-oxo-3-chloro-3-methylheptylphosphonate 
having the following physical characteristics:- 
Tlc (developing solvent, ethyl acetate): Rf = 0.41; 
Ir (liquid film): .nu.; 1715, 1450, 1374, 1258, 1183, 1032, 870, 860, 808 
cm.sup.-1 ; 
Nmr (cdcl.sub.3 solution): .delta.; 3.73 (6H, d), 3.39 (2H, d), 1.63 (3H, 
s). 
REFERENCE EXAMPLE 22 
Methyl 
9.alpha.-acetoxy-11.alpha.-(2-tetrahydropyrayloxy)-15.alpha.-hydroxy-16.xi 
.-chloro-16-methylprost-trans-13-enoate 
By proceeding as described in Example 1 but replacing the methyl 9.alpha. 
,11.alpha.-bis(2-tetrahydropyranyloxy)-15-oxo-16.xi.-chloroprosta-cis-5,tr 
ans-13-dienoate by 469 mg. of methyl 
9.alpha.-acetoxy-11.alpha.-(2-tetrahydropyranyloxy)-15-oxo-16.xi.-chloro-1 
6-chloro-16-methylprost-trans-13-enoate (prepared as described in Reference 
Example 21) dissolved in 7 ml. of methanol and utilizing 39.5 mg. of 
sodium borohydride, there were obtained 322 mg. of the title compound and 
84 mg. of its 15.beta.-hydroxy isomer. The title compound showed the 
following physical characteristics:- 
Tlc (developing solvent, benzene-ethyl acetate = 2:1): 
Rf = 0.38, (15.beta.-hydroxy isomer, Rf = 0.46); 
Ir (liquid film): .nu.; 3450, 1740, 1438, 1375, 1244, 1200, 1172, 1075, 
1020, 971 cm.sup.-1 ; 
Nmr (cdcl.sub.3 solution): .delta.; 5.82-5.52 (2H, m), 5.26-4.95 (1H, m), 
4.72-4.48 (1H, m), 4.28-3.26 (4H, m), 3.66 (3H, s), 2.06 (3H, s), 
1.64-1.47 (3H, m). 
REFERENCE EXAMPLE 23 
Methyl 
9.alpha.-acetoxy-11.alpha.,15.alpha.-bis(2-tetrahydropyranyloxy)-16.xi.-ch 
loro-16-methylprost-trans-13-enoate 
By proceeding as described in Reference Example 2 but replacing the 
15-oxo-PGF.sub.2.alpha. methyl ester by 304 mg. of methyl 
9.alpha.-acetoxy-11.alpha.-(2-tetrahydropyranyloxy)-15.alpha.-hydroxy-16.x 
i.-chloro-16-methylprost-trans-13-enoate (prepared as described in Example 
22) dissolved in 5 ml. of methylene chloride and utilizing a catalytic 
amount of p-toluenesulphonic acid and 0.1 ml. of 2,3-dihydropyran, there 
were obtained 390 mg. of the crude title compound having the following 
physical characteristics:- 
Tlc (developing solvent, benzene-ethyl acetate = 2:1): 
Rf = 0.54; 
Ir (liquid film):.nu.; 1740, 1438, 1373, 1350, 1221, 1130, 1118, 1078, 
1035, 1020, 972 cm.sup.-1. 
EXAMPLE 23 
Methyl 9.alpha.-hydroxy-11.alpha. ,15.alpha. 
-bis(2-tetrahydropyranyloxy)-16.xi.-chloro-16-methylprost-trans-13-enoate 
By proceeding as described in Reference Example 11 but replacing the methyl 
9.alpha.-acetoxy-11.alpha.,15.xi.-bis(2-tetrahydropyranyloxy)-16.xi.-chlor 
oprosta-cis-5,trans-13-dienoate by 390 mg. of methyl 
9.alpha.-acetoxy-11.alpha. 
,15.alpha.-bis(2-tetrahydropyranyloxy)-16.xi.-chloro-16-methylprost-trans- 
13-enoate (prepared as described in Reference Example 23) dissolved in 5 
ml. of methanol and utilizing 67 mg. of potassium carbonate, there were 
obtained 302 mg. of the title compound having the following physical 
characteristics:- 
Tlc (developing solvent, benzene-ethyl acetate = 2:1): 
Rf = 0.34; 
Ir (liquid film):.nu.; 3470, 1740, 1438, 1376, 1260, 1200, 1130, 1117, 
1077, 1020, 975 cm.sup.-1 ; 
Nmr (cdcl.sub.3 solution): .delta.; 5.70-5.35 (2H, m), 4.95-4.52 (2H, m), 
4.32-3.20 (7H, m), 3.66 (3H, s). 
EXAMPLE 24 
Methyl 9-oxo-11.alpha. 
,15.alpha.-bis(2-tetrahydropyranyloxy)-16.xi.-chloro-16-methylprost-trans- 
13-enoate 
By proceeding as described in Example 3 but replacing the methyl 
9.alpha.-hydroxy-11.alpha. 
,15.alpha.-bis(trimethylsilyloxy)-16.xi.-chloroprosta-cis-5,trans-13-dieno 
ate by 291 mg. of methyl 9.alpha.-hydroxy-11.alpha. 
,15.alpha.-bis(2-tetrahydropyranyloxy)-16.xi.-chloro-16-methylprost-trans- 
13-enoate (prepared as described in Example 23) dissolved in 5 ml. of 
toluene and utilizing a suspension of 398 mg. of N-chlorosuccinimide in 5 
ml. of toluene, 0.05 ml. of dimethyl sulphide and 0.5 ml. of 
triethylamine, there were obtained 310 mg. of the crude title compound 
having the following physical characteristic:- 
Tlc (developing solvent, benzene-ethyl acetate = 2:1): 
Rf = 0.51. 
EXAMPLE 25 
Methyl 9-oxo-11.alpha. 
,15.alpha.-dihydroxy-16.xi.-chloro-16-methylprost-trans-13-enoate [or 
16.xi.-chloro-16-methyl-PGE.sub.1 methyl ester] 
By proceeding as described in Example 2 but replacing the methyl 
9.alpha.,11.alpha.-bis(2-tetrahydropyranyloxy)-15.xi.-hydroxy-16.xi.-chlor 
oprosta-cis-5,trans-13-dienoate by 310 mg. of methyl 
9-oxo-11.alpha.,15.alpha.-bis(2-tetrahydropyranyloxy)-16.xi.-chloro-16-met 
hylprost-trans-13-enoate (prepared as described in Example 24) dissolved in 
a mixture of 1 ml. of tetrahydrofuran and 5 ml. of 65% aqueous acetic 
acid, there were obtained 117 mg. of the title compound having the 
following physical characteristics: 
Tlc (developing solvent, ethyl acetate): Rf = 0.47; 
Ir (liquid film): .nu.; 3415, 1740, 1435, 1377, 1243, 1161, 1075, 975 
cm.sup.-1 ; 
Nmr (cdcl.sub.3 solution): .delta.; 5.92-5.60 (2H, m), 4.32-3.76 (2H, m), 
3.65 (3H, s), 2.75 (1H, dd), 1.57-1.46 (3H, m). 
REFERENCE EXAMPLE 24 
Methyl 
9.alpha.-acetoxy-11.alpha.-(2-tetrahydropyranyloxy)-15-oxo-16.xi.-chloropr 
osta-trans-2,trans-13-dienoate 
By proceeding as described in Reference Example 12 but replacing the 
1.alpha.-acetoxy-2.alpha.-(6-methoxycarbonylhex-cis-3-enyl)-3.beta.-formyl 
-4.alpha.-(2-tetrahydropyranyloxy)-cyclopentane by 500 mg. of 
1.alpha.-acetoxy-2.alpha.-(6-methoxycarbonylhex-trans-5-enyl)-3.beta.-form 
yl-4.alpha.-(2-tetrahydropyranyloxy)cyclopentane (prepared as described 
hereafter) dissolved in 3 ml. of tetrahydrofuran and utilizing a 
suspension of 62.6 mg. of sodium hydride (63% content) in 5 ml of 
tetrahydrofuran and a solution of 486 mg. of dimethyl 
2-oxo-3-chloroheptylphosphonate (prepared as described in Reference 
Example 12) in 2 ml. of tetrahydrofuran, there were obtained 575 mg. of 
the title compound having the following physical characteristics: 
Tlc (developing solvent, benzene-ethyl acetate = 2:1): 
Rf = 0.56; 
Ir (liquid film): .nu.; 1740, 1700, 1660, 1628, 1435, 1376, 1244, 1137, 
1080, 1038, 1022, 980 cm.sup.-1 ; 
Nmr (cdcl.sub.3 solution): .delta.; 7.4-6.75 (2H, m), 6.57 (1H, dd), 5.81 
(1H, d), 5.35-5.04 (1H, m), 4.75-3.25 (5H, m), 3.74 (3H, s), 2.05 (3H, s). 
1.alpha.-Acetoxy-2.alpha.-(6-methoxycarbonylhex-trans-5-enyl)-3.beta.-formy 
l-4.alpha.-(2-tetrahydropyranyloxy)cyclopentane, used as a starting 
material in the above procedure, was prepared from 
2.alpha.-(6-methoxycarbonylhex-cis-2-enyl)-3.beta.-hydroxymethyl-4.alpha.- 
(2-tetrahydropyranyloxy)cyclopentan-1.alpha.-ol (prepared as described in 
Reference Example 6) as follows: 
1. 
2.alpha.-(6-methoxycarbonylhexyl)-3.beta.-hydroxymethyl-4.alpha.-(2-tetrah 
ydropyranyloxy)cyclopentan-1.alpha.-ol 
14.2 g. of 
2.alpha.-(6-methoxycarbonylhex-cis-2-enyl)-3.beta.-hydroxymethyl-4.alpha.- 
(2-tetrahydropyranyloxy)cyclopentan-1.alpha.-ol (prepared as described in 
Reference Example 6) was hydrogenated at a pressure of one atmosphere in 
300 ml. of methanol containing 3 g. of 5% palladium on charcoal. The 
reduction was stopped after the absorption of one equivalent of hydrogen 
gas. The catalyst was removed by filtration and the filtrate was 
concentrated under reduced pressure to give 13.8 g. of the title compound 
having the following physical characteristics: 
Tlc (developing solvent, benzene-ethyl acetate = 1:1): 
Rf = 0.28; 
Ir (liquid film): .nu.; 3450, 1740, 1440, 1030 cm.sup.-1 ; 
Nmr (cdcl.sub.3 solution): .delta.; 5.00-4.55 (1H, m), 3.70 (3H, s). 
2. 
2.alpha.-Phenylseleno-6-methoxycarbonylhexyl)-3.beta.-hydroxymethyl-4.alph 
a.-(2-tetrahydropyranyloxy)cyclopentan-1.alpha.-ol 
Under an atmosphere of nitrogen, a solution of 19.4 ml. of diisopropylamine 
in 350 ml. of tetrahydrofuran was cooled to -78.degree. C., and to it was 
added dropwise 114 ml. of a 1.2M solution of n-butyllithium in n-hexane 
and the mixture was stirred at -78.degree. C. for 20 minutes to give 
lithium diisopropylamide. To the lithium diisopropylamide solution was 
added dropwise a solution of 13.8 g. of 
2.alpha.-(6-methoxycarbonylhexyl)-3.beta.-hydroxymethyl-4.alpha.-(2-tetrah 
ydropyranyloxy)cyclopentan-1.alpha.-ol [prepared as described in (1) above] 
in 100 ml. of tetrahydrofuran at -78.degree. C. and the mixture was 
stirred at the same temperature for 30 minutes. A solution of 18.2 g. of 
diphenyldiselenide in 50 ml. of tetrahydrofuran was added dropwise to the 
reaction mixture at -78.degree. C. and the solution was stirred at the 
same temperature for one hour and then at 0.degree. C. for 20 minutes. The 
reaction mixture was poured into an aqueous solution of ammonium chloride 
and extracted with ethyl acetate. The extract was washed with water and an 
aqueous solution of sodium chloride, dried over magnesium sulphate and 
concentrated under reduced pressure. The residue was purified by column 
chromatography on silica gel using a mixture of benzene and ethyl acetate 
(3:2) as eluent to give 15.8 g. of the title compound having the following 
physical characteristics: 
Tlc (developing solvent, benzene-ethyl acetate = 1:1): 
Rf = 0.37; 
Ir (liquid film): .nu.; 3450, 1740, 1580, 1440, 1030 cm.sup.-1 ; 
Nmr (cdcl.sub.3 solution): .delta.; 7.75-7.10 (5H, m), 5.00-4.55 (1H, m), 
3.70 (3H, s). 
3. 
2.alpha.-(6-Methoxycarbonylhex-trans-5-enyl)-3.beta.-hydroxymethyl-4.alpha 
.-(2-tetrahydropyranyloxy)cyclopentan-1.alpha.-ol 
To a solution of 15.8 g. of 
2.alpha.-(6-phenylseleno-6-methoxycarbonylhexyl)-3.beta.-hydroxymethyl-4.a 
lpha.-(2-tetrahydropyranyloxy)cyclopentan-1.alpha.-ol [prepared as 
described in (2) above] in a mixture of 200 ml. of ethyl acetate and 100 
ml. of tetrahydrofuran, there were added 4.5 g. of sodium carbonate and 
6.2 ml. of 30% hydrogen peroxide and the mixture was stirred at 30.degree. 
C for 30 minutes. The reaction mixture was then poured into water, washed 
with an aqueous solution of sodium carbonate, water and an aqueous 
solution of sodium chloride, dried over magnesium sulphate and 
concentrated under reduced pressure to give 10.4 g. of the title compound 
having the following physical characteristics: 
Tlc (developing solvent, benzene-ethyl acetate = 1:1): 
Rf = 0.28; 
Ir (liquid film): .nu.; 3450, 1735, 1660, 1440, 1030 cm.sup.-1 ; 
Nmr (cdcl.sub.3 solution): .delta.; 6.90 (1H, dt), 5.82 (1H, d), 5.00-4.55 
(1H, m), 3.70 (3H, s). 
4. 
1.alpha.-Acetoxy-2.alpha.-(6-methoxycarbonylhex-trans-5-enyl)-3.beta.-hydr 
oxymethyl-4.alpha.-(2-tetrahydropyranyloxy)cyclopentane 
Under an atmosphere of nitrogen, a solution of 4.3 ml. of 
trimethylchlorosilane in 20 ml. of methylene chloride was added dropwise 
to a solution of 10.4 g. of 
2.alpha.-(6-methoxycarbonylhex-trans-5-enyl)-3.beta.-hydroxymethyl-4.alpha 
.-(2-tetrahydropyranyloxy)cyclopentan-1.alpha.-ol [prepared as described in 
(3) above] in a mixture of 150 ml. of methylene chloride and 18.8 ml. of 
pyridine at -20.degree. C., and the mixture was stirred at the same 
temperature for 20 minutes. To the solution thus obtained was added 
dropwise a solution of 2.45 ml. of acetyl chloride in 50 ml. of methylene 
chloride at -20.degree. C. and the mixture was stirred at room temperature 
for 30 minutes. Then 3 ml. of ethanol was added to the reaction mixture in 
order to decompose the excess of acetyl chloride. Pyridine in the solution 
was quenched with 80 g. of sodium bisulphate, and the resulting 
precipitate was filtered off. The filtrate was concentrated under reduced 
pressure. The residue was dissolved in 300 ml. of ethyl acetate, 100 ml. 
of a saturated aqueous solution of oxalic acid was added and the mixture 
was stirred vigorously at room temperature for 30 minutes. The reaction 
mixture was then extracted with ethyl acetate, the extract was washed with 
water, an aqueous solution of sodium bisulphate, water and an aqueous 
solution of sodium chloride, dried over magnesium sulphate and 
concentrated under reduced pressure. The residue was purified by column 
chromatography on silica gel using a mixture of benzene and ethyl acetate 
(3:1) as eluent to give 7.2 g. of the title compound having the following 
physical characteristics: 
Tlc (developing solvent, benzene-ethyl acetate = 1:1): 
Rf = 0.51; 
Ir (liquid film): .nu.; 3450, 1735, 1660, 1440, 1030 cm.sup.-1 ; 
Nmr (cdcl.sub.3 solution): .delta.; 6.90 (1H, dt), 5.82 (1H, d), 5.25-4.90 
(1H, m), 4.85-4.45 (1H, m), 3.71 (3H, s), 2.05 (3H, s). 
5. 
1.alpha.-Acetoxy-2.alpha.-(6-methoxycarbonylhex-trans-5-enyl)-3.beta.-form 
yl-4.alpha.-(2-tetrahydropyranyloxy)cyclopentane 
Under an atmosphere of nitrogen, 34 ml. of pyridine were dissolved in 440 
ml. of methylene chloride, 20.2 g. of chromium trioxide were added with 
stirring and the mixture was then stirred at room temperature for 15 
minutes. To the reaction mixture was added 88 g. of infusorial earth and 
the solution was cooled to 0.degree. C. To it was added a solution of 7.2 
g. of 
1.alpha.-acetoxy-2.alpha.-(6-methoxycarbonylhex-trans-5-enyl)-3.beta.-hydr 
oxymethyl-4.alpha.-(2-tetrahydropyranyloxy)cyclopentane [prepared as 
described in (4) above] in 100 ml. of methylene chloride at 0.degree. C. 
After 10 minutes of stirring at 0.degree. C., 155 g. of sodium bisulphate 
were added to the reaction mixture and stirring was continued for a 
further 10 minutes. The resulting precipitate was filtered through a pad 
of magnesium sulphate and the filtrate was concentrated under reduced 
pressure. The residue was purified by column chromatography on silica gel 
using a mixture of benzene and ethyl acetate (5:1) as eluent to give 5.85 
g. of the title compound having the following physical characteristics: 
Tlc (developing solvent, benzene-ethyl acetate = 2:1): 
Rf = 0.67; 
Ir (liquid film): .nu.; 1735, 1660, 1440, 1250, 1030 cm.sup.-1 ; 
Nmr (cdcl.sub.3 solution): .delta.; 10.00-9.70 (1H, m), 6.90 (1H, dt), 5.82 
(1H, d), 5.30-4.96 (1H, m), 4.75-4.10 (2H, m), 3.72 (3H, s), 2.06 (3H, 
s). 
REFERENCE EXAMPLE 25 
Methyl 
9.alpha.-acetoxy-11.alpha.-(2-tetrahydropyranyloxy)-15.xi.-hydroxy-16.xi.- 
chloroprosta-trans-2,trans-13-dienoate 
By proceeding as described in Example 1 but replacing the methyl 
9.alpha.,11.alpha.-bis(2-tetrahydropyranyloxy)-15 
-oxo-16.xi.-chloroprosta-cis-5,trans-13-dienoate by 570 mg. of methyl 
9.alpha.-acetoxy-11.alpha.-(2-tetrahydropyranyloxy)-15-oxo-16.xi.-chloropr 
osta-trans-2-trans,-13-dienoate (prepared as described in Reference Example 
24) dissolved in 8 ml. of methanol and utilizing 49.4 mg. of sodium 
borohydride, there were obtained 623 mg. of the title compound having the 
following physical characteristics: 
Tlc (developing solvent, benzene-ethyl acetate = 2:1): 
Rf = 0.35 and 0.40; 
Ir (liquid film): .nu.; 3450, 1738, 1654, 1434, 1242, 1132, 1035, 1020, 974 
cm.sup.-1 ; 
Nmr (cdcl.sub.3 solution): .delta.; 7.18-6.70 (1H, m), 5.94-5.45 (3H, m), 
5.22-4.96 (1H, s), 4.74-4.42 (1H, m), 4.30-3.30 (5H, m), 3.72 (3H, s), 
2.66 (3H, s). 
REFERENCE EXAMPLE 26 
Methyl 
9.alpha.-acetoxy-11.alpha.,15.xi.-bis(2-tetrahydropyranyloxy)-16.xi.-chlor 
oprosta-trans-2,trans-13-dienoate 
By proceeding as described in Reference Example 2 but replacing the 
15-oxo-PGF.sub.2.alpha. methyl ester by 610 mg. of methyl 
9.alpha.-acetoxy-11.alpha.-(2-tetrahydropyranyloxy)-15.xi.-hydroxy-16.xi.- 
chloroprosta-trans-2,trans-13-dienoate (prepared as described in Reference 
Example 25) dissolved in 10 ml. of methylene chloride and utilizing a 
catalytic amount of p-toluenesulphonic acid and 0.3 ml. of 
2,3-dihydropyran, there were obtained 730 mg. of the crude title compound 
having the following physical characteristics: 
Tlc (developing solvent, benzene-ethyl acetate = 2:1): 
Rf = 0.51; 
Ir (liquid film): .nu.; 1735, 1658, 1437, 1380, 1245, 1200, 1130, 1120, 
1080, 1040, 1023, 978 cm.sup.-1. 
EXAMPLE 26 
Methyl 
9.alpha.-hydroxy-11.alpha.,15.xi.-bis(2-tetrahydropyranyloxy)-16.xi.-chlor 
oprosta-trans-2,trans-13 -dienoate 
By proceeding as described in Reference Example 11 but replacing the methyl 
9.alpha.-acetoxy-11.alpha.,15.xi.-bis(2-tetrahydropyranyloxy)-16.xi.-chlor 
oprosta-cis-5,trans-13-dienoate by 730 mg. of methyl 
9.alpha.-acetoxy-11.alpha.,15.xi.-bis(2-tetrahydropyranyloxy)-16.xi.-chlor 
oprosta-trans-2,trans-13-dienoate (prepared as described in Reference 
Example 26) dissolved in 12 ml. of methanol and utilizing 228 mg. of 
potassium carbonate, there were obtained 552 mg. of the title compound 
having the following physical characteristics: 
Tlc (developing solvent, benzene-ethyl acetate = 2:1): 
Rf = 0.30; 
Ir (liquid film): .nu.; 3450, 1730, 1658, 1435, 1273, 1242, 1200, 1132, 
1117, 1080, 1036, 1022, 978 cm.sup.-1 ; 
Nmr (cdcl.sub.3 solution): .delta.; 7.18-6.70 (1H, m), 5.96-5.38 (3H, m), 
4.92-4.50 (2H, m), 4.34-3.30 (8H, m), 3.72 (3H, s). 
EXAMPLE 27 
Methyl 
9-oxo-11.alpha.,15.xi.-bis(2-tetrahydropyranyloxy)-16.xi.-chloroprosta-tra 
ns-2,trans-13-dienoate 
By proceeding as described in Example 3 but replacing the methyl 
9.alpha.-hydroxy-11.alpha.,15.alpha.-bis(trimethylsilyloxy)-16.xi.-chlorop 
rosta-cis-5,trans-13-dienoate by 536 mg. of methyl 
9.alpha.-hydroxy-11.alpha.,15.xi.-bis(2-tetrahydropyranyloxy)-16.xi.-chlor 
oprosta-trans-2,trans-13-dienoate (prepared as described in Example 26) 
dissolved in 10 ml. of toluene and utilizing a suspension of 703 mg. of 
N-chlorosuccinimide in 10 ml. of toluene, 0.5 ml. of dimethyl sulphide and 
1.75 ml. of triethylamine, there were obtained 422 mg. of the title 
compound having the following physical characteristics: 
Tlc (developing solvent, benzene-ethyl acetate = 2:1): 
Rf = 0.48; 
Ir (liquid film): .nu.; 1741, 1725, 1655, 1435, 1273, 1241, 1200, 1120, 
1075, 1034, 1020, 972 cm.sup.-1 ; 
EXAMPLE 28 
Methyl 
9-oxo-11.alpha.,15.alpha.-dihydroxy-16.xi.-chloroprosta-trans-2,trans-13-d 
ienoate [or 16.xi.-chloro-trans-.DELTA..sup.2 -PGE.sub.1 methyl ester] 
By proceeding as described in Example 2 but replacing the methyl 
9.alpha.,11.alpha.-bis(2-tetrahydropyranyloxy)-15.xi.-hydroxy-16.xi.-chlor 
oprosta-cis-5,trans-13-dienoate by 422 mg. of methyl 
9-oxo-11.alpha.,15.xi.-bis(2-tetrahydropyranyloxy)-16.xi.-chloroprosta-tra 
ns-2,trans-13-dienoate (prepared as described in Example 27) dissolved in a 
mixture of 1 ml. of tetrahydrofuran and 7 ml. of 65% aqueous acetic acid, 
there were obtained 94 mg. of the title compound and 68 mg. of its 
15.beta.-hydroxy isomer. The title compound showed the following physical 
characteristics: 
Tlc (developing solvent, ethyl acetate): Rf = 0.35, (15.beta.-hydroxy 
isomer, Rf = 0.45); 
Ir (liquid film): .nu.; 3410, 1743, 1727, 1656, 1435, 1275, 1200, 1177, 
1158, 1074, 1040, 974 cm.sup.-1 ; 
Nmr (cdcl.sub.3 solution)- .delta.; 6.92 (1H, dt), 5.95-5.53 (3H, m), 
4.34-3.57 (3H, m), 3.71 (3H, s), 2.75 (1H, dd). 
REFERENCE EXAMPLE 27 
Methyl 
9.alpha.-acetoxy-11.alpha.,20-bis(2-tetrahydropyranyloxy)-15-oxo-16.xi.-ch 
loroprost-trans-13-enoate 
By proceeding as described in Reference Example 15 but replacing the 
dimethyl 2-oxo-3-chloroheptylphosphonate by 2.83 g. of dimethyl 
2-oxo-3-chloro-7-(2-tetrahydropyranyloxy)heptylphosphonate (prepared as 
described hereafter) dissolved in 10 ml. of tetrahydrofuran and utilizing 
a suspension of 258 mg. of sodium hydride (63% content) in 5 ml. of 
tetrahydrofuran and a solution of 2.25 g. of 
1.alpha.-acetoxy-2.alpha.-(6-methoxycarbonylhexyl)-3.beta.-formyl-4.alpha. 
-(2-tetrahydropyranyloxy)cyclopentane (prepared as described in Reference 
Example 15) in 10 ml. of tetrahydrofuran, there were obtained 2.99 g. of 
the title compound having the following physical characteristics:- 
Tlc (developing solvent, benzene-ethyl acetate = 2:1): 
Rf = 0.27; 
Ir (liquid film):.nu.; 1738, 1694, 1625, 1437, 1373, 1355, 1322, 1240, 
1198, 1131, 1118, 1075, 1031, 1020, 970 cm.sup.-1 ; 
Nmr (cdcl.sub.3 solution): .delta.;7.16-6.74 (1H, m), 6.54 (1H, dd), 
5.25-5.01 (1H, m), 4.70-4.45 (2H, m), 4.45-4.25 (1H, m), 4.25-3.24 (7H, 
m), 3.66 (3H, s), 2.07 (3H, s). 
Dimethyl 2-oxo-3-chloro-7-(2-tetrahydropyranyloxy)-heptylphosphonate, used 
as a starting material in the above procedure, was prepared from ethyl 
6-hydroxyhexanote [prepared as described by S. R. Sandler and W. Karo, in 
`Organic Functional Group Preparation`, Academic Press, New York and 
London, Vol. 1, page 262. -cf. G. B. Hatch and H. Adkins, J. Amer. Chem. 
Soc., 59, 1694 (1937)] as follows. 
1. Ethyl 6-(2-tetrahydropyranyloxy)hexanoate 
To a solution of 66 g. of ethyl 6-hydroxyhexanoate in 400 ml. of methylene 
chloride were added 1 g. of p-toluenesulphonic acid and 45 g. of 
2,3-dihydropyran and the mixture was stirred at 25.degree. C. for 20 
minutes. The reaction mixture was then washed with an aqueous solution of 
sodium bicarbonate, dried and concentrated. The residue was distilled in 
vacuo to obtain 77 g. of the title compound having the following physical 
characteristics:- 
b.p. 135.degree. C./3 mm.Hg; 
Ir (liquid film): .nu.; 2940, 2860, 1740, 1445, 1370, 1350, 1325, 1260, 
1160, 1140, 1120, 1080, 1040, 985, 910, 870, 820 cm.sup.-1 ; 
Nmr (cdcl.sub.3 solution): .delta.; 4.70-4.35 (1H, m), 4.05 (2H, q), 
4.00-3.00 (4H, m), 2.24 (2H, t), 1.20 (3H, t). 
2. Dimethyl 2-oxo-7-(2-tetrahydropyranyloxy)heptylphosphonate 45 g. of 
dimethyl methylphosphonate were dissolved in 400 ml. of absolute 
tetrahydrofuran and 180 ml. of a 2M solution of n-butyllithium in diethyl 
ether were added dropwise whilst maintaining the temperature below 
-50.degree. C. Ten minutes later, 37 g. of ethyl 
6-(2-tetrahydropyranyloxy)-hexanoate (prepared as described above) in 100 
ml. of absolute tetrahydrofuran were added dropwise to the solution, and 
the reaction mixture stirred at the same temperature for 3 hours and then 
at 0.degree. C. for 16 hours. The reaction mixture was acidified with 
acetic acid and concentrated under reduced pressure. The residue was 
dissolved in a small amount of water and extracted with diethyl ether. The 
extract was dried over magnesium sulphate and concentrated under reduced 
pressure. The residue was distilled at 140.degree. C. (oil bath 
temperature) at a pressure of 0.2 mm.Hg. The residue was 31 g. of the 
title compound, the boiling point of which was too high to permit 
distillation and which had the following physical characteristics:- 
Ir (liquid film): .nu.; 2950, 2870, 1720, 1455, 1410, 1375, 1365, 1335, 
1275, 1200, 1190, 1140, 1120, 1110-990, 920, 880, 820 cm.sup.-1 ; 
Nmr (cdcl.sub.3 solution): .delta.; 4.75-4.30 (1H, m), 4.15-3.10 (4H, m), 
3.75 (6H, d), 3.06 (2H, d), 2.58 (2H, t). 
3. Dimethyl 2-oxo-3-chloro-7-(2-tetrahydropyranyloxy)-heptylphosphonate 
Under an atmosphere of nitrogen, a solution of 4.2 g. of dimethyl 
2-oxo-7-(2-tetrahydropyranyloxy)-heptylphosphonate (prepared as described 
above) in 15 ml. of tetrahydrofuran was added to a suspension of 596 mg. 
of sodium hydride (63% content) in 20 ml. of tetrahydrofuran at room 
temperature, and the mixture was stirred at the same temperature for 30 
minutes. After cooling to 0.degree. C., 14 ml. of a 1.3M solution of 
n-butyllithium in n-hexane were added to the solution and the mixture was 
stirred at 0.degree. C. for 30 minutes. After cooling the solution to 
-78.degree. C., there was added a solution of 3.23 g. of benzenesulphonyl 
chloride in 10 ml. of tetrahydrofuran. The mixture was stirred at 
-78.degree. C. for one hour and then at room temperature for one hour. The 
reaction mixture was acidified to pH 3 with acetic acid and concentrated 
under reduced pressure. The residue was dissolved in ethyl acetate, washed 
with water, dried over sodium sulphate and concentrated under reduced 
pressure. The residue was purified by column chromatography on silica gel 
using a mixture of ethyl acetate and benzene (5:1) as eluent to give 2.97 
g. of the title compound having the following physical characteristics:- 
Tlc (developing solvent, ethyl acetate): Rf = 0.25; 
Ir (liquid film): .nu.; 1720, 1440, 1348, 1225, 1180, 1130, 1118, 1025, 
862, 810 cm.sup.-1 ; 
Nmr (cdcl.sub.3 solution): .delta.; 4.75-4.20 (2H, m), 3.84 (6H, d), 
4.10-3.15 (6H, m). 
REFERENCE EXAMPLE 28 
Methyl 
9.alpha.-acetoxy-11.alpha.,20-bis(2-tetrahydropyranyloxy)-15.xi.-hydroxy-1 
6.xi.-chloroprost-trans-13-enoate 
By proceeding as described in Example 1 but replacing the methyl 
9.alpha.,11.alpha.-bis(2-tetrahydropyranyloxy)-15-oxo-16.xi.-chloroprosta- 
cis-5,trans-13-dienoate by 2.96 g. of methyl 
9.alpha.-acetoxy-11.alpha.,20-bis(2-tetrahydropyranyloxy)-15-oxo-16.xi.-ch 
loroprost-trans-13-enoate (prepared as described in Reference Example 27) 
dissolved in 20 ml. of methanol and utilizing 215 mg. of sodium 
borohydride, there were obtained 2.82 g. of the title compound having the 
following physical characteristics:- 
Tlc (developing solvent, benzene-ethyl acetate = 2:1): 
Rf = 0.29, 0.25 and 0.18; 
Ir (liquid film): .nu.; 3450, 1738, 1438, 1376, 1248, 1138, 1120, 1080, 
1038, 1027, 980 cm.sup.-1 ; 
Nmr (cdcl.sub.3 solution): .delta.; 5.75-5.54 (2H, m), 5.22-5.00 (1H, m), 
4.76-4.41 (2H, m), 4.41-3.20 (9H, m), 3.66 (3H, s), 2.04 (3H, s). 
REFERENCE EXAMPLE 29 
Methyl 
9.alpha.-acetoxy-11.alpha.,15.xi.,20-tris(2-tetrahydropyranyloxy)-16.xi.-c 
hloroprost-trans-13-enoate 
By proceeding as described in Reference Example 2 but replacing the 
15-oxo-PGF.sub.2.alpha. methyl ester by 2.41 g. of methyl 
9.alpha.-acetoxy-11.alpha.,20-bis(2-tetrahydropyranyloxy)-15.xi.-hydroxy-1 
6.xi.-chloroprost-trans-13-enoate (prepared as described in Reference 
Example 28) dissolved in 30 ml. of methylene chloride and utilizing a 
catalytic amount of p-toluenesulphonic acid and 1.4 ml. of 
2,3-dihydropyran, there were obtained 2.594 g. of the title compound 
having the following physical characteristics:- 
Tlc (developing solvent, benzene-ethyl acetate = 2:1): 
Rf = 0.46; 
Ir (liquid film): .nu.; 1738, 1437, 1373, 1352, 1243, 1200, 1133, 1120, 
1077, 1033, 1020, 973 cm.sup.-1 ; 
Nmr (cdcl.sub.3 solution): .delta.; 5.75-5.54 (2H, m), 5.22-5.00 (1H, m), 
4.77-4.40 (3H, m), 4.40-3.20 (11H, m), 3.66 (3H, s), 2.04 (3H, s). 
EXAMPLE 29 
Methyl 
9.alpha.-hydroxy-11.alpha.,15.xi.,20-tris(2-tetrahydropyranyloxy)16.xi.-ch 
loroprost-trans-13-enoate 
By proceeding as described in Reference Example 11 but replacing the methyl 
9.alpha.-acetoxy-11.alpha.,15.xi.-bis(2-tetrahydropyranyloxy)-16.xi.-chlor 
oprosta-cis-5,trans-13-dienoate by 2.56 g. of methyl 
9.alpha.-acetoxy-11.alpha.,15.xi.,20 
-tris(2-tetrahydropyranyloxy)-16.xi.-chloroprost-trans-13enoate (prepared 
as described in Reference Example 29) dissolved in 35 ml of methanol and 
utilizing 712 mg. of potassium carbonate, there were obtained 2.2 g. of 
the title compound having the following physical characteristics:- 
Tlc (developing solvent, benzene-ethyl acetate = 2:1): 
Rf = 0.27; 
Ir (liquid film): .nu.; 3470, 1740, 1438, 1355, 1261, 1200, 1137, 1120, 
1079, 1037, 1023, 977 cm.sup.-1 ; 
Nmr (cdcl.sub.3 solution): .delta.; 5.74-5.34 (2H, m), 4.86-4.42 (3H, m), 
4.30-3.18 (12H, m), 3.64 (3H, s). 
EXAMPLE 30 
Methyl 
9oxo-11.alpha.,15.xi.,20-tris(2-tetrahydropyranyloxy)-16.xi.-chloroprost-t 
rans-13-enoate 
by proceeding as described in Example 3 but replacing the methyl 
9.alpha.-hydroxy-11.alpha.,15.alpha.-bis(trimethylsilyloxy)-16.xi.-chlorop 
rosta-cis-5,trans-13-dienoate by 2.2 g. of methyl 
9.alpha.-hydroxy-11.alpha. ,15.xi.,20-tris(2-tetrahydropyranyloxy)-16.xi.- 
chloroprost-trans-13-enoate (prepared as described in Example 29) dissolved 
in 15 ml. of toluene and utilizing a suspension of 2.62 g. of 
N-chlorosuccinimide in 15 ml. of toluene, 1.93 g. of dimethyl sulphide and 
3.88 g. of triethylamine, there were obtained 2.19 g. of the title 
compound having the following physical characteristics:- 
Tlc (developing solvent, benzene-ethyl acetate = 2:1): 
Rf = 0.38; 
Ir (liquid film): .nu.; 1740, 1438, 1355, 1261, 1200, 1135, 1120, 1080, 
1037, 1022, 975 cm.sup.-1 ; 
Nmr (cdcl.sub.3 solution): .delta.; 5.88-5.50 (2H, m), 4.88-4.44 (3H, m), 
4.38-3.20 (11H, m), 3.66 (3H, s). 
EXAMPLE 31 
Methyl 
9-oxo-11.alpha.,15.alpha.,20-trihydroxy-16.xi.-chloroprost-trans13-enoate 
[or 16.xi.-chloro-20-hydroxy-PGE.sub.1 methyl ester] 
By proceeding as described in Example 2 but replacing the methyl 
9.alpha.,11.alpha.-bis(2-tetrahydropyranyloxy)-15.xi.-hydroxy-16.xi.-chlor 
oprosta-cis-5,trans-13-dienoate by 2.17 g. of methyl 
9-oxo-11.alpha.,15.xi.,20-tris(2-tetrahydropyranyloxy)-16.xi.-chloroprost- 
trans-13-enoate (prepared as described in Example 30) dissolved in a 
mixture of 5 ml. of tetrahydrofuran and 30 ml. of 65% aqueous acetic acid, 
there were obtained 532 mg. of the title compound and 299 mg. of its 
15.beta.-hydroxy isomer. The title compound showed the following physical 
characteristics:- 
Tlc (developing solvent, ethyl acetate-methanol = 95:5): 
Rf = 0.24 and 0.20, (15.beta.-hydroxy isomer, Rf = 0.27); 
Ir (liquid film): .nu.; 3400, 1740, 1438, 1250, 1165, 1075, 978 cm.sup.-1 ; 
Nmr (cdcl.sub.3 solution): .delta.; 5.82-5.60 (2H, m), 4.34-3.82 (3H, m), 
3.74-3.46 (2H, m), 3.65 (3H, s), 2.74 (1H, dd). 
EXAMPLE 32 
Methyl 
9-oxo-11.alpha.,15.alpha.,15.alpha.-dihydroxy-16.xi.-chloro-20-(p-toluenes 
ulphonyloxy)prost-trans-13-enoate 
To a solution of 262 mg. of methyl 
9-oxo-11.alpha.,15.alpha.,20-trihydroxy-16.xi.-chloroprost-trans-13-enoate 
(prepared as described in Example 31) in 5 ml. of methylene chloride were 
added 0.11 ml. of pyridine and 262 mg. of tosyl chloride at 0.degree. C., 
and the mixture was stirred at the same temperature for 6 hours and then 
overnight at room temperature. The reaction mixture was diluted with 50 
ml. of ethyl acetate, washed with dilute hydrochloric acid, an aqueous 
solution of sodium bicarbonate and an aqueous solution of sodium chloride, 
dried over sodium sulphate and concentrated under reduced pressure. The 
residue was purified by column chromatography on silica gel using a 
mixture of benzene and ethyl acetate (3:1) as eluent to give 234 mg. of 
the title compound having the following physical characteristics:- 
Tlc (developing solvent, ethyl acetate): Rf = 0.44; 
Ir (liquid film): .nu.; 3450, 1740, 1600, 1440, 1362, 1250, 1190, 1180, 
1100, 1050, 975, 940, 820 cm.sup.-1 ; 
Nmr (cdcl.sub.3 solution): .delta.; 7.89-7.68 (2H, m), 6.44-6.16 (2H, m), 
5.83-5.61 (2H, m), 4.38-3.76 (5H, m), 3.66 (3H, s), 2.46 (3H, s). 
EXAMPLE 33 
Methyl 
9-oxo-11.alpha.,15.alpha.-dihydroxy-16.xi.,20-dichloroprost-trans-13-enoat 
e [or 16.epsilon.,20-dichloro-PGE.sub.1 methyl ester] 
To a solution of 221 mg. of methyl 
9-oxo-11.alpha.,15.alpha.-dihydroxy-16.xi.-chloro-20-(p-toluenesulphonylox 
y)prosttrans-13-enoate (prepared as described in Example 32) in 10 ml. of 
N,N-dimethylformamide were added 33 mg. of lithium chloride and the 
mixture was stirred overnight at room temperature. The reaction mixture 
was then diluted with 50 ml. of ethyl acetate, washed with water and an 
aqueous solution of sodium chloride, dried over sodium sulphate and 
concentrated under reduced pressure. The residue was purified by column 
chromatography on silica gel using a mixture of benzene and ethyl acetate 
(3:1) as eluent to give 118 mg. of the title compound having the following 
physical characteristics:- 
Tlc (developing solvent, ethyl acetate): Rf = 0.44; 
Ir (liquid film): .nu.; 3420, 1733, 1435, 1248, 1162, 1077, 975 cm.sup.1 ; 
NMR (CDCl.sub.3 solution): .delta.; 5.71-5.64 (2H, m), 4.84-3.74 (3H, m), 
3.74-3.42 (2H, m), 3.64 (3H, s), 2.74 (1H, dd). 
EXAMPLE 34 
9.alpha.-Hydroxy-11.alpha.,15.alpha.-bis(2-tetrahydropyranyloxy)-16.xi.-chl 
oroprosta-cis-5,trans-13-dienoic acid 
To a solution of 330 mg. of methyl 
9.alpha.-hydroxy-11.alpha.,15.alpha.-bis(2-tetrahydropyranyloxy)-16.xi.-ch 
loroprostacis-5, trans-13-dienoate (prepared as described in Example 7) in 
3 ml. of methanol was added 1 ml. of a 50% aqueous solution of potassium 
hydroxide and the mixture was stirred at room temperature for 20 minutes. 
The reaction mixture was then acidified to pH 4 with a saturated aqueous 
solution of oxalic acid and extracted with ethyl acetate. The extract was 
washed with water and an aqeuous solution of sodium chloride, dried over 
sodium sulphate and concentrated under reduced pressure. The residue was 
purified by column chromatography on silica gel using a mixture of benzene 
and acetate (1:1) as eluent to give 260 mg. of the title compound having 
the following physical characteristics:- 
Tlc (developing solvent, ethyl acetate-benzene = 2:1): 
Rf = 0.31; 
Ir (liquid film): .nu.; 3450, 1710, 1432, 1350, 1240, 1200, 1130, 1112, 
1075, 1020, 975 cm.sup.-1. 
EXAMPLE 35 
9.alpha.,11.alpha.,15.alpha.-Trihydroxy-16.xi.-chloroprosta-cis-5,trans-13- 
dienoic acid [or 16.epsilon.-chloro-PGF.sub.2.alpha. ] 
To a solution of 260 mg. of 
9.alpha.-hydroxy-11.alpha.,15.alpha.-bis(2-tetrahydropyranyloxy)-16.xi.-ch 
loroprosta-cis-5,trans13-dienoic acid (prepared as described in Example 34) 
in 4 ml. of methanol were added 20 mg. of p-toluenesulphonic acid, and the 
mixture was stirred at room temperature for 30 minutes. The reaction 
mixture was concentrated under reduced pressure and the residue was 
purified by column chromatography on silica gel using ethyl acetate as 
eluent to give 100 mg. of the title compound having the following physical 
characteristics:- 
Tlc (developing solvent, ethyl acetate-methanol = 95:5): 
Rf = 0.23; 
Ir (liquid film): .nu.; 3380, 1710, 1408, 1242, 1050, 973 cm.sup.-1 ; 
Nmr (cdcl.sub.3 solution): .delta.; 5.74-5.52 (2H, m), 5.52-5.25 (2H, m), 
4.27-3.75 (4H, m). 
EXAMPLE 36 
Methyl 9-oxo-11.alpha.,15.alpha.-dihydroxy-16.xi.-chloroprostanoate 
[or 16.epsilon.-chloro-13,14-dihydro-PGE.sub.1 methyl ester] 
By proceeding as described in Example 10 but replacing the methyl 
9.alpha.-hydroxy-11.alpha.,15.alpha.-bis(2-tetrahydropyranyloxy)-16.xi.-ch 
loroprosta-cis-5,trans-13-dienoate by 78 mg. of methyl 
9-oxo-11.alpha.,15.alpha.-dihydroxy-16.xi.-chloroprosta-cis-5,trans-13-die 
noate (prepared as described in Example 4) dissolved in 3 ml. of methanol 
and utilizing 30 mg. of 5% palladium on charcoal, there was obtained a 
crude product. The crude product was purified by column chromatography on 
silica gel using a mixture of benzene and ethyl acetate (2:1) as eluent to 
give 66 mg. of the title compound having the following physical 
characteristics:- 
Tlc (developing solvent, ethyl acetate): Rf = 0.52; 
Ir (liquid film): .nu.; 3650-3100, 1740, 1720, 1438, 1242, 1200, 1170, 1070 
cm.sup.-1 ; 
Nmr (cdcl.sub.3 solution): .delta.; 4.3-3.55 (3H, m), 3.67 (3H, s), 2.71 
(1H, dd). 
The present invention includes within its scope pharmaceutical compositions 
which comprise at least one pharmacologically active prostaglandin 
analogue of general formula VII or a cyclodextrin clathrate or, when 
R.sup.1 represents a hydrogen atom, a non-toxic salt thereof, together 
with a pharmaceutical carrier or coating. In clinical practice such novel 
compounds will normally be administered orally, rectally, vaginally or 
parenterally. 
Solid compositions for oral administration include compressed tablets, 
pills, dispersible powders, and granules. In such solid compositions one 
or more of the active compounds is, or are, admixed with at least one 
inert diluent such as calcium carbonate, potato starch, alginic acid, 
mannitol or lactose. The compositions may also comprise, as is normal 
practice, additional substances other than inert diluents, e.g. 
lubricating agents, such as magnesium stearate. Liquid compositions for 
oral administration include pharmaceutically-acceptable emulsions, 
solutions, suspensions, syrups and elixirs containing inert diluents 
commonly used in the art, such as water and liquid paraffin. Besides inert 
diluents such compositions may also comprise adjuvants, such as wetting 
and suspending agents, and sweetening, flavouring, perfuming and 
preserving agents. The compositions according to the invention for oral 
administration also include capsules of absorbable material such as 
gelatin containing one or more of the active substances with or without 
the addition of diluents or excipients. 
Solid compositions for rectal administration include suppositories 
formulated in manner known per se and containing one or more of the active 
compounds. 
Solid compositions for vaginal administration include pessaries formulated 
in manner known per se and containing one or more of the active compounds. 
Preparations according to the invention for parenteral administration 
include sterile aqueous or non-aqueous solution, suspensions, or 
emulsions. Examples of non-aqueous solvents or suspending media are 
propylene glycol, polyethylene glycol, vegetable oils such as olive oil, 
and injectable organic esters such as ethyl oleate. These compositions may 
also include adjuvants such as preserving, wetting, emulsifying, and 
dispersing agents. They may be sterilised, for example, by filtration 
through a bacteria-retaining filter, by incorporation of sterilising 
agents in the compositions or by irradiation. They may also be 
manufactured in the form of sterile solid compositions, which can be 
dissolved in sterile water or some other sterile injectable medium 
immediately before use. 
The percentage of active ingredient in the compositions of the invention 
may be varied, it being necessary that it should constitute a proportion 
such that a suitable dosage for the therapeutic effect desired shall be 
obtained. Obviously several unit dosage forms may be administered at about 
the same time. In general, the preparations should normally contain at 
least 0.025% by weight of active substance when required for 
administration by injection; for oral administration the preparations will 
normally contain at least 0.1% by weight of active substance. The dose 
employed depends upon the desired therapeutic effect, the route of 
administration and the duration of the treatment. 
In the human adult, the doses per person are generally between 0.005 and 5 
mg. by oral administration in the treatment of hypertension, between 0.005 
and 5 mg. by oral administration in the treatment of disorders of the 
peripheral circulation, between 0.01 and 50 mg. by oral administration in 
the prevention and treatment of cerebral thrombosis and myocardial 
infarction, between 0.0005 and 1 mg. by oral administration in the 
treatment of gastric ulceration, between 0.00005 and 5 mg. by oral, 
intravaginal, intrauterine, intravenous, intramuscular and extra-ovular 
administration in the termination of pregnancy and induction of labour in 
pregnant female mammals and in the treatment of imparied fertility, in the 
control of oestrus, contraception and menstrual regulation in female 
mammals. In domestic female mammals such as cows, mares, sows, ewes and 
bitches, the doses are generally between 0.01 and 50 mg./animal by 
intramuscular, subcutaneous, intrauterine, intravaginal and intravenous 
administration for the synchronisation of oestrus, treatment of impaired 
fertility and the induction of abortion and labour. 
Prostaglandin compounds according to the present invention may be 
administered orally by any method known per se for administration by 
inhalation of drugs which are not themselves gaseous under normal 
conditions of administration. Thus, a solution of the active ingredient in 
a suitable pharmaceutically-acceptable solvent, for example water, can be 
nebulized by a mechanical nebulizer, for example a Wright Nebulizer, to 
give an aerosol of finely divided liquid particles suitable for 
inhalation. Advantageously, the solution to be nebulized is diluted, and 
aqueous solutions containing from 0.001 to 5 mg., and preferably 0.01 to 
0.5 mg., of active ingredient per ml. of solution are particularly 
suitable. The solution may contain stabilizing agents such as sodium 
bisulphite and buffering agents to give it an isotonic character, e.g., 
sodium chloride, sodium citrate and citric acid. 
The active ingredients may also be administered orally by inhalation in the 
form of aerosols generated from self-propelling pharmaceutical 
compositions. Compositions suitable for this purpose may be obtained by 
dissolving or suspending in finely-divided form, preferably micronized to 
an average particle size of less than 5 microns, the active ingredients in 
pharmaceutically-acceptable solvents, e.g. ethanol, which are co-solvents 
assisting in dissolving the active ingredients in the volatile liquid 
propellants hereinafter described, or pharmaceutically-acceptable 
suspending or dispersing agents, for example aliphatic alcohols such as 
oleyl alcohol, and incorporating the solutions or suspensions obtained 
with pharmaceutically-acceptable volatile liquid propellants, in 
conventional pressurized packs which may be made of any suitable material, 
e.g. metal, plastics or glass, adequate to withstand the pressures 
generated by the volatile propellant in the pack. Pressurized 
pharmaceutically-acceptable gases, such as nitrogen, may also be used as 
propellants. The pressurized pack is preferably fitted with a metered 
valve which dispenses a controlled quantity of the self-propelling aerosol 
composition as a single dose. 
Suitable volatile liquid propellants are known in the art and include 
fluorochlorinated alkanes containing from one to four, and preferably one 
or two, carbon atoms, for example dichlorodifluoromethane, 
dichlorotetrafluoroethane, trichloromonofluoromethane, 
dichloromonofluoromethane and monochlorotrifluoromethane. Preferably, the 
vapour pressure of the volatile liquid propellant is between about 25 and 
65 pound, and more especially between about 30 and 55 pounds, per square 
inch gauge at 21.degree. C. As is well-known in the art, volatile liquid 
propellants of different vapour pressures may be mixed in varying 
proportions to give a propellant having a vapour pressure appropriate to 
the production of a satisfactory aerosol and suitable for the chosen 
container. For example dichlorodifluoromethane (vapour pressure 85 pounds 
per square inch gauge at 21.degree. C.) and dichlorotetrafluoroethane 
(vapour pressure 28 pounds per square inch gauge at 21.degree. C.) may be 
mixed in varying proportions to give propellants having vapour pressures 
intermediate between those of the two constituents, e.g. a mixture of 
dichlorofluoromethane and dichlorotetrafluoroethane in the proportions 
38:62 respectively by weight has a vapour pressure of 53 pounds per square 
inch gauge at 21.degree. C. 
The self-propelling pharmaceutical compositions may be prepared by 
dissolving the required quantity of active ingredient in the co-solvent or 
combining the required quantity of active ingredient with a measured 
quantity of suspending or dispersing agent. A measured quantity of this 
composition is then placed in an open container which is to be used as the 
pressurized pack. The container and its contents are then cooled below the 
boiling temperature of the volatile propellant to be used. The required 
quantity of liquid propellant, cooled below its boiling temperature, is 
then added and the contents of the container mixed. The container is then 
sealed with the required valve fitting, without allowing the temperature 
to rise above the boiling temperature of the propellant. The temperature 
of the sealed container is then allowed to rise to ambient with shaking to 
ensure complete homogeneity of the contents to give a pressurized pack 
suitable for generating aerosols for inhalation. Alternatively, the 
co-solvent solution of the active ingredient or combination of active 
ingredient and suspending or dispersing agent is placed in the open 
container, the container sealed with a valve, and the liquid propellant 
introduced under pressure. 
Means for producing self-propelling compositions for generating aerosols 
for the administration of medicaments are, for example, described in 
detail in U.S. Pat. Nos. 2,868,691 and 3,095,355. 
Preferably, the self-propelling pharmaceutical compositions according to 
the present invention contain from 0.001 to 5 mg., and more particularly 
0.01 to 0.5 mg., of active ingredient per ml. of solution or suspension. 
It is important that the pH of solutions and suspensions used, according 
to the present invention, to generate aerosols should be kept within the 
range 3 to 8 and preferable that they should be stored at or below 
4.degree. C., to avoid pharmacological deactivation of the active 
ingredient. 
The following Examples illustrate pharmaceutical compositions according to 
the invention. 
EXAMPLE 37 
16.xi.-Chloro-PGE.sub.2 methyl ester (2 mg.) was dissolved in ethanol (10 
ml.), mixed with mannitol (18.5 g.), sieved through a 30-mesh sieve, dried 
at 30.degree. C. for 90 minutes and again sieved through a 30-mesh sieve. 
Aerosil (microfine silica; 200 mg.) was added and the powder obtained was 
machine-filled into one hundred No. 2 hard gelatin capsules to give 
capsules each containing 20 .mu.g. of 16.xi.-chloro-PGE.sub.2 methyl 
ester, which after swallowing of the capsules is released into the 
stomach. 
EXAMPLE 38 
16.xi.-Chloro-20-hydroxy-PGE.sub.1 methyl ester (2 mg) was dissolved in 
ethanol (10 ml.), mixed with mannitol (18.5 g.), sieved through a 30-mesh 
sieve, dried at 30.degree. C. for 90 minutes and again sieved through a 
30-mesh sieve. Aerosil (microfine silica; 200 mg.) was added and the 
powder obtained was machine-filled into one hundred No. 2 hard gelatin 
capsules to give capsules each containing 20 .mu.g. of 
16.xi.-chloro-20-hydroxy-PGE.sub.1 methyl ester, which after swallowing of 
the capsules is released into the stomach.